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Abstract
A common feature of many neurodegenerative diseases is the deposition of filamentous protein aggregates in
the central nervous system (CNS), including neurofibrillary tangles (NFTs) composed of tau, and Lewy
bodies (LBs) consisting of α-synuclein (α-syn), which are the hallmark lesions of Alzheimer's disease (AD)
and Parkinson's disease (PD) respectively. What causes the conversion of normally soluble proteins into
insoluble fibrils has always been enigmatic, and cell models that recapitulate the abnormal accumulation of tau
into NFT-like aggregates were lacking due to high solubility of tau. Enlightened by in vitro studies showing
nucleation-dependent fibrillization of tau, we tested the hypothesis that preformed tau fibrils (tau pffs)
assembled from recombinant protein may act as seeds to nucleate the fibrillization of soluble tau in cultured
cells. Indeed, we found that minute quantities of tau pffs internalized into cells over-expressing tau can rapidly
recruit large amounts of endogenous tau into detergent-insoluble filamentous inclusions with properties very
similar to NFTs. Moreover, the spontaneous uptake of tau pffs was shown to be mediated by endocytosis.
Together with similar studies on tau and other disease-associated proteins, our study implicates cell-to-cell
transmission of misfolded proteins through templated recruitment as a plausible mechanism for the onset and
progression of CNS amyloidosis. Another mysterious phenomenon of neurodegenerative diseases is the
frequent co-occurrence of different protein aggregates, such as NFTs and LBs. To test whether fibrillar α-syn
can directly cross-seed tau into pathological aggregates, we utilized our recently developed synucleinopathy
models in primary neurons and transgenic mice involving delivery of α-syn pffs. Intriguingly, we discovered
two distinct strains of α-syn fibrils demonstrating striking difference in the efficiency of cross-seeding tau
pathology both in neurons and transgenic mice. Biochemical analyses indicated conformational differences
between the two strains, thereby revealing the ability of a single molecule to assemble into more than one
misfolded conformers. We speculate that the existence of conformationally diverse strains may be another
shared feature of amyloid aggregates, accounting for the tremendous heterogeneity of neurodegenerative
diseases with differential extent of concomitant pathologies and highly variable but sometimes overlapping
clinical symptoms.
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ABSTRACT 
 
PATHOGENESIS OF NEURODEGENERATIVE DISEASES VIA  
TEMPLATED RECRUITMENT 
Jing Guo 
Virginia M.Y. Lee 
A common feature of many neurodegenerative diseases is the deposition of filamentous protein 
aggregates in the central nervous system (CNS), including neurofibrillary tangles (NFTs) 
composed of tau, and Lewy bodies (LBs) consisting of α-synuclein (α-syn), which are the 
hallmark lesions of Alzheimer’s disease (AD) and Parkinson’s disease (PD) respectively. What 
causes the conversion of normally soluble proteins into insoluble fibrils has always been 
enigmatic, and cell models that recapitulate the abnormal accumulation of tau into NFT-like 
aggregates were lacking due to high solubility of tau. Enlightened by in vitro studies showing 
nucleation-dependent fibrillization of tau, we tested the hypothesis that preformed tau fibrils (tau 
pffs) assembled from recombinant protein may act as seeds to nucleate the fibrillization of soluble 
tau in cultured cells. Indeed, we found that minute quantities of tau pffs internalized into cells 
over-expressing tau can rapidly recruit large amounts of endogenous tau into detergent-insoluble 
filamentous inclusions with properties very similar to NFTs. Moreover, the spontaneous uptake of 
tau pffs was shown to be mediated by endocytosis. Together with similar studies on tau and other 
disease-associated proteins, our study implicates cell-to-cell transmission of misfolded proteins 
through templated recruitment as a plausible mechanism for the onset and progression of CNS 
amyloidosis. Another mysterious phenomenon of neurodegenerative diseases is the frequent co-
occurrence of different protein aggregates, such as NFTs and LBs. To test whether fibrillar α-syn 
can directly cross-seed tau into pathological aggregates, we utilized our recently developed 
synucleinopathy models in primary neurons and transgenic mice involving delivery of α-syn pffs. 
Intriguingly, we discovered two distinct strains of α-syn fibrils demonstrating striking difference in 
the efficiency of cross-seeding tau pathology both in neurons and transgenic mice. Biochemical 
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analyses indicated conformational differences between the two strains, thereby revealing the 
ability of a single molecule to assemble into more than one misfolded conformers. We speculate 
that the existence of conformationally diverse strains may be another shared feature of amyloid 
aggregates, accounting for the tremendous heterogeneity of neurodegenerative diseases with 
differential extent of concomitant pathologies and highly variable but sometimes overlapping 
clinical symptoms. 
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CHAPTER 1: GENERAL INTRODUCTION 
1.1 Overview of Neurodegenerative diseases 
Neurodegenerative diseases refer to a wide variety of pathological conditions caused by 
progressive dysfunction and deterioration of the nervous system, including Alzheimer’s disease 
(AD), the most common type of dementia (Alzheimer's Association, 2012), and Parkinson’s 
disease (PD), the most common neurodegenerative movement disorder (de Lau and Breteler, 
2006). The greatest risk factor for these devastating diseases is advancing age. As the average 
life expectancy of humans rapidly increases, an escalating number of the world population is now 
suffering from various types of neurodegeneration. It was estimated that in 2010, about 35.6 
millions of people worldwide were afflicted with dementia, and this number is expected to double 
every 20 years (Alzheimer's Disease International, 2009). In United States alone, around 5.4 
millions of people are living with AD (Alzheimer's Association, 2012). Unfortunately, to date, 
almost all neurodegenerative disorders are considered terminal illnesses with no cure. All 
currently approved treatments merely alleviate disease-associated symptoms without reversing or 
slowing down disease course (Alzheimer's Disease International, 2009; Melnikova, 2007). 
Therefore, there is a pressing need for the discovery of disease-modifying drugs, which 
necessitates more advanced understanding of biological processes underlying the pathogenesis 
and progression of neurodegenerative diseases. 
Despite tremendous diversity in clinical phenotypes, the majority of neurodegenerative 
diseases share a common feature, which is the accumulation of disease-specific proteins into 
insoluble aggregates, including senile plaques consisting of β-amyloid (Aβ) and neurofibrillary 
tangles (NFT) consisting of tau in AD (Glenner and Wong, 1984; Lee et al., 1991), Lewy bodies 
(LB) and Lewy neurites (LN) composed of α-synuclein (α-syn) in PD (Spillantini et al., 1997), 
TDP-43 aggregates in Amyotrophic Lateral Sclerosis (Neumann et al., 2006), and polyglutamine 
inclusions in Huntington’s disease (DiFiglia et al., 1997), and prion protein aggregates in 
Creutzfeldt-Jakob disease (Bolton et al., 1982). Most of these protein aggregates are 
characterized by enriched β–pleated sheet structures and are shown to consist of 8-20 nm wide 
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filaments by electron microscopy (reviewed by Forman et al., 2004; Goedert, 1999). What triggers 
the conversion of normally soluble proteins into filamentous polymers remains a topic of active 
research and also forms the basis of my thesis study. Importantly, the identification of pathogenic 
mutations in the genes coding for various disease-associated proteins provides the strongest 
argument that these proteins are causally linked to the pathogenesis of neurodegenerative 
diseases instead of merely serving as pathological markers. 
However, there is an ongoing debate on the exact toxic species along the aggregation 
pathway, whether it is oligomers, proto-fibrils, or mature fibrils. Traditionally, mature filamentous 
aggregates are believed to be detrimental to cells since they are consistently found in regions 
undergoing neurodegeneration. It is easily conceivable that thick bundles of intracellular fibrils 
may create physical obstacles for important cellular processes, such as protein trafficking and 
axonal transport, and due to their inherent stickiness, they could also sequester critical 
cytoplasmic proteins including their soluble counterparts, resulting in loss-of-function toxicity 
(reviewed by Ballatore et al., 2007; Forman et al., 2004). More recently, multiple lines of evidence 
suggested that pre-fibrillar protein species could be harmful to cells as well. For example, soluble 
Aβ oligomers were demonstrated to be toxic to cultured neurons (Dahlgren et al., 2002; Lambert 
et al., 1998) and impair long-term potentiation both in cultured hippocampal slices and in vivo 
(Walsh et al., 2002; Wang et al., 2002); α-syn was shown to form annular or pore-like proto-fibrils 
which can potentially disrupt membrane structures (Ding et al., 2002; Lashuel et al., 2002); in 
animal models over-expressing tau, neuronal dysfunction or death sometimes precedes NFT 
formation or occurs independent of NFTs (Santacruz et al., 2005; Wittmann et al., 2001; 
Yoshiyama et al., 2007). These studies led to the provocative hypothesis that soluble oligomers 
rather than insoluble fibrillar aggregates may be the real culprit of neuronal demise, and formation 
of the latter may actually represent a protective cellular mechanism to sequester diffusible toxic 
oligomers (reviewed by Caughey and Lansbury, 2003; Haass and Selkoe, 2007). Nevertheless, 
none of these studies has truly refuted the toxicity of mature aggregates, and the pathological 
relevance of soluble oligomers, on the other hand, remains to be established since only a limited 
3 
 
number of studies have reported the existence of such species in the disease brains (Maeda et 
al., 2007; Patterson et al., 2011). 
The following two sections will discuss in greater detail about tau and α-syn, the two 
proteins that are the focus of my thesis study. 
1.2 Tau and tauopathies 
Tau is a microtubule (MT)-associated protein predominantly expressed in the neurons 
with a primary cellular function of stabilizing MTs and promoting their assembly (Cleveland et al., 
1977b; Drechsel et al., 1992; Witman et al., 1976). In the adult brain, there are 6 isoforms of tau, 
which arise from alternative splicing of the MAPT gene and differ in the number of MT-binding 
repeats as well as the number of N-terminal inserts (Andreadis et al., 1992; Goedert et al., 1989). 
There can be 3 or 4 MT-binding repeats (referred to as 3R or 4R tau) that bind to the inner 
surface of the MTs, and 0-2 of the highly acidic N-terminal inserts (referred to as 0N, 1N or 2N 
tau) that project away from MTs. It has been shown that 4R tau binds MTs more avidly than 3R 
tau (Butner and Kirschner, 1991; Gustke et al., 1994). In addition, the MT-binding property of tau 
is regulated by post-translational modifications, particularly serine/threonine phosphorylation, 
which reduces binding affinity of tau for MTs presumably due to electrostatic repulsion between 
negatively charged phosphate groups and tubulin residues (Biernat et al., 1993; Bramblett et al., 
1993; Drechsel et al., 1992). Both the isoform composition and phosphorylation of tau are 
developmentally regulated, whereby only the shortest 3R isoform is expressed in fetal brains and 
fetal tau is more phosphorylated than adult tau (Goedert et al., 1993; Goedert et al., 1989; 
Kanemaru et al., 1992), giving rise to more dynamic MT structures in developing brains (Panda et 
al., 2003). 
Physiologically, tau is a highly soluble protein due to abundant charged residues, such as 
lysines that are particularly enriched in the MT-binding repeats (Jones et al., 2012; Mandelkow et 
al., 2007). Biophysical studies demonstrated that tau is a natively unfolded protein without well-
defined secondary or tertiary structures (Cleveland et al., 1977a; Schweers et al., 1994). 
4 
 
Interestingly, recent studies suggested that tau actually has a more compact structure than an 
ideal random coil, owing to at least transiently existing long-range intramolecular interactions 
among the different domains (N-terminus, proline-rich region, MT-binding repeats, C-terminus), 
but it is controversial whether such interactions promote or inhibit pathological aggregation 
(Elbaum-Garfinkle and Rhoades, 2012; Jeganathan et al., 2006; Mukrasch et al., 2009). 
 In AD brains, the normally soluble tau protein accumulates into insoluble β-sheet-rich 
paired helical filaments as well as straight filaments both in neuronal somas (pathology termed as 
NFTs) and processes (pathology termed as neuropil threads) (Berriman et al., 2003; Kidd, 1963; 
Wischik et al., 1985), whereby neuropil threads account for >95% of total tau pathology (Mitchell 
et al., 2000). Tau aggregates are also found extracellularly as “ghost tangles”, which presumably 
come from dead neurons (Bondareff et al., 1994; Braak et al., 1994). For a long time, tau 
aggregation was thought to be merely a downstream consequence of extracellular Aβ deposition, 
since all mutations identified in familial AD are linked to Aβ but not tau (Duff and Hardy, 1995; 
Masters and Beyreuther, 1998). However, a significant correlation between total NFT burden and 
cognitive deficits of patients (Arriagada et al., 1992; Wilcock and Esiri, 1982), and a correlation 
between the abundance of ghost tangles and the extent of neuron loss (Cras et al., 1995), 
suggest that tau aggregation may be a critical player in the disease mechanism. Moreover, the 
discovery of a heterogeneous subgroup of frontotemporal dementia (FTD) characterized by tau 
inclusions in the absence of Aβ plaques (now collectively termed as tauopathies together with 
AD) and, most importantly, the identification of >30 autosomal dominant mutations of the MAPT 
gene encoding tau in FTD with parkinsonism linked to chromosome 17 (FTDP-17) strongly 
suggest that abnormality in tau alone is sufficient to cause neurodegeneration (Goedert and 
Jakes, 2005; Hutton et al., 1998; Rizzu et al., 1999). Interestingly, the majority of mutations are 
clustered around the MT-binding repeats. While most missense mutations compromise the ability 
of tau in promoting MT assembly (Dayanandan et al., 1999; Hong et al., 1998) and/or increase its 
propensity to fibrillize in vitro (Goedert et al., 1999; Nacharaju et al., 1999; von Bergen et al., 
2001), mutations in intron 10 and a number of mutations in the nearby coding regions alter the 
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ratio of 4R to 3R isoforms (Hutton et al., 1998). Given that all pathogenic tau mutations alter 
either physiological/pathological properties of tau or the isoform composition of tau, and that 
NFTs are found in both sporadic and familial FTDP-17 cases, tau must be causally involved in the 
pathogenesis of tauopathies. 
Since the discovery of tau as the integral building blocks of NFTs (Kosik et al., 1986; Lee 
et al., 1991), a large number of studies have been dedicated to investigating in vitro fibrillization of 
tau. Although the earliest studies managed to show self-assembly of tau into NFT-like filaments, 
the efficiency of fibrillization was very low, despite extremely high concentration of tau and non-
physiological conditions used (Crowther et al., 1992; Crowther et al., 1994; Wille et al., 1992). 
Truncated tau consisting of the MT-binding repeats alone shows higher tendency to fibrillize than 
full-length tau, consistent with the observation that the repeat region forms the core of NFTs 
(Wischik et al., 1988). A breakthrough in the field was achieved when a series of studies 
demonstrated that polyanionic cofactors, such as RNA, heparin and arachidonic acid, 
dramatically promote fibrillization of tau (Chirita et al., 2003; Goedert et al., 1996; Kampers et al., 
1996). Among them, arachidonic acid is the most potent facilitating cofactor, which can induce 
physiological concentrations of tau (low μM range) to form fibrils within hours. The exact 
mechanism by which polyanionic cofactors stimulate tau fibrillization is not well understood, but it 
is proposed that negative charges carried by these molecules likely neutralize excess positive 
charges in the MT-binding domains and flanking regions of tau, thereby enabling intermolecular 
interactions of tau through these regions or stabilizing aggregation-prone structures of tau (Sibille 
et al., 2006). In addition, micelles formed by arachidonic acid may attract positively charged tau to 
their surface so as to increase local concentration of tau (Chirita et al., 2003). However, it remains 
unresolved whether any of these inducers of tau fibrillization in vitro is truly involved in the 
genesis of NFTs in human brains. RNA is usually highly complexed in the cytoplasm without free 
access to tau; heparan sulfate, which is structurally related to heparin, is largely on the 
extracellular side of the cell membranes; anionic fatty acids can be found on the cytoplasmic side 
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of the cell membranes, but their normal levels inside cells are insufficient to trigger tau fibrillization 
(Chirita et al., 2003). 
Post-translational modifications on tau itself may play important roles in the onset and 
progression of tauopathies. Since phosphorylation inhibits tau-MT interactions and tau is found to 
be always hyperphosphorylated in NFTs, it is proposed that upregulated phosphorylation and/or 
downregulated dephosphorylation of tau may promote disengagement of tau from the MTs, 
resulting in elevated levels of free tau in the cytoplasm, which in turn enhances the chance of tau-
tau interactions (reviewed by Ballatore et al., 2007). Indeed, a study on adult human brain 
biopsies demonstrated downregulation of phosphatase in AD brains as compared to control 
brains (Matsuo et al., 1994). However, it is still debatable whether hyperphosphorylation precedes 
tau aggregation or occurs post-aggregation, and the effect of phosphorylation on the fibrillization 
propensity of tau is controversial (Alonso et al., 2001; Schneider et al., 1999). Tau acetylation, a 
recently discovered modification of tau on lysine residues, not only serves as a reliable 
pathological marker of tauopathies, but was also found to both impair the physiological function of 
tau in promoting MT assembly and enhance the pathological aggregation of tau in vitro (Cohen et 
al., 2011; Irwin et al., 2012). Importantly, potential acetylation sites mostly lie within the MT-
binding repeats which are embedded in the core of NFTs, making acetylation unlikely to occur 
after NFT formation. Future studies are required to confirm the pathogenic role of tau acetylation 
in tauopathy brains. 
1.3 α-syn and synucleinopathies 
 α-syn is a 140-amino acid cytoplasmic protein abundantly expressed in neurons (Iwai et 
al., 1995a; Jakes et al., 1994). Its subcellular localization is developmentally regulated, such that 
it only becomes highly concentrated in the synaptic terminals when neurons are mature (Murphy 
et al., 2000). The exact physiological functions of α-syn are not clearly defined. Its physical 
location in the synapses and close association with synaptic vesicles (Iwai et al., 1995a) suggest 
it may play a role in synaptic functions. Indeed, downregulation of α-syn, both in primary neurons 
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by antisense oligonucleotide and in mice by genetic knock-out (KO), led to reduced distal pool of 
synaptic vesicles (Cabin et al., 2002; Murphy et al., 2000), providing evidence for a possible 
regulatory function of α-syn in synaptic transmission. On the other hand, the functional deficits of 
dopaminergic neurons in α-syn KO mice occur in the absence of morphological or structural 
abnormalities (Abeliovich et al., 2000), suggesting α-syn is not essential for the formation of 
synapses per se. Additionally, α-syn was shown to be neuroprotective by acting as a co-
chaperone together with cysteine-string protein-alpha to protect nerve terminals against stress or 
injury (Chandra et al., 2005). More recently, the non-classical chaperone function of α-syn was 
demonstrated to be important for maintaining continuous assembly of presynaptic SNARE 
complex, which in turn is required by repetitive neurotransmitter release (Burre et al., 2010). 
Similar to tau, α-syn is a heat-stable, highly soluble protein, belonging to the family of 
natively unfolded protein (Eliezer et al., 2001; Weinreb et al., 1996). However, unlike tau, 
recombinant α-syn readily assembles into β-sheet-rich fibrils in vitro under physiological 
conditions without any cofactors (Conway et al., 1998; Giasson et al., 1999), although fatty acids 
and anionic detergents were shown to further accelerate fibrillization (Necula et al., 2003). The 
first 60 amino acids of α-syn on the N-terminus are homologous to a lipid-binding domain of 
apolipoproteins (George et al., 1995), and assume α-helical structure upon binding to acidic 
phospho-lipids (Davidson et al., 1998; Eliezer et al., 2001). The hydrophobic central domain 
(amino acids 61-95), known as non-amyloid component (NAC) of the amyloid precursor protein 
due to its initial co-purification with Aβ plaques from AD brains (Weinreb et al., 1996), is both 
necessary and sufficient for fibril assembly of α-syn (Giasson et al., 2001; Han et al., 1995), 
analogous to the MT-binding domain of tau. The amyloidogenic property of the NAC domain is 
also supported by fibrillization incompetency of β-syn, which shares extensive sequence 
homology with α-syn but lacks the NAC domain (Giasson et al., 2001). The C-terminus of α-syn, 
highly acidic due to enriched glutamate residues, is the most unstructured region of the whole 
molecule (Eliezer et al., 2001; Maroteaux et al., 1988). Deletion of C-terminus greatly promotes 
the fibrillization rate of α-syn (Crowther et al., 1998; Murray et al., 2003), and since C-terminal 
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truncated α-syn was found in PD brains (Baba et al., 1998; Campbell et al., 2001; Li et al., 2005), 
proteolytic cleavage has been proposed to be an important pathogenic event in LB diseases. 
 In PD and other synucleinopathies, such as dementia with Lewy Bodies (DLB), 
filamentous α-syn aggregates deposit as LBs and LNs within neuronal somas and processes in a 
variety of subcortical and neocortical regions (Spillantini et al., 1998a). Classical LBs found in the 
substantia nigra of PD brains are characterized by a dense core surrounded by a halo of radiating 
filaments (Forno, 1996), while cortical LBs are morphologically less defined and lack a halo 
(Goedert et al., 2012). Biochemical identification of α-syn as the major component of LBs was 
only accomplished (Spillantini et al., 1997) after the discovery of an autosomal dominant 
pathogenic mutation in α-syn causing early-onset PD (Polymeropoulos et al., 1997). Two 
additional mutations were identified later, providing important insight into the pathogenesis of PD 
(Kruger et al., 1998; Zarranz et al., 2004). A53T mutation greatly accelerates fibrillization of α-syn 
in vitro, whereas A30P mutation promotes oligomerization but not fibrillization of α-syn, 
supporting the hypothesis that enhanced formation of pre-fibrillar oligomers may be the shared 
toxic mechanism of both mutations (Conway et al., 2000b). However, this hypothesis was 
challenged by E46K mutant α-syn, which fibrillizes faster than wt α-syn (Greenbaum et al., 2005) 
but forms pore-like proto-fibrils less readily than wt α-syn (Fredenburg et al., 2007). On the other 
hand, A30P mutation was shown to significantly reduce the lipid-binding affinity of α-syn (Jensen 
et al., 1998), suggesting that the primary toxicity of A30P mutation may be a loss of physiological 
functions, rather than gains-of-function toxicity exhibited by A53T and E46K mutations. Together 
with disease-causing gene amplification of α-syn (Chartier-Harlin et al., 2004; Singleton et al., 
2003), these genetic studies highlight the key roles of α-syn in the onset and progression of 
synucleinopathies. 
 Phosphorylation of α-syn at serine 129 is a widely accepted pathological marker specific 
for LBs (Anderson et al., 2006) and was shown to promote aggregation and toxicity of over-
expressed α-syn in rodents (Lee et al., 2011; Sato et al., 2011), but it remains controversial if 
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phosphorylation at this residue occurs prior to LB formation. A cell culture study showed that this 
modification is not required for the formation of α-syn inclusions, suggesting that it may represent 
a post-aggregation event in LB diseases (Luk et al., 2009). In addition, nitrated α-syn has been 
identified extensively and specifically in α-syn aggregates in a wide variety of synucleinopathies 
(Duda et al., 2000; Giasson et al., 2000a), pointing to a possible role of oxidative stress in the 
pathogenesis of these diseases. 
1.4 Existing models of tauopathies and synucleinopathies 
 To date, a large number of animal models have been generated, predominantly using 
transgene over-expression systems, in an attempt to recapitulate the cardinal features of various 
tauopathies and synucleinopathies. The earliest tau transgenic mouse models over-expressed wt 
tau of either the longest isoform (4R2N) or the shortest isoform (3R0N) (Gotz et al., 1995; 
Ishihara et al., 1999; Probst et al., 2000; Spittaels et al., 1999). The 4R2N tau-expressing mice 
only develop pre-tangle structures in the form of somatodendritic accumulations of 
hyperphosphorylated tau or axonal deposits of tau-immunoreactive spheroids. Axonopathy that is 
commonly observed in these mice is most likely due to excessive binding of over-expressed tau 
to the MTs (Terwel et al., 2005). Such an over-expression artifact in the absence of NFT-like 
pathology deviates this model from real disease conditions, whereby the sequestration of soluble 
tau into NFTs is expected to compromise MT stability. The 3R0N tau-expressing mice do form 
insoluble tau filaments at 18 months of age, but apart from the long incubation period, NFT-like 
aggregates are much more abundant in the spinal cord than in the cortex, rendering it another 
unsatisfactory model of tauopathies. After the discovery of tau mutations causing FTDP-17, 
numerous mouse models expressing mutant tau (P301L, P301S, R406W) succeeded in 
generating filamentous tangle-like pathology in relatively young mice (~3-5 month-old) (Allen et 
al., 2002; Gotz et al., 2001a; Lewis et al., 2000; Yoshiyama et al., 2007; Zhang et al., 2004). 
Moreover, unlike Aβ-oriented AD mouse models which show minimal neurodegeneration in the 
presence of abundant plaques (Irizarry et al., 1997a; Irizarry et al., 1997b), the formation of tau 
tangles is frequently accompanied by neuron loss, consistent with the correlation of cognitive 
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impairment with NFT burden but not plaque load in AD patients (Arriagada et al., 1992). In 
addition, tau aggregation was found to result in reduced MT density (Brunden et al., 2010; 
Ishihara et al., 1999), demonstrating the loss-of-function toxicity associated with tangle formation. 
However, there is no evidence suggesting upregulation of tau levels is a cause of human 
tauopathies, thus over-expression animal models may not be suitable for studying the etiology of 
tauopathies. Furthermore, as demonstrated by in vitro and cell culture studies, high concentration 
of tau can compete with MT motor proteins and result in cellular trafficking defects (Dixit et al., 
2008; Ebneth et al., 1998; Stamer et al., 2002). Therefore, early deficits observed in tau 
transgenic mouse models before the appearance of NFTs could be partly due to over-saturation 
of MT-binding sites by tau and/or over-stabilization of the MTs, and hyperphosphorylation of tau, 
which is observed in all tau over-expressing models, may actually represent a protective strategy 
of cells to reduce excessive MT binding by tau (Stamer et al., 2002). 
 The causal link between genetic amplification of α-syn and familial PD legitimates the use 
of α-syn over-expression to model PD and related synucleinopathies. While transgenic mice over-
expressing wt α-syn do not form any α-syn inclusions, mice over-expressing A53T or E46K 
mutant α-syn age-dependently develop widespread filamentous α-syn aggregates accompanied 
by motor phenotypes (Emmer et al., 2011; Giasson et al., 2002). Curiously, and unsatisfactorily, 
in these mouse models, α-syn inclusions are abundantly found in regions that are normally not 
affected in PD, such as spinal cord and cerebellum, whereas brain structures that are most 
vulnerable to α-syn pathology in human, such as substantia nigra and olfactory bulbs, are spared 
of inclusions. Therefore, these models do not accurately reproduce human synucleinopathies in 
animals. Aggregation of α-syn in the substantia nigra was later achieved by over-expression of 
aggregation-prone C-terminal truncated α-syn under the tyrosine hydroxylase promoter which 
restricts expression to dopaminergic neurons (Tofaris et al., 2006), and by direct injection of 
adeno-associated virus or lentivirus carrying α-syn-expressing vectors into the substantia nigra 
(Kirik et al., 2002; Lo Bianco et al., 2002). However, these new approaches still fail to address the 
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apparent contradictions of brain region-specific vulnerability to α-syn pathology in rodent brains 
vs. human brains. 
While animal models provide significant in vivo evidence for the pathogenicity of protein 
aggregation, the relatively long incubation periods and lack of amenability for experimental 
manipulations limit their usefulness in mechanistic studies and therapeutic investigations 
involving high-throughput screening. Therefore, cellular models would be an invaluable 
complementary tool to conduct studies that cannot be readily accomplished in animal models. 
Unfortunately, due to the high solubility of tau and α-syn, they do not spontaneously aggregate in 
cells within the time window of cell culture experiments (days, in contrast to months for animal 
experiments) even with massive over-expression. One additional obstacle in generating tau cell 
models is that high levels of tau expression are not well-tolerated by dividing cells since 
excessive MT stabilization by over-expressed tau can arrest cell division (Kanai et al., 1989).  
Over the years, a variety of approaches have been employed to enhance tau or α-syn 
aggregation in cells, including expression of mutant or truncated molecules that are more prone 
to fibrillization than wt full-length protein (Khlistunova et al., 2006; Vogelsberg-Ragaglia et al., 
2000); subjecting cells to elevated oxidative/nitrative/proteolytic stress which induces protein 
misfolding (Lee et al., 2002; McLean et al., 2001; Paxinou et al., 2001); addition of amyloid-
binding dyes, such as Congo red, to stabilize aggregation-competent conformations 
(Bandyopadhyay et al., 2007); creating conditions that promote hyperphosphorylation (Ferrari et 
al., 2003; Sato et al., 2002). Apart from the low efficiency of tau or α-syn aggregation induced in 
these models, very few of them gave rise to bona fide filamentous aggregates that are both 
Congo Red/ThT/ThS-positive and ultrastructurally similar to NFTs or LBs as seen in disease 
brains. Moreover, many of the manipulations utilized to promote intracellular protein aggregation 
are inherently detrimental to cells, thereby precluding the use of these models to investigate toxic 
mechanisms of protein aggregation. 
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1.5 New paradigm of neurodegenerative disease modeling and the transmission 
hypothesis 
 Failures of existing cell culture models in recapitulating disease pathologies call for 
alternative strategies. Notably, in vitro studies showed that fibrillization of tau and α-syn occurs 
via a nucleation-elongation mechanism, whereby the formation of oligomeric species (the 
“nucleus”) is the rate-limiting step responsible for the initial lag phase, while the addition of 
monomers to the nucleus happens relatively quickly resulting in a rapid elongation phase 
(Friedhoff et al., 1998; Wood et al., 1999). Therefore, seeding with preformed fibrils can 
effectively speed up fibrillization of tau and α-syn monomers through bypassing the kinetic barrier 
of nucleation. Enlightened by these in vitro studies, we hypothesized that the major road block 
towards efficient intracellular fibrillization of tau and α-syn may lie in the slow formation of 
fibrillization-competent nucleus. Therefore, we set on applying the same strategy of “seeding” on 
cultured cells by introducing preformed tau or α-syn fibrils into cells over-expressing tau or α-syn 
respectively. Intriguingly, it was shown by my colleagues that exogenously supplied α-syn fibrils 
can indeed act as seeds to efficiently recruit endogenous soluble α-syn into insoluble aggregates 
that are highly reminiscent of LBs (Luk et al., 2009). 
Around the same time, another research group published a study demonstrating that tau 
fibrils can spontaneously enter cells and induce endogenous tau to form aggregates (Frost et al., 
2009). However, endogenous tau aggregates shown in this study appear to be exclusively small 
puncta which do not exceed the size of internalized exogenous fibrils, thereby indicating limited 
recruitment, and also do not bear any resemblance to NFTs. The inefficient recruitment seen in 
this study may be partly due to the large GFP tag on endogenous tau which could interfere with 
tau fibrillization and/or due to the omission of protein delivery reagent which can facilitate the 
internalization of exogenous fibrils. Therefore, while this was an important proof-of-concept study 
for intracellular seeding of tau, the data were not robust enough to support the pathological 
relevance of templated recruitment in NFT formation. In Chapter 2, I will describe my effort of 
developing and optimizing a cellular system to demonstrate convincingly the formation of NFT-
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like tau inclusions seeded by preformed fibrils, and altered MT stability resulted from the 
sequestration of soluble tau by aggregates. In addition, I will show that exogenous tau fibrils can 
indeed be taken up by cells via endocytosis, as suggested by the previous study. In Chapter 3, I 
will present an extension of this effort to primary neurons, cells that are most relevant for 
neurodegenerative tauopathies, and provide further evidence that templated recruitment is a 
plausible mechanism underlying the pathogenesis of tauopathies. 
Remarkably, in the past few years, an escalating number of studies have employed the 
seeding paradigm to model the onset and progression of neurodegenerative diseases both in 
cultured cells and in living animals. Intracerebral inoculation of lysates containing tau aggregates 
from aged transgenic mice expressing mutant tau were shown to induce tau inclusions in wt tau-
expressing mice which do not normally develop tau aggregates (Clavaguera et al., 2009). Two 
recent studies conducted in our lab further demonstrated that synthetic fibrils assembled from 
recombinant tau or α-syn are wholly sufficient to induce the aggregation of respective proteins in 
transgenic mice expressing mutant tau or α-syn (Iba et al., 2013; Luk et al., 2012b). Notably, in all 
three studies, inoculate-induced pathology not only develops near the injection site, but also 
spreads to synaptically connected distant brain regions, consistent with two recent studies 
reporting trans-synaptic transfer of aggregated tau and two earlier studies showing possible 
spreading of LB pathology from host dopaminergic neurons to embryonic transplants (Kordower 
et al., 2008; Li et al., 2008). Furthermore, wt human α-syn fibrils were shown to induce robust LB 
and LN-like inclusions even in non-transgenic neurons without over-expression of α-syn 
(Volpicelli-Daley et al., 2011), and intracerebral injection of mouse α-syn fibrils into non-
transgenic mice were found to efficiently initiate and spread endogenous mouse α-syn pathology 
to various brain regions, including the substantia nigra, which is normally spared of α-syn 
inclusions in α-syn over-expressing transgenic mice (Luk et al., 2012a). Intriguingly, LB formation 
in the substantia nigra of non-transgenic mice leads to progressive loss of dopaminergic neurons, 
recapitulating a key feature of PD that is missing in most of pre-existing mouse models. 
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The abovementioned studies have presented converging evidence for transcellular and 
cell-to-cell transmission of tau and α-syn pathologies, whereby fibrillar protein aggregates 
constitute the sufficient transmissible agent. Moreover, studies on other disease-associated 
proteins, such as Aβ and polyglutamine repeats, demonstrated very similar phenomenon (Eisele 
et al., 2010; Ren et al., 2009; Stohr et al., 2012), thereby implicating a shared property of 
amyloidogenic proteins. It is difficult to imagine that only a few years ago, protein aggregates in 
neurodegenerative diseases were still thought to develop in a cell-autonomous manner, and 
intercellular transmission was believed to be a unique property of infectious prion particles. The 
recent paradigm shift in disease modeling has therefore revolutionized the whole field’s 
understanding on the mechanism underlying the onset and progression of central nervous system 
amyloidosis. This newly evolved hypothesis of protein-only transmission provides a viable 
explanation for the stereotypical progression of tau and α-syn pathologies in AD and PD brains 
that has long been observed (Braak and Braak, 1991; Braak et al., 2003). 
1.6 Convergence and divergence in tauopathies and synucleinopathies 
 Neurodegenerative diseases are commonly classified according to the predominant 
clinical manifestations (e.g. AD is considered as a cognitive disorder, whereas PD is considered 
as a movement disorder) or the major protein lesions (e.g. AD is a tauopathy, but PD is a 
synucleinopathy). In reality, however, there are substantial overlaps among the various diseases 
in terms of both clinical symptoms and neuropathologies (Galpern and Lang, 2006). It has been 
increasingly recognized that PD is not simply a movement disorder, but it also involves significant 
non-motor symptoms, including cognitive deficits. A population-base study revealed >40% of PD 
patients fulfilling the clinical criteria for dementia (Mayeux et al., 1992). Conversely, it has been 
reported by longitudinal studies that parkinsonism occurs in 36% of pathologically confirmed AD 
patients (Morris et al., 1989). With respect to neuropathological substrates, LBs, the hallmark 
lesions of PD and DLB, were found in ~50-60% of both familial and sporadic AD cases – most 
frequently in the amygdala (Hamilton, 2000; Jellinger, 2003; Kotzbauer et al., 2001; Lippa et al., 
1998), while 33-43% of PD brains showed sufficient senile plaques and NFTs for a pathological 
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diagnosis of AD (Jellinger et al., 2002; Mattila et al., 1998), and as high as 87% of DLB cases 
reach the pathological criteria for AD (McKeith et al., 2000). While PD with dementia (PD) and 
DLB are arbitrarily divided based on the “1-year rule” (a classification of DLB is made if the onset 
of dementia occurs within 1 year of the onset of motor symptoms, otherwise the patient is given a 
diagnosis of PDD when dementia sets in), the extensive overlaps among PD, PDD, DLB and AD 
suggest that all of these diseases may represent a continuum of disorders along the axis of motor 
dysfunction and dementia. 
 Mechanisms underlying frequent co-occurrence of different protein aggregates in various 
neurodegenerative diseases are not fully understood. As proposed by the protein homeostasis 
theory, aging, the greatest risk factor for most neurodegenerative diseases, is associated with 
increased oxidative stress, deteriorated cellular degradation machinery, and consequently 
elevated levels of damaged proteins, which can initiate a “damage cascade” that further impairs 
the protein quality control systems and leads to even higher amounts of misfolded proteins (Kikis 
et al., 2010). Moreover, proteostatic stress arising from the aggregation of one major protein can 
elicit a global effect on the structural stability of many other unrelated proteins, possibly resulting 
in their misfolding and aggregation (Gidalevitz et al., 2006). An alternative but not mutually 
exclusive hypothesis is that filamentous aggregates consisting of one protein may directly seed 
the fibrillization of another aggregation-prone protein. The feasibility of such a heterotypic seeding 
mechanism is supported by the generation of conformation-dependent and sequence-
independent antibodies which can recognize fibrillar aggregates composed of different proteins, 
implicating a generic conformation shared by amyloid fibrils (Kayed et al., 2007; O'Nuallain and 
Wetzel, 2002). In line with this possibility, several histological studies have reported close 
physical association of tau and α-syn in pathological inclusions (Duda et al., 2002; Galloway et 
al., 1989; Ishizawa et al., 2003). Importantly, an earlier study from our lab directly demonstrated 
that α-syn and tau promote the fibrillization of each other in the test tube, whereby α-syn can 
substitute for anionic factors that are normally required for tau fibrillization and tau also 
accelerates the fibril assembly of α-syn (Giasson et al., 2003). Lastly, genome-wide association 
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studies consistently identified the H1 haplotype of tau as one of the two most prominent genetic 
risk factors for idiopathic PD, besides polymorphisms in the α-syn-coding gene (Satake et al., 
2009; Simon-Sanchez et al., 2009). Although the exact mechanism for increased susceptibility of 
the H1 haplotype is unknown, a study showing enhanced expression level of tau conferred by the 
H1 variant (Healy et al., 2004) suggests a mechanistic role of tau in the pathogenesis of 
synucleinopathies. 
 Although there are significant overlaps between diseases that were traditionally thought 
to be distinct entities, on the other side of the coin, diseases characterized by aggregates made 
from the same protein can be highly divergent (reviewed by Lee et al., 2001). Among tauopathies, 
all 6 isoforms of tau with an equal ratio of 3R and 4R are found in AD NFTs (Goedert et al., 1992; 
Lee et al., 1991), whereas NFTs in progressive supranuclear palsy (PSP) and corticobasal 
degeneration (CBD) predominantly consist of 4R tau (Sergeant et al., 1999), while Pick’s disease 
(PiD) primarily shows 3R tau inclusions (Sergeant et al., 1997). While tau inclusions are mostly 
located in neurons for AD, abundant glial lesions are a distinguishing feature of PSP and CBD, 
including tufted astrocytes in PSP, astrocytic plaques in CBD, and coiled bodies (tau inclusions in 
oligodendrocytes) in both diseases (Feany and Dickson, 1995; Komori, 1999; Yamada et al., 
1992). Morphologically, NFTs in AD are usually flame-shaped; Pick’s bodies, the signature lesion 
of PiD, are spherical tau inclusions; NFTs in PSP and CBD are mostly globose in appearance but 
occasionally flame-shaped in PSP (reviewed by Dickson, 1998; Dickson, 1999). Electron 
microscopy examination revealed ultrastructural differences in the tau filaments found in different 
tauopathies (Crowther, 1991; Crowther and Wischik, 1985; Ksiezak-Reding et al., 1994; Powell et 
al., 1974; Takauchi et al., 1984). Furthermore, unlike NFTs in AD, tau aggregates in PiD, PSP 
and CBD are mostly thioflavin S (ThS)-negative or Gallyas-negative, and missing tau epitopes 
that are present in late-stage AD (Guillozet-Bongaarts et al., 2007), suggesting tau inclusions in 
these diseases may be less mature and conformationally different from those found in the AD 
brains. Although subcortical pathology is present in all of these disorders, it is especially 
pronounced in PSP, which typically shows profound neuronal loss in the basal ganglia, 
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diencephalon and brainstem (reviewed by Dickson, 1999). In terms of clinical features, AD and 
PiD are primarily associated with dementia, whereas the dominant signs of PSP and CBD are 
motor dysfunctions (reviewed by Dickson, 1998, 1999; Steele et al., 1964). 
Similarly, synucleinopathies are marked by considerable heterogeneity, both clinically 
and pathologically. As mentioned previously, α-syn inclusions occur in the neuronal cell bodies 
and processes as LBs and LNs respectively in PD an DLB. In contrast, in multiple system atrophy 
(MSA), α-syn aggregates are predominantly found as cytoplasmic inclusions in the 
oligodendrocytes, which consist of α-syn filaments that are morphologically different from those 
found in LBs and LNs (Forno, 1996; Kato and Nakamura, 1990; Tu et al., 1998). Not only do MSA 
patients present distinct clinical features from other synucleinopathies, but MSA itself can be 
categorized into several subtypes with substantial clinical variability (Halliday et al., 2011). Along 
the PDD-DLB continuum, there are also large variations in the relative abundance of concomitant 
AD pathologies as well as the time interval between the onset of motor symptoms and the onset 
of dementia, which can vary by several decades (Gearing et al., 1999; McKeith, 2006; Tsuboi and 
Dickson, 2005). While there is a long-standing controversy over the relative importance of LB 
pathology vs. co-morbid AD pathologies to cognitive impairment in DLB patients (Colosimo et al., 
2003; Compta et al., 2011; Hurtig et al., 2000), multiple studies have suggested the presence of 
two subgroups of PDD patients, one group with relatively young onset, long motor-dementia 
interval and less aggressive disease duration, and the other group with older onset, short motor-
dementia interval and more malignant disease course (Compta et al., 2011; Halliday et al., 2008; 
Jellinger et al., 2002). Moreover, the former usually presents mostly pure LB pathologies, but the 
latter more frequently shows co-existing AD pathologies. 
 In Chapter 4, I will describe my project which was aimed to explore the cross-seeding of 
tau by α-syn fibrils in cultured neurons. The discovery of different strains of α-syn fibrils with 
distinct templating activity in this study may offer a potential explanation for both the convergence 
and divergence of neurodegenerative diseases. 
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CHAPTER 2: SEEDING OF NORMAL TAU BY PATHOLOGICAL TAU CONFORMERS 
DRIVES PATHOGENESIS OF ALZHEIMER-LIKE TANGLES* 
*This research was originally published in Journal of Biological Chemistry. Guo, J.L., and Lee, 
V.M. Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-
like tangles. The Journal of biological chemistry. 2011; 286:15317-15331. © the American Society 
for Biochemistry and Molecular Biology. 
2.1 Abstract 
Neurofibrillary tangles (NFTs) in Alzheimer’s disease and related tauopathies are 
comprised of insoluble hyperphosphorylated tau protein, but the mechanisms underlying the 
conversion of highly soluble tau into insoluble NFTs remain elusive. Here we demonstrate that 
introduction of minute quantities of misfolded preformed tau fibrils (tau pffs) into tau-expressing 
cells rapidly recruit large amounts of soluble tau into filamentous inclusions resembling NFTs with 
unprecedented efficiency, suggesting a “seeding”-recruitment process as a highly plausible 
mechanism underlying NFT formation in vivo. Consistent with the emerging concept of prion-like 
transmissibility of disease-causing amyloidogenic proteins, we found that spontaneous uptake of 
tau pffs into cells is likely mediated by endocytosis, suggesting a potential mechanism for the 
propagation of tau lesions in tauopathy brains. Furthermore, sequestration of soluble tau by pff-
induced tau aggregates attenuates microtubule over-stabilization in tau-expressing cells, 
supporting the hypothesis of a tau loss-of-function toxicity in cells harboring NFTs. In summary, 
our study establishes a cellular system that robustly develops authentic NFT-like tau aggregates 
which provides mechanistic insights into NFT pathogenesis and a potential tool for identifying tau-
based therapeutics. 
2.2 Introduction 
Neurodegenerative tauopathies, including Alzheimer’s disease (AD) and frontotemporal 
dementias (FTD), are characterized by neurofibrillary tangles (NFTs) composed of intracellular 
hyperphosphorylated tau aggregates (Goedert et al., 1988; Kosik et al., 1986; Lee et al., 1991; 
Pollock et al., 1986). Predominantly expressed in neurons, tau is a microtubule (MT)-binding 
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protein which stabilizes and promotes the assembly of MTs (Drechsel et al., 1992; Witman et al., 
1976), and the tau-MT interactions are negatively regulated by phosphorylation of tau (Biernat et 
al., 1993; Bramblett et al., 1993). In adult brains, alternative splicing of the MAPT gene 
(Andreadis et al., 1992; Goedert et al., 1989) generates 6 tau isoforms containing either 3 or 4 
MT-binding repeats (3R or 4R tau) and 0-2 N-terminal inserts (0N, 1N or 2N tau). 
A naturally unfolded soluble protein under normal conditions, tau acquires highly-ordered 
β-pleated sheet structures as it assembles into insoluble, hyperphosphorylated, 15-20 nm-
diameter paired helical filaments as well as less frequent straight filaments that constitute NFTs in 
AD and related tauopathies (Berriman et al., 2003; Kidd, 1963). Mechanisms underlying such 
dramatic conversions remain a conundrum. Significant correlations of total NFT burden with 
cognitive decline are observed in AD patients (Arriagada et al., 1992; Wilcock and Esiri, 1982) 
and, importantly, discoveries of over 30 dominantly inherited mutations in the MAPT gene in FTD 
with Parkinsonism linked to chromosome 17 (FTDP-17) (Goedert and Jakes, 2005; Hutton et al., 
1998; Rizzu et al., 1999; Spillantini et al., 1998c) strongly suggest a causal link between tau 
abnormality and neuronal dysfunction. Although the exact mechanisms of tau-mediated 
neurodegeneration are not well understood, both the loss of the MT-binding function of tau due to 
sequestration of soluble tau into tangles and toxic gains of function owing to the sheer physical 
occupancy of large intracellular aggregates have been proposed to explain the dire 
consequences of tau aggregation (Ballatore et al., 2007; Lee et al., 1994).  
A cellular system recapitulating features of tauopathies would provide a useful tool to 
study the cause and consequences of tau aggregation. However, because tau is a highly soluble 
protein, overexpressed tau resists aggregation despite spontaneous hyperphosphorylation in 
most cell lines. Moreover, high expression of tau over-stabilizes MTs and inhibits cell division, 
and is therefore not well tolerated by dividing cultured cells (Kanai et al., 1989; Vogelsberg-
Ragaglia et al., 2000). Thus, our current understanding of tau fibrillization has relied on studies 
using cell-free systems in which the formation of tau amyloid fibrils is greatly enhanced by 
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polyanionic factors (Chirita et al., 2003; Goedert et al., 1996; Kampers et al., 1996). It has been 
shown that the MT-binding repeats of tau are both necessary and sufficient for in vitro 
fibrillization, and the repeat domain alone assembles into fibrils more readily than full-length tau 
(Wille et al., 1992). Importantly, tau fibril assembly occurs by a nucleation-dependent mechanism, 
whereby the formation of oligomeric intermediates constitutes an initial lag phase followed by a 
relatively rapid elongation phase (Friedhoff et al., 1998). Therefore, “seeding” tau fibrillization 
reactions with preformed tau fibrils (tau pffs) can bypass the rate-limiting nucleation step and 
accelerate fibrillization of monomeric tau. We hypothesized that similar “seeding” strategies could 
be employed to promote tau aggregation in cultured cells, and in fact several recent cell culture 
studies have demonstrated induction of intracellular aggregates by exogenously derived amyloid 
fibrils from several disease proteins involved in neurodegenerative disorders, including tau (Frost 
et al., 2009; Luk et al., 2009; Nonaka et al., 2010; Ren et al., 2009). Moreover, two recent studies 
on transgenic mice demonstrated the induction of wt tau pathology by injection of brain extracts 
containing mutant tau aggregates (Clavaguera et al., 2009) or by expression of truncated tau that 
is aggregation-prone (de Calignon et al., 2010), exemplifying the in vivo relevance of seeded 
aggregation of tau. However, although two previous studies claimed to have demonstrated the 
recruitment of soluble tau into insoluble aggregates in cultured cells (Frost et al., 2009; Nonaka et 
al., 2010), it is unclear if these tau aggregates resemble NFTs. Here, we provide unequivocal 
evidence for the “seeding” phenomenon in cultured cells by demonstrating high efficiency 
recruitment of endogenous tau into authentic NFT-like aggregates. Furthermore, the 
establishment of a cellular system with significant number of NFT-like aggregates enables 
investigation on the pathological mechanisms of tau tangle formation as well as cellular 
transmission of pathological tau which are more difficult to be studied in animal models.  
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2.3 Results 
Intracellular tangle-like aggregates can be induced by preformed fibrils (pffs)  
To explore the capability of tau pffs to seed intracellular fibrillization of soluble tau, QBI-
293 cells were transiently transfected with wild type T40 (wt-T40), the longest human  tau isoform 
(2N4R), and transduced with pffs generated from myc-tagged full-length human tau (myc-T40) or  
 
Figure 2-S1. Negative stained transmission electron microscopy of preformed fibrils. Fibrils were 
assembled from recombinant myc-T40 (A and B), myc-K18 (C and D), or myc-K18/P301L (E and F). 
(A), (C) and (E) show unsonicated fibril preparation; (B), (D) and (F) show sonicated fibrils used for 
transduction experiments. Magnification: 100,000x. Scale bar: 200 nm.
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truncated tau containing only the 4 MT-binding repeats (myc-K18) (Fig. 2-S1) using BioPORTER 
protein delivery reagent. Unlike wt-T40-expressing cells treated with transduction reagent alone, 
in which phosphorylated tau recognized by monoclonal antibody (mAb) PHF-1 (pSer396/404) 
was completely soluble and extracted by 1% Triton-X100 during fixation (Figure 2-1A), cells 
transduced with either myc-T40 or myc-K18 tau pffs showed accumulations of Triton-insoluble 
fibrillar phospho-tau aggregates (Figure 2-1B). These induced aggregates were also detected by 
anti-phospho-tau mAb AT8 (pSer202/pThr205) and conformation-dependent mAb MC-1 (Figure 
2-1C) which specifically recognizes tau in a pathological conformation (Jicha et al., 1997). 
Interestingly, pff-induced aggregates exhibited a variety of morphologies, ranging from widely 
distributed short fibrils, skein-like accumulations, to localized dense NFT-like inclusions and 
sometimes a mixture of phenotypes (Figure 2-1C).  
Significantly, double-labeling immunofluorescence in wt-T40-expressing cells using anti-
myc antibody to detect myc-K18 and myc-T40 pffs, and PHF-1 to detect phosphorylated T40 
showed that anti-myc only labeled a fraction of the fibrils detected by PHF1, thus supporting a 
“seeding” and recruitment mechanism of tau aggregate formation (Figure 2-1B). Moreover, 
phosphorylated tau was non-existent or rare in non-transfected cells transduced with myc-T40 
pffs, suggesting a lack of phosphorylation of internalized full-length fibrils (data not shown). 
Furthermore, since epitopes recognized by these three tau specific mAbs (PHF-1, AT8 and MC-
1) are absent from myc-K18, their immunoreactivities in myc-K18 fibril transduced cells can be 
entirely attributed to endogenously expressed wt-T40. Thus, exogenously supplied tau pffs do not 
constitute the insoluble phospho-tau species we detect in wt-T40 cells treated with pffs. Finally, 
accumulation of insoluble tau aggregates failed to occur when pffs were transduced into cells 
expressing fibrillization-incompetent tau with K311D mutation (data not shown), further confirming 
the de novo fibrillization of soluble tau in wt-T40-expressing cells. 
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Figure 2-1. Tau pffs seed endogenous tau fibrillization in wtT40-transfected QBI-293 
Cells. (A). Phosphorylated tau recognized by phospho-tau antibody PHF-1(green) was 
completely soluble in wtT40-transfected cells treated with BioPORTER reagent alone. Soluble 
proteins were extracted by 1% Triton-X100 during fixing in (b) but not in (a). (B). Intracellular 
accumulation of insoluble tau recognized by PHF-1 can be induced by both myc-T40 and 
myc-K18 pffs transduced using BioPORTER reagent. Exogenous pffs were immunostained 
with polyclonal anti-myc antibody (red). (C). Induced tau aggregates showed a range of 
morphologies which can be recognized by phospho-tau antibody AT8 and conformational-
dependent antibody MC-1. In (B) and (C), cells were extracted with 1% Triton-X100 during 
fixing. In all panels, cell nuclei were stained by DAPI (blue). Magnification: 20x for (A); 40x for 
(B) and (C). Scale bars: 100 µm for (A); 10 µm for (B) and (C). 
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P301L mutation enhances seeded recruitment of endogenous tau  
To assess the efficacy of recruitment by pffs of 4R tau, with or without N-terminal inserts, 
as well as disease-associated mutant tau, fibril transduction was performed on QBI-293 cells 
transiently transfected with human T43 (0N4R), T40/∆K280 (FTDP-17 mutation in the MT-binding 
domain), T40/P301L (FTDP-17 mutation in the MT-binding domain), and T40/R406W (FTDP-17 
mutation outside the MT-binding domain). Quantification of the percentage of aggregate-bearing 
cells induced by these various combinations revealed a similar extent of aggregation in T43- and 
T40-transfected cells upon myc-K18 fibril transduction (about 8% of cells had aggregates with 
either treatment), suggesting the number of N-terminal inserts does not affect fibrillization (Table 
2-1). Among the dominantly inherited tau mutations in FTDP-17 studied here, T40 with the P301L 
mutation demonstrated the highest propensity of pff-induced aggregation. Specifically,  
transduction of myc-K18 pffs and myc-K18 pffs with P301L mutation (myc-K18/P301L fibrils) led 
to about 20% and 35% of cells bearing aggregates, respectively (Table 2-1), corresponding to 
~40% and ~70% of the transfected cells assuming 50% transfection efficiency (Figure 2-2A). 
Although myc-K18/P301L fibrils appeared to be better “seeds” for T40/P301L recruitment as 
monitored by number of aggregate-bearing cells, they were comparable to, or even slightly less 
efficient than, myc-K18 fibrils in nucleating the fibrillization of wt-T40 (Table 2-1). Enhanced 
aggregation of T40/P301L as compared to wt-T40 corresponded to significantly more 
accumulation of Triton-insoluble tau as shown on immunoblots (compare Figure 2-2B with Fig. 2-
S2B). The induced tau aggregates were also Sarkosyl-insoluble, with the immunoblot of Sarkosyl 
extraction indistinguishable from that of Triton extraction (Fig. 2-S3). 
Quantification by tau sandwich ELISA indicated that myc-K18/P301L pffs always resulted 
in higher amounts of Triton-insoluble T40/P301L tau than myc-K18 pffs, confirming a more 
efficient recruitment of soluble tau with the combination of myc-K18/P301L pffs and T40/P301L-
expressing cells (Figure 2-2C). Interestingly, both myc-K18 and myc-K18/P301L pff transduction 
on T40/P301L-expressing cells invariably led to a reduction of Triton-soluble tau when compared  
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Figure 2-2. P301L mutation enhances pff-induced aggregation. (A). QBI-293 cells were 
transiently transfected with T40 with P301L mutation (T40/P301L) and transduced with myc-
K18 fibrils (a) or myc-K18/P301L fibrils (b) using BioPORTER reagent. Abundant tau 
aggregates were detected using mAb PHF-1 (green) after simultaneous 1% Triton-X100 
extraction during fixation to remove soluble proteins. (B). Sequential extraction was 
performed on T40/P301L-transfected cells treated with Bioporter reagent alone (control), or 
with myc-K18 fibrils (K18 fib) or myc-K18/P301L fibrils (K18/PL fib). T: cellular fraction 
recovered in 1% Triton-X100 lysis buffer. S: Triton-insoluble fraction solubilized in 1% SDS 
lysis buffer. Equal proportions of Triton and SDS fractions were loaded on SDS-PAGE gels. 
Immunobloting with polyclonal tau Ab 17025 and PHF-1 revealed accumulation of abundant 
Triton-insoluble tau in fibril transduced cells. GAPDH served as a loading control. (C). 
Sandwich tau ELISA on cell lysates from 4 independent experiments confirmed induction of 
significant amount of Triton-insoluble tau with fibril transduction which was always 
accompanied by a reduction in soluble tau. Magnification: 40x. Scale bar: 50 µm. 
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Figure 2-S2. Comparison of myc-K18 and mycK18/P301L pff transduction on wtT40-
expressing cells. (A). Triton-insoluble tau aggregates in wtT40-transfected cells with myc-
K18 (a) or myc-K18/P301L (b) fibril transduction. Green: PHF-1 staining with soluble proteins 
removed by 1% Triton-X100 during fixing. (B). Small amount of Triton-insoluble tau could be 
detected on western blot with both myc-K18 and myc-K18/P301L pff transduction (K18 fib and 
K18/PL fib respectively). T: cellular fraction recovered in 1% Triton-X lysis buffer. S: Triton-
insoluble fraction solubilized in 1% SDS lysis buffer. Equal proportions of Triton and SDS 
fractions were loaded on SDS-PAGE gels. Magnification: 40x. Scale bar: 50 µm. 
 
Figure 2-S3. Immunoblots of Sarkosyl extraction are indistinguishable from that of 
Triton-X100 extraction. Cells transfected with T40/P301L and treated with transduction 
reagent alone (control) or transduced with myc-K18 or myc-K18/P301L fibrils (K18 fib and 
K18/PL fib respectively) with reagent were sequentially extracted with 1% Sarkosyl lysis 
buffer (S) followed by 1% SDS lysis buffer (D). Immunoblotting using polyclonal tau Ab 17025 
and mAb phospho-tau Ab PHF-1 showed abundant Sarkosyl-insoluble tau induced by pff 
transduction. Equal proportions of Sarkosyl and SDS fractions were loaded on SDS-PAGE 
gels. 
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with non-transduced cells, further supporting that the accumulation of insoluble tau is through 
sequestration/recruitment of soluble tau.   
Intriguingly, live immunostaining followed by immunofluorescence after fixation and 
permeabilization (two-stage staining) revealed that the majority of pffs associated with cells were 
merely membrane-associated despite extensive trypsinization before replating cells to coverslips, 
while only a small amount of pffs were truly internalized (Figure 2-3A). Moreover, double labeling 
using anti-myc antibody and PHF-1 in cells extracted with 1% Triton X-100 showed that less than 
half of the induced aggregates contained detectable colocalizing pffs (Figure 2-3B), suggesting 
that small amounts of pff seeds are sufficient to induce robust endogenous tau fibrillization. 
Pff-induced tau aggregates are comprised of filamentous NFT-like amyloid structures.  
Immuno-EM using PHF-1 revealed abundant cytoplasmic filaments in pff-transduced 
cells (Figure 2-4) but not in those treated with transduction reagent alone. Moreover, diverse 
organelles, including mitochondria, lysosomes and other vesicular structures, were detected 
within and adjacent to PHF-1 positive filamentous structures (Figures 2-4A (a),(b)). The lack of 
diffuse PHF-1 staining in the cytoplasm outside of the PHF inclusions further supports the 
concept of “seeding” and recruitment of soluble tau to form NFT-like structures in pff-transduced 
cells. 
To examine the progression of pff-induced endogenous tau aggregation, we fixed cells at 
different time points after the addition of pff/reagent complex. At t = 1 hr, there was little 
accumulation of Triton-insoluble tau, except for a few rare cells showing focal PHF-1 
immunoreactivities with small but intensely labeled inclusions surrounded by slender, discrete 
fibrillar structures (Fig. 2-S4A). At t = 3 hr, focal inclusions became more frequent and a small 
population of cells developed skein-like accumulations throughout the cytoplasm (Figure 2-5A). It 
is noteworthy that the earliest focal accumulations were almost always colocalized with myc 
immunoreactivities, suggesting that aggregation first begins in cells containing more abundant 
fibril seeds which rapidly initiate the conversion of endogenous tau into insoluble aggregates  
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Figure 2-3. Internalization of small quantities of tau pffs is sufficient to induce robust 
tau aggregation. QBI-293 cells were transiently transfected with mutant T40/P301L tau and 
transduced with myc-K18/P301L pffs using BioPORTER reagent. (A). Incubation of fibril 
transduced cells with polyclonal anti-myc antibody before fixing (live, red) followed by staining 
of fixed and permeabilized cells with anti-myc mAb 9E10 (fixed, green) showed extensive 
colocalization, suggesting the majority of the pffs detected were merely extracellularly 
associated with cell membranes. Arrows point to truly internalized fibrils which were only 
recognized by 9E10 applied to fixed and permeabilized cells but not polyclonal anti-myc 
antibody used on live cells. (B). Double-labeling of phospho-aggregates by PHF-1 (green) 
and exogenous pffs by polyclonal anti-myc (red) showed very little colocalization. Arrows 
point to aggregates with colocalizing pff seeds. Aggregates without arrows do not contain 
obvious pff seeds. Magnification: 20x. Scale bar: 100 µm. 
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Figure 2-4. Pff-induced tau aggregates consist of filamentous structures. T40/P301L-
transfected QBI-293 cells were transduced with myc-K18/P301L fibrils using BioPORTER 
reagent. (A). Immuno-EM using mAb PHF-1 showed abundant filamentous tau aggregates in 
the cytoplasm. Arrows indicate mitochondria and/or vesicular structures in close association 
with tau fibrils. (B). Routine EM showing tau fibrils. Magnification: 12,000x for (A) (a); 30,000x 
for (A) (b); 50,000 for (B). Scale bars: 2 µm for (A) (a); 500 nm for (A) (b) and (B). 
 
Figure 2-S4. Pff-induced tau aggregates at early time points. (A). One hour after the 
addition of myc-K18/P301L fibril/BioPORTER reagent complex to T40/P301L-transfected 
cells, a few rare cells showed local accumulation of insoluble tau (PHF-1) colocalizing with 
exogenous pffs (myc). (B). Up to t = 3 hr after fibril addition, ThS staining entirely overlapped 
with pff staining (myc). 1% Triton-X100 was added during fixing to remove soluble proteins. 
Magnification: 40x for (A); 20x for (B). Scale bar: 10 µm in (A); 100 µm in (B). 
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Figure 2-5. Time-dependent development of insoluble tau aggregates. QBI-293 cells 
transfected with T40/P301L mutant tau were transduced with myc-K18/P301L fibrils using 
BioPORTER reagent. (A). At t = 3 hr after the addition of fibril/reagent complex, a small 
percentage of cells started showing accumulations of insoluble tau (PHF-1) with focal 
inclusions colocalizing with pff staining (myc). (B). At t = 6 hr, more cells developed 
aggregates, most of which are skein-like and diffusely distributed throughout the cytoplasm. A 
small population of cells showed ThS-positive large aggregates. (C). Large aggregates 
recognized by ThS were more frequently seen at t = 24 hr after fibril addition. Soluble proteins 
were extracted by 1% Triton-X100 during fixing for all. Magnification: 40x. Scale bar: 50 µm. 
 
through physical recruitment. At t = 6 hr, insoluble tau was found in about 4% of total cells; 
although diffuse fibrillar accumulations remained the most common phenotype at this stage, 
some aggregates started showing signs of coalescence, and large compact inclusions appeared 
in a small subset of cells (Figure 2-5B). Twenty-four hr after fibril transduction, about 25% of total 
cells were replete with Triton-insoluble tau, with a significant portion of cells bearing large, 
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densely packed aggregates (Figure 2-5C). Thioflavin S (ThS) was used to determine if pff-
induced tau aggregates form amyloid fibrils. Up to t = 3 hr, ThS staining completely overlapped 
with myc immunoreactivities, indicating exclusive recognition of β-pleated sheet in myc-
K18/P301L pffs (Fig. 2-S4B). ThS staining that colocalized with PHF-1 positive endogenous tau 
aggregates first emerged at t = 6 hr, and became more abundant at t = 24 hr (Figure 2-5B,C). 
Interestingly, only the large compact aggregates, but not diffuse skein-like inclusions, were 
recognized by ThS. We speculate that dispersed fibrillar aggregates probably represent early fibril 
species which eventually coalesce and mature into β sheet-rich inclusions.  
Newly synthesized tau is recruited rapidly into insoluble tau fibrils  
To directly monitor the recruitment of newly synthesized tau into insoluble aggregates, we 
performed pulse-chase experiments on myc-K18/P301L pff-transduced T40/P301L-expressing 
cells. In cells treated with transduction reagent alone, [35S]-radiolabeled tau remained soluble 
over a 6 hr chase period despite a time-dependent electrophoretic mobility shift indicative of 
phosphorylation of the newly synthesized tau. In contrast, an increasing proportion of 
radiolabeled T40/P301L tau emerged in the Triton-insoluble fraction of fibril-transduced cells, 
accompanied by more rapid reduction of soluble tau than in the control cells, demonstrating 
active recruitment of newly synthesized tau into an insoluble pool (Figure 2-6). After 1 hr chase, 
an appreciable amount of T40/P301L tau was already detected in the insoluble fraction, 
highlighting the rapid solubility change of tau in the presence of misfolded seeds. Moreover, the 
detection of slower migrating insoluble radiolabeled tau suggests continuous recruitment of 
soluble tau that is being modified by phosphorylation over time. 
Reduced MT stability is associated with tau aggregation  
Consistent with previous studies in other cell lines, overexpression of tau in QBI-293 cells 
led to the formation of thick MT bundles due to excessive stabilization of MTs (Kanai et al., 1989; 
Matsumura et al., 1999). We hypothesized that seeded recruitment of tau into insoluble fibrils 
may attenuate the over-stabilization of MTs by sequestering the soluble pool of tau. As expected,  
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Figure 2-6. Newly synthesized tau is rapidly recruited into insoluble aggregates. One 
day after myc-K18/P301L fibril transduction on QBI-293 cells transiently transfected with 
T40/P301L, cells were pulsed with [35S]-methionine for 20 min and chased for different 
durations (0 to 6 hr). Cell lysates were sequentially extracted using 1% Triton-X100 followed 
by 1% SDS lysis buffer, and tau was immunoprecipitated from both fractions with mAbs T46 
and Tau 5. Equal proportions of Triton (T) and SDS (S) fractions were loaded on SDS-PAGE 
for autoradiography. (A). Autoradiograph indicating that newly synthesized tau remained 
soluble in cells treated with reagent alone (Rg control) but rapidly turned insoluble in fibril-
transduced cells (Fib Td). (B). Quantification from 2 independent experiments showing the 
distribution of radiolabeld tau in the soluble and insoluble fractions over time (Error bar: 
standard error). 
 
T40/P301L-expressing cells that were transduced with myc-K18 or myc-K18/P301L pffs showed 
significantly less MT bundling revealed by immunostaining of acetylated-tubulin (Ac-tub), a 
marker of stable MTs, as compared to those treated with transduction reagent alone (~40% and 
~60% reduction in the percentage of cells with MT bundles by myc-K18 and myc-K18/P301L pff 
transduction respectively) (Figure 2-7A,C). The majority of cells with aggregates showed an 
absence of MT bundles and cells that retained bundles typically showed diffuse tau staining 
(Figure 2-7B). Reduced Ac-tub levels associated with pff-induced aggregation was further 
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confirmed using an Ac-tub sandwich ELISA (Figure 2-7D). In addition, there was a significant 
correlation between Ac-tub level and soluble tau, but not insoluble tau, suggesting that the loss of 
soluble tau rather then aggregation per se was responsible for the reduced MT stability (Figure 2-
7E,F). This observation likely accounts for the occasional MT bundles observed in cells carrying 
aggregates (data not shown). 
Spontaneous fibril uptake is mediated by endocytosis  
To determine if tau pffs can be taken up spontaneously in the absence of protein delivery 
reagent, we incubated T40/P301L-transfected cells with myc-K18/P301L pffs for 30 hr, followed 
by trypsinization and incubation for an additional 18 hr. Aggregation of endogenous tau was 
detected in about 10% of total cells, accompanied by appreciable accumulation of Triton-insoluble 
tau detected on immunoblots (Figure 2-8A(a),B). Interestingly, exogenous pffs were barely visible 
by immunostaining (Figure 2-8E), suggesting that internalization of minute quantities of pffs 
without transduction reagent is sufficient to induce recruitment of endogenous tau into fibrils. To 
investigate whether this uptake of tau pffs occurs by endocytosis, we incubated T40/P301L-
expressing cells with myc-K18/P301L pffs for 4 hr at either 37°C or 4°C; the latter temperature 
blocks endocytosis. Since the amount of pff internalized by cells is too low to be easily detected 
by either immunostaining or immunoblotting (Figure 2-8E,F), we quantified Triton-insoluble 
endogenous tau aggregates as an indirect readout of pff entry. Pff incubation at 37°C for 4 hr 
prior to trypsinization and an additional 44 hr incubation resulted in ~ 3% of total cells with tau 
inclusions, whereas 4 hr pff incubation at 4°C followed by exactly the same treatments resulted in 
a dramatic and significant reduction in the percentage of tau aggregate-bearing cells (Figure 2-
8A,C,D), suggesting pff uptake is a temperature-dependent process. The small number of cells 
with tau aggregates (~0.5% of total cells) detected after 4°C pff incubation could be due to the 
internalization of residual membrane-associated fibrils following trypsinization and additional 
incubation. Moreover, the difference in the extent of aggregation induced by 4 hr versus 30 hr 
incubation of pffs (~3% vs. ~10% aggregate-bearing cells) indicated a time-dependent  
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Figure 2-7. Tau aggregation results in reduced MT stability. (A). QBI-293 cells transfected with 
T40/P301L and transduced with Myc-K18 (K18 fib) or myc-K18/P301L (K18/PL fib) pffs showed 
significant reductions in MT-bundling compared to control cells treated with BioPORTER transduction 
reagent alone (control), as revealed by acetylated-tubulin (Ac-tub) staining. (B). Double-staining of PHF-
1 and Ac-tub showed that cells with MT bundles usually showed diffuse tau immunostaining (arrows), 
whereas those with tau aggregates often lacked bundling (arrow heads). (C). Quantification from 3 
independent experiments demonstrated statistically significant reduction in the percentage of cells with 
MT bundles in the presence of fibril transduction (Error bar: standard error; *: p < 0.05). (D). Ac-tub 
sandwich ELISA on samples from 4 independent experiments showed significant decrease in Ac-tub 
levels associated with fibril transduction (Error bar: standard error; *: p < 0.05). (E,F). Ac-tub and tau 
sandwich ELISA revealed highly significant correlation of Ac-tub levels with Triton-soluble tau (E: p < 
0.0005), but not with Triton-insoluble tau (F: p > 0.05), across control and fibril transduced samples from 
4 independent experiments. Magnification: 20x for (A); 40x for (B). Scale bar: 100 µm for (A); 50 µm for 
(B). 
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Figure 2-8. Spontaneous uptake of pffs without transduction reagent also induces intracellular 
tau aggregation. (A). T40/P301L aggregation induced by myc-K18/P301L pffs alone after 30 hr 
incubation at 37°C (a) or 4 hr incubation at 37°C (b). Minimal aggregation was observed with 4 hr 
incubation at 4°C (c). For all conditions, cells were trypsinized and replated after the designated 
incubation period and fixed 48 hr after the initial addition of fibrils. Soluble proteins were extracted with 
1% Triton-X100 during fixing. White: PHF-1. (B). 48 hr incubation with myc-K18/P301L pffs at 37°C led 
to significant accumulation of Triton-insoluble T40/P301L detected on immunoblots. Control cells were 
transfected with T40/P301L without fibril transduction. (C). 4 hr incubation with myc-K18/P301L fibrils at 
37°C but not at 4°C resulted in detectable T40/P301L Triton-insoluble aggregates. (D). Quantification 
from 4 independent experiments showed significant reduction in aggregate-bearing cells when a 4 hr 
fibril incubation was performed at 4°C instead of 37°C (Error bar: standard error; *: p < 0.05 compared to 
4 hr incubation at 37°C). Thirty-hour incubation with tau pffs at 37°C resulted in the highest incidence of 
aggregates (n = 3; Error bar: standard error; **: p < 0.01 compared to 4 hr incubation at 37°C). (E). Myc-
tagged pffs were barely visible in cells transduced with fibrils alone without BioPORTER reagent. White: 
anti-myc Ab. (F). Exogenous myc-tagged tau pffs were non-detectable with anti-myc mAb 9E10 via 
immunoblot under various transduction paradigms: transduction of pffs with BioPORTER reagent (fib Td 
with Rg), 30 hr incubation with pffs alone (30hr fib alone), or 4 hr incubation with fibrils alone (4hr fib 
alone). Cells were trypsinized and replated to new wells after the designated incubation time so that the 
majority of extracelluarly associated pffs were removed. Total fib input: the amount of tau pffs used for 
transduction was added to cells immediately before lysing. *: non-specific bands. For (B), (C) and (F), T: 
1% Triton-X100 fraction; S: 1% SDS fraction. Equal proportions of Triton and SDS fractions were loaded 
on SDS-PAGE gels. Magnification: 20x. Scale bar: 100 µm. 
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internalization of fibrils (Figure 2-8D). These results suggest spontaneous uptake of pffs probably 
occurs by endocytosis. 
Adsorptive endocytosis enhances tau pff uptake  
To further explore potential mechanisms of endocytosis-mediated pff entry, we incubated 
cells with pffs in the presence of WGA, a plant lectin that has high affinity for N-acetyl 
glucosamine (GlcNAc) and sialic acid on the plasma membrane and is readily internalized by 
cells via adsorptive endocytosis (Broadwell et al., 1988; Gonatas and Avrameas, 1973). Apart 
from being a substrate of the endocytic pathway, WGA was also shown to potentiate the uptake 
of other proteins mediated by the same endocytic pathway (Banks et al., 1998; Banks et al., 
1997). Interestingly, we found that WGA increased the prevalence of tau aggregate-bearing cells 
(Figure 2-9A,B) and the amount of Triton-insoluble tau in fibril transduced cells (Figure 2-9C) in a 
dose-dependent manner, which paralleled increased cellular association with pffs (Figure 2-9D). 
Without WGA treatment, there was minimal fibril staining even without trypsinization. Increasing 
the dose of WGA not only led to progressively more abundant cell-associated pffs, but two-stage 
staining revealed that a substantial percentage of these fibrils were indeed intracellular (Figure 2-
9E). Furthermore, the effects of WGA on pff uptake and tau aggregation were significantly 
attenuated by adding 0.1 M GlcNAc to the medium, which reduces WGA-plasma membrane 
interactions through competition with GlcNAc on the plasma membrane (Gonatas and Avrameas, 
1973), suggesting that WGA-mediated induction of adsorptive endocytosis is necessary for 
increased pff uptake and augmented tau aggregation (Fig. 2-S5B and Figure 2-9F,G). On the 
other hand, up to 15 µg/ml of WGA does not increase the expression level of tau, nor does it 
induce accumulation of insoluble tau in the absence of pffs (Fig. 2-S5A). Therefore, increased 
intracellular tau aggregate formation by WGA treatment is primarily due to enhanced 
internalization of pffs. Taken together, spontaneous pff entry seems to occur at least in part 
through adsorptive endocytosis which can be potentiated by WGA. 
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Figure 2-9. Wheat germ agglutinin (WGA) promotes pff-induced tau aggregation by 
enhancing spontaneous pff uptake. (A). T40/P301L-transfected cells were incubated with 
myc-K18/P301L pffs in the presence of 0, 5, 10 and15 µg/ml of WGA (0, 5, 10, 15) without 
BioPORTER reagent. Increasing dose of WGA resulted in more frequent phospho-tau 
aggregates. Green: PHF-1 with 1% Triton-X100 added during fixing. (B). Quantification from 3 
independent experiments indicated that WGA dose-dependently increased the percentage of 
cells with aggregation (Error bar: standard error; *: p < 0.05; **: p < 0.01). (C). WGA treatment 
increased accumulation of Triton-insoluble tau shown on immunoblots. T: 1% Triton-X fraction; 
S: 1% SDS fraction. Equal proportions of Triton and SDS fractions were loaded on SDS-PAGE. 
(D). WGA also dose-dependently (0, 5, 10 and15 µg/ml) increased the amount of cell-associated 
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pffs revealed by myc immunoreactivities (red). (E). Two-stage immunostaining (see method 
section) performed on cells treated with 15 µg/ml of WGA showed frequent occurrence of truly 
internalized pffs that were only labeled by 9E10 (green, fixed) applied to fixed and permeabilized 
cells but not polyclonal anti-myc antibody incubated with live cells (red, live). Arrows point to 
examples of truly intracellular pffs. (F). N-acetyl glucosamine (GlcNAc), which inhibits binding of 
WGA to plasma membrane, dramatically attenuated the aggregation-enhancing effects of WGA. 
(G). Quantification from 3 independent experiments showed significant reduction of tau 
aggregation in WGA-treated fibril transduced cells in the presence of GlcNAc (Error bar: 
standard error; *: p < 0.05). Magnification: 20x in (A) and (F); 40x in (D) and (E). Scale bars: 100 
µm in (A) and (F); 50 µm in (D) and (E). 
 
 
Figure 2-S5. WGA promotes pff association with cells without changing tau expression 
levels. (A). Cells transiently transfected with T40/P301L mutant tau were treated with 
different doses of WGA. WGA did not dose-dependently increase the expression level of tau 
and there was no accumulation of Triton-insoluble tau without fibril transduction. T: 1% Triton-
X fraction; S: 1% SDS fraction. Equal proportions of Triton and SDS fractions were loaded on 
SDS-PAGE.  (B). Enhanced cellular association with pffs induced by WGA was blocked by 
GlcNAc treatment. Red: Pffs recognized by polyclonal anti-myc Ab. Magnification: 40x. Scale 
bar: 50 µm. 
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2.4 Discussion 
Our study convincingly demonstrates that exogenously supplied tau pff seeds can recruit 
soluble endogenous tau into insoluble fibrillar aggregates which highly resemble NFTs based on 
a variety of criteria, including immunofluorescence, amyloid dye binding, immuno-EM and 
biochemical analysis. Interestingly, a small quantity of internalized tau pffs appears sufficient to 
recruit and sequester large amounts of endogenous tau into filamentous tau inclusions. 
Sequestration of soluble tau by pff-induced aggregation significantly attenuates MT over-
stabilization resulting from tau overexpression, supporting the concept that there is a reduction of 
soluble tau in neurodegenerative tauopathies. Intriguingly, substantial aggregation of soluble tau 
can also be induced by the spontaneous uptake of pffs, which seems to occur via adsorptive 
endocytosis that is potentiated by the plant lectin WGA, demonstrating a cellular transmissibility 
of tau pathology. 
Although the uptake and “seeding” capacity of preformed tau fibrils in cultured cells was 
reported recently (Frost et al., 2009; Nonaka et al., 2010), the induction and formation of 
intracellular aggregates in our current study are fundamentally different from those previous 
studies in several ways. First, the intracellular aggregates induced in our model are 
morphologically different from previous studies. The inclusions we observed are clearly fibrillar in 
nature and mature into β-pleated sheet rich fibrils recognized by ThS. Second, similar to tau 
tangles detected in AD and other tauopathies, the intracellular aggregates exhibit a diversity of 
morphologies, ranging from spatially distributed skein-like accumulations to large and densely 
packed aggregates, which probably represent different stages of aggregation. Third, unlike 
previous reports, detectable pff seeds rarely coincide with the intracellular inclusions in our 
system; instead, the majority of aggregates that are composed of recruited, phosphorylated 
endogenous tau greatly exceed the physical size of the seeds. Fourth, our use of protein delivery 
reagent to augment introduction of pffs into cells provides better efficiency of tau pff entry as 
compared to previous reports. Finally, unlike previous studies that expressed endogenous tau 
tagged with a fluorescent protein, our system employs untagged tau which facilitates recruitment 
40 
 
since the large fluorescent protein tag may interfere with the conformational change required for 
efficient tau fibril assembly. 
For the past 20 years, significant efforts have been devoted to produce cell-based 
models that develop tau aggregates similar to those observed in tauopathies but with little 
success. This is because tau is a highly soluble and naturally unfolded protein, and therefore it 
has been notoriously difficult to make it aggregate in cultured cells. Strategies have been used in 
the past with minimal success to produce tau tangles in cells, including overexpression of 
aggregation-prone tau mutants (Vogelsberg-Ragaglia et al., 2000), overexpression of truncated 
tau that fibrillizes more readily than full-length tau (Khlistunova et al., 2006; Wang et al., 2007), 
addition of pre-aggregated amyloid-beta fibrils (Ferrari et al., 2003), treatment conditions that 
promote tau phosphorylation (Sato et al., 2002), and the addition of aromatic dyes such as Congo 
red to overcome the kinetic barrier of fibrillization (Bandyopadhyay et al., 2007). In our optimized 
system, however, tau aggregation could be rapidly induced within hours after the introduction of 
small quantities of misfolded tau pffs and result in the accumulation of large amounts of insoluble 
tau fibrils. Thus, such robust induction of authentic NFT-like accumulations suggests that a 
seeding-recruitment process is a highly plausible mechanism underlying NFT formation in vivo in 
the absence of tau overexpression. Conceivably, pff-induced aggregation that occurs within 
hours/days in tau-overexpressing cultured cells could be prolonged into a pathological event that 
happens over years or even decades under physiological conditions, i.e. in human brains. 
Although our time-course experiments which reveal close association of pff seeds with 
endogenous phosphorylated tau aggregates at early time points suggest a direct physical 
recruitment of soluble endogenous tau by exogenous pffs to account for the solubility change of 
the former, we do not rule out possible conformational changes of soluble tau templated by 
misfolded seeds before it elongates onto the existing intracellular fibrils. 
Our studies also demonstrate that the formation of intracellular tau tangles can be 
accelerated by FTDP-17 genetic mutations that were shown previously to increase the 
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fibrillization propensity and/or reduce the MT-binding affinity of tau (Hasegawa et al., 1998; Hong 
et al., 1998; Nacharaju et al., 1999; von Bergen et al., 2001). Among the FTDP-17 associated 
mutations (∆K280, P301L and R406W) tested in our model, only P301L, the most aggressive 
disease causing mutation found in FTDP-17 patients, dramatically promoted aggregation. This 
correlates well with the rapid clinical onset and progression observed in FTDP-17 patients (Mirra 
et al., 1999; Spillantini et al., 1998b; van Swieten et al., 1999) and transgenic mice harboring 
P301L mutant tau (Gotz et al., 2001a; Lee et al., 2005; Lewis et al., 2000). However, unlike a 
previous study that was unable to demonstrate recombinant P301L mutant tau seeding wt tau in 
a cell-free system (Aoyagi et al., 2007), we found that wt and P301L mutant tau can cross-seed 
each other readily, although fibril seeds composed of P301L mutant are slightly less efficient in 
recruiting wt-T40 than wt seeds. In addition, the difference in aggregation propensity between wt 
tau and P301L tau observed in our cellular model may be further magnified in a physiological 
setting where tau is not over-expressed. This may explain the absence of insoluble wt tau 
deposition in FTDP-17 patients with P301L mutation (Miyasaka et al., 2001), where the 
overwhelmingly higher fibrillization propensity of P301L mutant tau could mask the much slower 
aggregation of wt tau that may not occur to an appreciable extent during a short disease course.  
Despite lower MT-binding affinity of T40/P301L compared with wt-T40, QBI-293 cells 
transiently over-expressing T40/P301L mutant tau are still capable of MT bundling. Interestingly, 
pff-induced aggregation resulted in significant attenuation of this phenotype. Reduced stable MTs 
is a well-established feature of tauopathy brains (Boutte et al., 2005; Hempen and Brion, 1996; 
Paula-Barbosa et al., 1987), but studies exploring the relationship between compromised MT 
stability and tau aggregation were based on postmortem brain examination and therefore are only 
correlative. Our study demonstrates a direct causal link between tau aggregation and reduced MT 
stability, although we showed earlier that MT stability is reduced following phosphatase inhibitor 
treatment of cultured neurons which increases tau phosphorylation (Merrick et al., 1997). Thus, 
both tau aggregation and hyperphosphorylation could act synergistically to reduce MT stability. 
Significantly, we observed a strong correlation between MT stability and the amount of soluble 
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tau, but not insoluble tau, suggesting depletion of soluble tau into fibrillar aggregates rather than 
aggregates themselves are responsible for a diminution of stable MTs. Although our observations 
were made in an artificial cell system with overexpression of tau, it is highly plausible that tangle 
formation in human brains, where the majority of tau is normally bound to MTs for maintaining 
their stability, could impair the integrity of MTs by a similar mechanism of soluble tau 
sequestration. Given the critical role of MTs in axonal transport and consequently neuronal 
survival, our study supports the loss-of-function hypothesis of NFT toxicity. Consistent with this 
interpretation are studies demonstrating the beneficial effects of MT-stabilizing drugs in mouse 
models of tauopathy without direct modulation of tau aggregation (Brunden et al., 2010; Zhang et 
al., 2005). 
Although our study did not address the origination of misfolded seeds in vivo, we 
discovered that the amount of internalized pffs required for robust aggregation to occur was 
surprisingly small and barely detectable in our system. This finding holds important implications 
for tauopathies: it is conceivable that a small amount of misfolded seeds of tau slowly 
accumulated over decades in post-mitotic neurons can eventually initiate a full-blown cascade of 
massive aggregation of soluble tau, rendering tangle formation a self-perpetuating event once 
initiated. The sonicated pffs we introduced into cells contain a heterogeneous mixture of fibrillar 
species with varying dimensions, and intracellular aggregates that formed without coincident 
detectable pffs were likely seeded by species that were too small to be visualized by light 
microscopy. Further studies are required to characterize the exact biophysical properties of the 
seeding species and to explore possible mechanisms underlying the formation of recruitment-
competent aggregation seeds in vivo. 
Consistent with recent studies pointing to the possible transmissibility of disease-
associated amyloidogenic proteins (Aguzzi and Rajendran, 2009; Goedert et al., 2010), we found 
that tau pffs alone can also induce formation of tangle-like accumulations in a substantial 
population of cells, albeit to a lower extent than in the presence of protein delivery reagent. Our 
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study thus complements an earlier in vivo study on the transmission of tau pathology in mouse 
brains (Clavaguera et al., 2009) by implicating tau fibrils present in the brain extracts as the entity 
solely responsible for the induction and spreading of tau pathology. Moreover, faster induction of 
tau aggregation and easier manipulation of our cell culture model than animal models allow us to 
conduct mechanistic studies that cannot be accomplished in vivo.  In fact, we discovered from our 
cellular system that spontaneous uptake of tau fibrils appears to occur via endocytic pathways 
that are temperature- and time-dependent, and the potentiation of tau aggregate formation by 
WGA treatment suggests that fibril entry is probably mediated, at least partly, by adsorptive 
endocytosis. This indicates a potential mechanism through which aggregated tau released from 
dying/dead neurons or from extracellular ‘ghost tangles’ may gain access into surrounding 
healthy neurons where it nucleates fibrillization of soluble tau. Taken together, our study provides 
further evidence for the “prion-like” properties of tau, and offers plausible explanation for the 
stereotypical propagation of tau pathology in AD brains (Braak and Braak, 1991) and the 
successful application of immunotherapy in ameliorating tau pathology in a mouse model (Asuni 
et al., 2007). Further studies are needed to investigate whether misfolded tau can also be 
routinely secreted into the extracellular space, which would provide additional insight into the 
transmission cycle of tau lesions. 
In summary, we have established a simple, and yet highly reproducible and robust, 
cellular system of tau aggregation recapitulating key features of tauopathies. We have employed 
this system to gain important insights into the onset and progression of tau pathology. Our cell-
based tauopathy model not only provides an invaluable tool for studying the pathogenesis of tau 
aggregation, but also offers a potential system for identifying therapeutic strategies against 
neurodegenerative tauopathies, such as small molecules inhibiting fibrillization of tau or 
antibodies blocking the spontaneous cellular uptake of fibril seeds. 
 
 
44 
 
Table 2-1. % of aggregate-bearing cells with specific combinations of endogenous tau 
transfection (Tf) and fibril transduction. 
 wtT40 
(2N4R) 
T43 (0N4R) T40/P301L T40/∆K280 T40/R406W 
5’myc-K18 ~8% ~8% ~20% ~5% ~6% 
5’myc-
K18/P301L  
~5% NTa ~35% NTa NTa 
a: not tested 
2.5 Materials and Methods 
Reagents and antibodies  
BioPORTER® Quikease™ Protein Delivery Kit for fibril transduction, wheat germ 
agglutinin (WGA) and N-acetyl glucosamine (GlcNAc) were purchased from Sigma. Antibodies 
used in this study are listed and described in Table 2-S1. 
Recombinant tau purification and in vitro fibrillization  
The cDNAs coding for (1) the longest isoform of tau (2N4R) with a myc tag at the 3’ end 
(3’myc-T40), (2) truncated tau containing only 4 MT-binding repeats with a myc tag at the 5’ end 
(5’myc-K18) and (3) 5’myc-K18 containing P301L mutation (5’myc-K18/P301L) were cloned into 
NdeI/EcoRI sites in pRK172 bacterial expression vector. Each protein was expressed in BL21 
(DE3) RIL cells and purified by cationic exchange using a Fast Protein Liquid Chromatography 
(FPLC) column as previously described (34). In vitro fibrillization was conducted by mixing 40 µM 
recombinant tau with 40 µM low-molecular-weight heparin and 2 mM DTT in 100 mM sodium 
acetate buffer (pH 7.0). Except 3’myc-T40 which was agitated at 1,000 rpm for 5 days, the other 
proteins were incubated at 37°C without shaking for 2-3 days. Successful fibrillization was 
confirmed using ThT fluorescence assay, sedimentation test and negative stain electron 
Fibrils 
Tf 
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microscopy (Fig. 2-S1) as previously described (Li and Lee, 2006). Before being used for 
transduction on cells, fibrillization mixture was centrifuged at 100,000g for 30 min at 4°C. The 
resulted pellet was resuspended in equal volume of 100 mM sodium acetate buffer (pH 7.0) 
without heparin and DTT, and frozen as single-use aliquots at -80°C. 
Cell culture and fibril transduction  
QBI-293 cells (QBiogene) were grown in full media (DMEM, 10% FBS) supplemented 
with penicillin/streptomycin and L-glutamine. For fibril transduction, cells were plated at 400K/well 
in a 6-well tissue culture plate one day before transient transfection with WT or mutant tau in 
pcDNA5/TO or pcDNA3.1 (+) using FuGENE® 6 (Roche) as per manufacturer’s instructions at 2 
µg DNA per well. About 16 hr after transfection, resuspended fibril aliquots were diluted into 10 
µM using 100 mM sodium acetate buffer (pH 7.0) and sonicated with 20-30 pulses, 80 µL of 
which was added to one tube of BioPORTER reagent, gently vortexed for 5 sec and allowed to 
stand at room temperature (RT) for 5-10 min. During the formation of pffs/reagent complex, cells 
were washed once with 2 mL OptiMEM (Invitrogen) and placed on 500 µL OptiMEM before the 
fibril-reagent complex was diluted with 420 µL OptiMEM and added to cells. For experiments 
performed on cells plated on 12-well plates, all reagents were reduced by half. Six to seven hr 
after the addition of fibrils, cells were placed on starvation medium (DMEM, 0.5% FBS, 
penicillin/streptomycin, L-glutamine) to reduce cell division, 24 hr after which they were washed 
once with versene/EDTA, incubated with 0.05% trypsin/EDTA for 10 min at 37°C to remove the 
majority of membrane-associated fibrils and replated to poly-D-lysine-coated glass coverslips for 
immunostaining. Fixing was performed one night after replating. 
For fibril-alone transduction without BioPORTER reagent, cells were placed on starvation 
medium right before the addition of fibrils. Fibrils were processed in exactly the same way and the 
same amount was used as in reagent-mediated transduction. Cells were trypsinized and replated 
either 4 hr or 30 hr after the initial addition of fibrils. For experiments using WGA, different doses 
of WGA were added to starvation medium together with pffs. To inhibit endocytosis of WGA, 0.1 
46 
 
M GlcNAc was incubated with medium containing pffs and 10 µg/ml WGA for 1 hr at 37°C before 
being added to cells which were pre-incubated in 0.1M GlcNAc-containing medium for 1 hr. Cells 
were placed on WGA-free starvation medium 5-6 hr after fibril addition and fixed after overnight 
incubation to minimize possible toxicity resulted from WGA treatment. 
No replating was done for biochemical analysis except for experiments attempting to 
quantify cell-associated pffs (Figure 7F) and 4 hr fibril-alone transduction experiments (Figure 7C) 
in which cells were transferred to new 6-well plates after the incubation period. 
Immunocytochemistry  
Immunocytochemistry was performed 48 hr after the initial addition of fibrils unless 
indicated otherwise. Cells were fixed in 4% paraformaldehyde (PFA) for 10 min and 
permeabilized with 0.1% Triton-X100 for 15 min, or fixed with 4% PFA containing 1% Triton-X100 
for 15 min to remove soluble proteins. For visualization of microtubules, cells were fixed with 
0.3% glutaraldehyde in PEM buffer (80 mM PIPES, pH6.8, 5 mM EGTA, 1 mM MgCl2) for 10 min, 
extracted with 1% Triton-X100 for 15 min before being quenched with 10 mg/ml sodium 
borohydride for 7 min followed by 0.1 M glycine for 20 min. After blocking with 3% BSA and 3% 
FBS for at least 1 hr at RT, cells were incubated with specific primary antibodies (see Table 2-S1) 
for 2 hr at RT or overnight at 4°C followed by staining with appropriate Alexa fluor 594 or 488-
conjugated secondary antibodies (goat anti-mouse/rabbit/mouse IgG1/mouse IgG2b) for 1-3 hr at 
RT. DAPI was added to PBS wash to label cell nuclei. For ThS staining, cells were incubated with 
0.005% ThS for 8 min and differentiated with 70% ethanol 4 times, 5 min each. 
Two-stage immunostaining was employed to distinguish between membrane-associated 
and truly internalized pffs. Live cells were incubated with rabbit polycloncal anti-myc Ab diluted in 
medium containing 25 mM HEPES for 1 hr at 4°C. After 3 washes with cold medium, cells were 
fixed with 4% PFA and permeabilized with 0.1% Triton-X100. Following blocking, cells were 
incubated with monoclonal anti-myc Ab 9E10 for 1-2 hr at RT. Rabbit myc Ab is expected to bind 
to cell membrane-associated pffs only, where 9E10 would bind to both membrane-associated and 
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intracellular pffs, therefore truly internalized pffs should only be recognized by 9E10 but not rabbit 
myc Ab.  
Epifluorescence images were acquired using Olympus BX 51 microscope (B&B 
Microscopes) equipped with a digital camera DP71 (Olympus) and DP manager (Olympus). 
Sequential extraction and western blot  
Cells were washed once with PBS before being scraped into Triton lysis buffer (1% 
TritonX-100 in 50 mM Tris, 150 mM NaCl, pH 7.6) or Sarkosyl lysis buffer (1% Sarkosyl in 50 mM 
Tris, 150 mM NaCl, pH 7.6) containing protease and phosphatase inhibitors and incubated on ice 
for 10-15 min. For Sarkosyl extraction, lysates were rotated at room temperature for 1 hr before 
the next step. Following sonication, lysates were centrifuged at 100,000g for 30 min at 4°C. 
Supernatants were kept as “Triton/Sarkosyl fraction”, while pellets were washed once in 
Triton/Sarkosyl lysis buffer, resuspended and sonicated in SDS lysis buffer (1% SDS in 50 mM 
Tris, 150 mM NaCl, pH 7.6). After centrifugation at 100,000g for 30 min at 22°C, supernatants 
were saved as “SDS fraction”. Equal proportions of Triton/Sarkosyl and SDS fractions were 
resolved on 10% SDS polyacrylamide gels, transferred to nitrocellulose membranes, and blocked 
in 5% milk in TBS before probing with specific Abs (see Table 2-S1). Protein-Free block 
(ThermoFisher) was used for PHF-1 blots. 
Pulse chase  
Reagent-mediated transduction was performed as described above. One day after 
transduction, cells were placed on methionine-free medium for 15 min and then pulsed with 
methionine-free medium containing [35S]-methionine (150 µCi for each well on 12-well plate) for 
20 min, following which cells were switched into complete medium containing 5 mM cold 
methionine and chased for different durations. During harvest, cells were washed once in HBSS 
and sequentially extracted using 1% Triton-X followed by 1% SDS lysis buffer. Tau was 
immunoprecipitated from cell lysates diluted in RIPA using a combination of mAbs T46 and Tau 
5. 
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Electron microscopy (EM) 
To visualize pffs made in vitro, 6 μL unsonicated or sonicated fibrils was placed on 300 
meshed Formvar/carbon film-coated copper grids (Electron Microscopy Sciences) for 3 min, 
washed twice with 50 mM Tris buffer (pH 7.6) for 5 min each, stained with 10-15 drops of 2% 
uranyl acetate, and visualized with Jeol 1010 transmission electron microscope (Peabody). 
Immuno-EM of reagent alone treated cells and fibril transduced cells were performed as 
described previously (Luk et al., 2009) using PHF-1 as the primary antibody. 
Sandwich ELISA for quantifying Ac-tub and tau in cell lysates  
Levels of acetylated tubulin (Ac-tub) and tau in cell lysates were quantified using 
sandwich ELISA in 384-well plate format. For Ac-tub ELISA, tubulin mAb 12G10 was used as the 
capture antibody, and horseradish peroxidase (HRP)-conjugated Ac-tub mAb was used as the 
reporting antibody. Standard curves were generated using serially diluted brain lysates from wt 
mouse. 18 μg of cell lysates diluted in EC buffer (0.02 M sodium phosphate buffer pH7.0, 2mM 
EDTA, 0.4M NaCl, 0.2% BSA, 0.05% CHAPS, 0.4% Blockace, 0.05% NaN3) was loaded to each 
well and incubated overnight at 4°C. On the following day, after 4 hr incubation with reporting 
antibody at room temperature, trimethy benzidine (TMB) peroxidase substrate solution was 
added and the plate was read using SpectraMax at 450 nm absorbance. For quantifying tau in 
Triton and SDS fractions, cell lysates from sequential extraction were diluted 1,000 times in EC 
buffer. Serially diluted recombinant human T40 was used to generate standard curves. 30 μL of 
diluted samples were loaded into each well of the plate coated with capture antibody Tau 5. After 
overnight incubation at 4°C, captured proteins were reported using biotin-labeled BT2 and HT7 
which were left to incubate overnight at 4°C. On the next day, following 1 hr incubation with HRP-
conjugated streptavidin at 25°C, the plate was developed using TMB peroxidase substrate 
solution. 
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Quantifications and statistical analysis  
For quantifying % of cells developing tau aggregates with different combinations of 
endogenous tau and pffs, 10-20 random-field images were taken at 40x magnification for each 
combination and at least two independent experiments were performed. For quantification of MT-
bundling and pff alone-induced tau aggregation under various conditions (i.e. different 
temperatures, with or without WGA/GlcNAc), 10 random-field images were taken at 20x 
magnification for each condition in each experiment and 3-4 independent experiments were 
performed. Two-tailed paired student’s t-test was used for all the comparisons in the study and 
differences with p values less than 0.05 were considered significant. 
2.6 Supplementary Materials 
Table 2-S1. Antibodies used in Chapter 2. 
Antibody Specificity Host species Dilution Source 
17025 Human recombinant tau 
rabbit 
polyclonal 1:1000 (WB, ICC) 
(Ishihara et al., 
1999) 
PHF-1 
p-Tau 
(phosphorylated 
at Ser 396 and 
404)  
mouse 
monoclonal 
1:1000 (WB, 
immuno-EM); 1:2000 
(ICC) 
(Otvos et al., 
1994) 
AT8 
p-Tau 
(phosphorylated 
at Ser 202)  
mouse 
monoclonal 1:500 (ICC) Innogenetics 
MC-1 
Tau in the 
pathological 
conformation 
mouse 
monoclonal 1:500 (ICC) 
Gift from Dr. Peter 
Davies Lab 
Tau 5 Tau (210-230aa) 
mouse 
monoclonal 
5ug/ml as capture 
antibody in tau 
ELISA; 6ug for 
immunoprecipitating 
tau from ~100ug 
protein 
Gift from Dr. 
Lester Binder Lab 
biotinylated 
BT2 
Tau (194-
198aa) 
mouse 
monoclonal 
125ng/ml as 
reporting antibody in 
tau ELISA together 
with HT7 
Pierce (Thermo 
Scientific) 
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biotinylated 
HT7 
Tau (159-
163aa) 
mouse 
monoclonal 
125ng/ml as 
reporting antibody in 
tau ELISA together 
with BT2 
Pierce (Thermo 
Scientific) 
T46 Tau (404-441aa) 
mouse 
monoclonal 
11ug for 
immunoprecipitating 
tau from ~100ug 
protein 
 (Kosik et al., 
1988) 
myc 9E10  myc tag mouse monoclonal 1:1000 (WB, ICC) 
Developmental 
Studies 
Hybridoma Bank 
(DSHB) 
Anti-c-myc c-myc tag rabbit polyclonal 
1:5000 (regular ICC); 
1:1000 (live staining) Sigma 
GAPDH 
(6C5) 
Glyceraldehyde-
3-phosphate 
dehydrogenase  
mouse 
monoclonal 1:3000 (WB) 
Advanced 
Immunochemical 
12G10 tubulin mouse monoclonal 
10ug/ml as capture 
antibody in Ace-tub 
ELISA 
DSHB 
Acetylated 
tubulin (6-11 
B-1) 
Acetylated-
tubulin 
mouse 
monoclonal 
1:4000 (ELISA); 
1:1000 (ICC) Sigma 
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CHAPTER 3: NEUROFIBRILLARY TANGLE-LIKE TAU PATHOLOGY INDUCED BY 
SYNTHETIC TAU FIBRILS IN PRIMARY NEURONS OVER-EXPRESSING MUTANT 
TAU* 
*This study was originally published in FEBS letters. Guo, J.L., and Lee, V.M. Neurofibrillary 
tangle-like tau pathology induced by synthetic tau fibrils in primary neurons over-expressing 
mutant tau. FEBS letters. doi: 10.1016/j.febslet.2013.01.051. © Elsevier 
3.1 Abstract 
Increasing evidence demonstrates the transmissibility of fibrillar species of tau protein, 
but this has never been directly tested in neurons, the cell type most affected by formation of tau 
inclusions in neurodegenerative tauopathies. Here we show that synthetic tau fibrils made from 
recombinant protein not only time-dependently recruit normal tau into neurofibrillary tangle-like 
insoluble aggregates in primary hippocampal neurons over-expressing human tau, but also 
induce neuritic tau pathology in non-transgenic neurons. This study provides highly compelling 
support for the protein-only hypothesis of pathological tau transmission in primary neurons and 
describes a useful neuronal model for studying the pathogenesis of tauopathies. 
3.2 Introduction 
Tau, a microtubule-binding protein enriched in axons, accumulates into intracellular 
hyperphosphorylated aggregates known as neurofibrillary tangles (NFT) in a wide variety of 
neurodegenerative diseases, including Alzheimer’s disease, frontotemporal dementia with 
Parkinsonism linked to chromosome 17, progressive supranuclear palsy, corticobasal 
degeneration and Pick’s disease, which are collectively termed neurodegenerative tauopathies 
(Ballatore et al., 2007). It has always been enigmatic what initiates the conversion of tau from a 
highly soluble protein without defined secondary structure into insoluble beta-sheet rich fibrils. 
Recently, numerous studies have shown that exogenously supplied pathological tau, including 
synthetic tau fibrils, can drive soluble tau into tangle-like inclusions in both cell culture systems 
and mouse models (Clavaguera et al., 2009; Frost et al., 2009; Guo and Lee, 2011; Iba et al., 
2013; Nonaka et al., 2010), implicating a seeding-recruitment process as well as cell-to-cell 
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transmission of pathology as possible underlying mechanisms for the initiation and progression of 
tauopathies. Similar results have been demonstrated for other amyloidogenic proteins, such as β-
amyloid and α-synuclein (α-syn) (Eisele et al., 2010; Luk et al., 2012a; Luk et al., 2012b; Stohr et 
al., 2012; Volpicelli-Daley et al., 2011), therefore suggesting a unifying pathogenic mechanism for 
neurodegenerative diseases involving protein aggregation. 
We previously found that synthetic tau fibrils can spontaneously enter non-neuronal cells 
and recruit normal tau into pathological accumulations (Guo and Lee, 2011), but it was unclear 
whether this phenomenon could also happen in post-mitotic neurons, which are the more relevant 
cell type for studying tauopathies. While a recent study from our lab showed that intracerebral 
inoculation of preformed tau fibrils (tau pffs) into transgenic (Tg) mice overexpressing human 
mutant P301S tau (PS19) dramatically accelerated development of tau pathology (Iba et al., 
2013) thereby providing in vivo evidence for transmissibility of synthetic tau fibrils, a study in 
cultured neurons would provide an in vitro system more amenable for mechanistic interrogations 
and investigation of novel therapies. Here, we demonstrate that synthetic tau fibrils made from 
recombinant protein triggered robust aggregation of otherwise soluble endogenous tau into NFT-
like inclusions in primary neurons dissociated from embryonic mouse hippocampus. 
3.3 Results 
Despite the over-expression of human tau harboring P301S mutation, primary 
hippocampal neurons dissociated from PS19 mouse embryos showed phosphorylated tau 
recognized by AT8 that remained Triton X-100 soluble up to 24 d  in vitro (Figure 3-1A). 
Remarkably, addition of tau pffs consisting of only the MT-binding domain with P301L mutation 
(myc-K18/P301L) to neuron medium at 6 d in vitro , without any transduction reagent, led to 
robust accumulation of phosphorylated tau throughout soma and neurites that resisted detergent 
extraction at 18 d post-transduction (24 d in vitro) (Figure 3-1A). In addition, perikaryal 
aggregates in pff-treated neurons were intensely labeled by disease-specific conformational 
antibody MC-1 (Jicha et al., 1997), indicating pathological conformation acquired by pff-induced 
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aggregates. Higher magnification images revealed AT8 and MC-1 labeled inclusions as bundles 
of aggregates highly reminiscent of NFTs filling up the soma of a subset of neurons (Figure 3-
1B). Since both AT8 and MC-1 recognize epitopes absent from myc-K18/P301L pffs and pff-
transduced tau knock-out neurons displayed no immunoreactivity for any tau antibodies tested 
(Figure 3-S1 and Figure 3-3C), the observed tau aggregates in PS19 neurons must represent 
fibrillization of endogenous full-length tau seeded by exogenous pffs that spontaneously entered 
neurons. Furthermore, K18/P301L pffs without a myc tag also induced widespread accumulation 
of pathological tau within the same time frame, ruling out non-specific effects associated with the 
tag (Figure 3-S2). 
Pff-induced solubility change of endogenous tau was further assessed by sequentially 
extracting pff-transduced neurons as well as PBS-treated control neurons into Triton X-100 lysis 
buffer followed by SDS lysis buffer and immunoblotting with different tau antibodies. Prominent 
Triton-soluble tau was present in PBS- and pff treated cultures but SDS-soluble tau was 
recovered only in pff-transduced neurons (Figure 3-1C).  
Ultrastructural analysis using routine transmission EM revealed cytoplasmic filaments in 
neurons treated with pffs (Figure  3-2A) but not in PBS-treated control neurons (data not 
shown). Immuno-EM with both HRP-labeling and nanogold-amplification demonstrated MC-1 
immunoreactivity of pff-induced fibrillar accumulations, further supporting the recruitment of 
endogenous full-length tau into NFT-like filamentous aggregates (Figure 3-2B and C). 
A time-course analysis demonstrated that the prevalence of aggregate-bearing cells 
increased over time, from sparse distribution at 6 d post-pff addition to about 20% of neurons 
carrying perikaryal aggregates at 18 d post-transduction (Figure 3-3A). Moreover, diffuse tau 
accumulations seen as punctate AT8 and MC-1 immunoreactivity at 6 d turned into densely 
packed aggregates at 12 d (Figure 3-3B), while NFT-like aggregate bundles described earlier 
were only observed at 18 d post-transduction (Figure 3-1C). The progressive augmentation in 
insoluble tau aggregates was also evident on immunoblots of sequentially extracted neuron 
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lysates at different time points with about 33% of total human tau sequestered into Triton-
insoluble fraction at 18 d post-transduction (Figure 3-3C).  
Figure 3-1. Insoluble tau accumulated in PS19 primary hippocampal neurons after 
incubation with myc-K18/P301L pffs. (A) PS19 neurons treated with PBS (PBS control) or 
myc-K18/P301L fibrils (pff Td) were immunostained with phospho-tau mAb AT8 and 
conformational mAb MC-1 with or without 1% Triton-X100 extraction during fixing (ext, no ext, 
respectively). DAPI staining was used to visualize nuclei (blue). Scale bar: 100 µm.  (B) 
Perikaryal tau aggregates recognized by AT8 and MC-1. Scale bar: 50 µm. (C) Neurons treated 
with PBS or myc-K18/P301L fibrils (pff) were sequentially extracted with 1% Triton-X100 lysis 
buffer (T) followed by 1% SDS lysis buffer (S) and immunoblotted with AT8, polyclonal antibody 
against total tau (17025), and mAb against human tau (T14). GAPDH served as loading control. 
Results from two independent sets of neurons were shown. 
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Figure 3-S1. Primary hippocampal neurons from tau knock-out mice transduced with tau 
pffs showed no immunoreactivity for various tau antibodies. Cell nuclei were visualized 
using DAPI staining (blue). 1% Triton-X was added to 4% PFA during fixing to remove soluble 
proteins. Scale bar: 50µm. 
 
Figure 3-S2. Non-tagged K18/P301L fibrils also induced extensive tau aggregation 
throughout cell bodies and neurites of PS19 neurons. Soluble proteins were removed by 1% 
Triton-X during fixing and neurons were double-labeled with polyclonal antibody for total tau 
(17025) and antibody specific for neuronal nuclei (NeuN). Scale bar: 50µm. 
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Figure 3-2. Ultrastructural analysis of tau pff-induced aggregates by EM and immuno-EM. 
Routine EM (A) revealed filamentous structures in the cytoplasm of tau pff transduced neurons, 
which were recognized by MC-1 in immuno-EM using both HRP-labeling (B) and nanogold-
amplification (C) detecting methods. Scale bar: 500 nm.
 
Interestingly, early inclusions did not contain endogenous mouse tau recognized by mAb 
T49, which appeared at 12 d post-pff transduction and became more abundant after 18 d 
incubation in aggregates co-labeled with polyclonal tau antibody 17025 that preferentially 
recognizes human tau on immunostaining (Figure 3-3D). Therefore, mouse tau can be recruited 
into pff-seeded aggregates although the process occurred more slowly compared to over-
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expressed human tau. Unlike immunostaining by human tau specific mAb T14 which completely 
overlapped with 17025 staining (Figure 3-S3), mouse tau immunoreactivity only partially  
colocalized with that of 17025 even at 18 d post-transduction (Figure 3-3D), suggesting not all 
inclusions contained misfolded mouse tau. The time-dependent emergence of insoluble mouse 
tau was also detected on immunoblot, although the insoluble pool only constituted a very small 
fraction of total mouse tau (Figure 3-3C). 
 The differential seeding capacity of wt versus mutant and truncated versus full-length tau 
pffs was compared in PS19 neurons. Full-length tau pffs carrying P301S mutation (myc-
T40/P301S pffs) were similarly efficient as myc-K18/P301L pffs (Figure 3-4A and B). In contrast, 
wt tau pffs, both full-length and truncated (myc-T40 and myc-K18), demonstrated significantly 
lower seeding efficiency with especially pronounced reduction in neuritic pathology than mutant 
pffs, although myc-T40 pffs appeared to be slightly more potent than myc-K18 pffs (Figure 3-4A 
and B).  
Myc-K18 and myc-K18/P301L pffs were also tested in non-Tg primary neurons for their 
capability to seed endogenous mouse tau fibrillization without over-expressed human mutant tau. 
Interestingly, wt myc-K18 pffs, but not mutant myc-K18/P301L pffs, were able to induce punctate 
accumulations of insoluble mouse tau in the neurites of non-Tg neurons after 18 d incubation 
(Figure 3-4C).  Notably, the amount of tau inclusions induced in non-Tg neurons was highly 
limited as compared to that observed in PS19 neurons, most likely owing to lack of tau over-
expression and mutation. In addition, unlike pff-induced tau pathology that were throughout the 
soma and processes of PS19 neurons, mouse tau aggregation was never found in the soma of 
pff-transduced non-Tg neurons, likely due to predominant expression of endogenous tau in the 
axons.  
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Figure 3-3. Time-dependent increase in pff-induced tau pathology and recruitment of mouse tau into 
aggregates. (A) Increasing population of cells developed tau pathology from 6 d to 18 d incubation after pff 
addition. Green: AT8. Blue: DAPI. Scale bar: 100 µm. (B) Morphological difference between 6 d and 12 d 
post-transduction aggregates immunostained with AT8 and MC-1. Scale bar: 50 µm. (C) Sequentially 
extracted PS19 neuron lysates at different time points after pff addition (6 d, 12 d, 18 d) or at 18 d after PBS 
treatment (PBS) and tau knock-out neuron lysates (tau KO) at 18 d post-addition of PBS or pffs were 
immunoblotted with AT8, 17025, T14 as well as mAb specific for mouse tau (T49). (D) Double-labeling of 
aggregates by T49 and 17025 at different time points after pff addition. Scale bar: 50 µm. For (A), (B) and 
(D), soluble proteins were removed by 1% Triton-X100 during fixing.
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Figure 3-S3. Double-labeling of insoluble tau aggregates. Triton-insoluble tau aggregates 
induced by tau pffs were double labeled with total tau antibody (17025) and human tau specific 
antibody (T14). Scale bar: 50µm.
 
3.4 Discussion 
 The current study demonstrated induction of robust tau aggregation inside primary 
neurons by the simple addition of synthetic tau fibrils to neuronal culture  medium without any 
transduction reagent, suggesting that the previously described phenomenon of spontaneous 
uptake of fibrillar tau and templated conversion of normal tau into pathological aggregates (Frost 
et al., 2009; Guo and Lee, 2011; Nonaka et al., 2010) is also applicable to neurons, the cell type 
most relevant for  neurodegenerative tauopathies. Importantly, pff-induced tau aggregation also 
occurred in non-Tg neurons in the absence of over-expression, albeit to a much less extent than 
in PS19 neurons which over-express mutant tau, suggesting that the seeding-recruitment process 
can indeed take place at physiological conditions and underlie the etiology of NFT formation in 
tauopathies. 
 As a highly soluble protein, tau resists aggregation under normal conditions. It was 
therefore a breakthrough in the field when polyanionic cofactors, such as heparin, RNA, and fatty 
acids, were found to greatly promote in vitro fibrillization of tau (Chirita et al., 2003; Goedert et al., 
1996; Kampers et al., 1996). Even though preformed tau fibrils can dramatically accelerate the 
kinetics of in vitro fibril assembly by acting as seeds, efficient seeding reaction still requires the 
presence of cofactors (Friedhoff et al., 1998). Curiously, tau pffs alone are sufficient to drive 
aggregation of soluble tau inside the cells without the addition of any cofactor, especially  
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Figure 3-4. Differential seeding capacity of distinct forms of tau pffs on PS19 and non-Tg 
primary neurons. (A) Tau pathology (green: AT8) induced in PS19 neurons by myc-K18, myc-
K18/P301L (myc-K18/PL), myc-T40 and myc-T40/P301S (myc-T40/PS) fibrils. Scale bar: 100 
µm. (B) Quantification of percentage area occupied by AT8-positive pathology induced by the 
different pffs (mean + SEM). Number of independent sets of PS19 neurons tested: n = 2 for myc-
K18, n = 3 for the other three. *: < 0.05. **: < 0.005. (C) Transduction of myc-K18 but not myc-
K18/P301L pffs on non-Tg neurons resulted in neuritic tau pathology (green: AT8). Scale bar: 50 
µm. For both (A) and (C), soluble proteins were removed by 1% Triton-X100 during fixing.
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considering the fact that pffs we added to neurons were re-suspended in heparin-free buffer. 
Therefore, intracellular environment appears to be more permissive for seeded fibrillization than a 
cell-free system. Consequently, while polyanionic cofactors may catalyze the initial formation of 
misfoded tau seeds in human brains, their involvement in NFT genesis may not be obligatory, 
since seeded fibrillization of tau is a self-perpetuating process in cells once pathological 
conformers are generated. 
 Although mutant tau pffs resulted in dramatically more abundant pathology than wt tau 
pffs in PS19 neurons overexpressing mutant tau, they showed even lower seeding capacity than 
wt pffs in non-Tg neurons expressing wt mouse tau. The asymmetrical seeding between wt and 
P301L mutant tau was also observed in our previous non-neuronal model albeit less dramatically 
(Guo and Lee, 2011). Together with the finding that NFTs in human patients harboring P301L 
mutation are nearly exclusively composed of mutant tau (Miyasaka et al., 2001), these studies 
point to possible conformational disparities between wt and mutant tau fibrils. Since we have 
never detected obvious differences in the morphologies of the two types of fibrils at EM level, we 
speculate any structural differences are likely more subtle as suggested by a previous study 
(Aoyagi et al., 2007). 
Interestingly, full-length wt tau (myc-T40) pffs showed a tendency to seed better than 
truncated wt (myc-K18) pffs despite equal mass thus a lower molarity of the former being added 
to PS19 neurons. In our previous study when transduction reagent was used to facilitate pff 
uptake in non-neuronal cells (Guo and Lee, 2011), wt T40 pffs actually demonstrated less 
efficient seeding than wt K18 pffs (unpublished data), therefore the observed difference between 
full-length and truncated tau pffs in primary neurons is probably not due to differential recruiting 
capacity per se, but possibly due to more efficient uptake of full-length pffs. With the N-terminus 
of tau was shown to be critical for extracellular secretion (Kim et al., 2010), it would be interesting 
to explore whether the same domain is playing a role in the uptake of fibrillar tau into neurons. 
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Unlike the recently developed neuronal model of synucleinopathy in which robust Lewy 
body- and Lewy neurite-like accumulations composed of mouse α-syn can be induced in non-Tg 
neurons by α-syn pffs (Volpicelli-Daley et al., 2011), low abundance of tau aggregates form upon 
wt tau pff transduction on non-Tg neurons. The difference could be attributed to several reasons. 
First, non-Tg mice naturally express α-syn of the A53T variant which is a pathogenic mutation in 
human. Not only does A53T mutation greatly enhance fibrillization of α-syn (Conway et al., 
2000a), but mouse α-syn even fibrillizes much more readily than human α-syn carrying the A53T 
mutation (unpublished data). Lack of such a “natural” mutation in mouse tau limits the extent of 
tau pathology that can develop within our experimental time window. Second, α-syn is highly 
concentrated at presynaptic terminals in mature neurons (Murphy et al., 2000) and the local high 
concentration probably facilitates efficient recruitment by internalized pff seeds. In contrast, tau is 
more diffusely located throughout axons in non-Tg neurons. Third, the adult isoform of tau with 
four repeats (4R) only constitutes a small fraction of total tau in developing neurons (Dotti et al., 
1987; Ferreira et al., 1997), while the predominantly expressed 3R-tau has lower propensity to 
aggregate than 4R-tau (Zhong et al., 2012) in addition to a seeding barrier between 3R- and 4R-
tau as previously reported (Dinkel et al., 2011). Nonetheless, seeding endogenous mouse tau in 
non-Tg neurons provides a more physiological system for studying tau aggregation and pathology 
spreading.  
 In summary, our study directly demonstrates the transmissibility of fibrillar tau in neurons, 
thereby presenting a neuronal model suitable for both mechanistic studies on the pathogenesis of 
NFTs and therapeutic investigation to identify drugs that can reverse or prevent tau pathology. 
3.5 Materials and Methods 
Recombinant Tau Purification and in Vitro Fibrillization Assays 
The cDNAs coding for (1) the longest isoform of wildtype (wt) human tau with a myc tag 
at the 3’ end (myc-T40), (2) truncated human tau containing four MT-binding repeats with a myc 
tag at the 5’ end (myc-K18), (3) 3’myc-T40 with P301S mutation (myc-T40/P301S), (4) 5’myc-
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K18 containing P301L mutation (myc-K18/P301L) were cloned into pRK172 bacterial expression 
vector. Each protein was expressed in BL21 (DE3) RIL cells and purified by cationic exchange 
using a Fast Protein Liquid Chromatography (FPLC) as previously described (Li and Lee, 2006). 
For in vitro fibrillization, 40 µM recombinant tau was incubated with 40 µM low-molecular-
weight heparin and 2 mM DTT in 100 mM sodium acetate buffer (pH 7.0) at 37°C. Myc-T40 and 
myc-T40/P301S were agitated at 1000 rpm for 5 to 7 d and 1 d respectively, but myc-K18 and 
myc-K18/P301L were incubated without agitation for 2-3 d. Before they were used for 
transduction in neurons, fibrillization mixtures were centrifuged at 100,000 g for 30 min at 22°C, 
and the resulted pellet was re-suspended in equal volume of 100 mM sodium acetate buffer (pH 
7.0) without heparin and DTT. Successful fibrillization was verified by sedimentation test, ThT 
test and negative stain EM. 
Primary Neuron Cultures and Fibril Transduction 
Primary neuron cultures were prepared from E15-E17 embryos from het/het or homo/het 
crosses of PS19 mice (Yoshiyama et al., 2007), non-Tg CD1 mice (Charles River, Wilmington, 
MA) and tau knock-out mice (Dawson et al., 2001). Dissociated hippocampal neurons were 
plated onto poly-D-lysine coated 13 mm coverslips or 6-well plates. Pff transduction was 
performed at 6 d in vitro, whereby tau pffs were diluted in PBS and sonicated with 60 pulses 
before being added to neuron medium. Neurons on each coverslip received 1.5 µg of tau pffs 
and those on the 6-well plate received 6 µg of pffs per well. Transduced neurons were 
harvested for immunocytochemistry or sequential extraction at 18 d post-pff transduction unless 
otherwise indicated. 
Immunocytochemistry 
Neurons were fixed in 4% paraformaldehyde (PFA) containing 2% sucrose for 15 min 
and permeabilized with 0.1% Triton-X100 for 15 min, or fixed with 4% PFA containing 2% 
sucrose and 1% Triton-X100 for 15 min to remove soluble proteins. After blocking with 3% BSA 
and 3% FBS for at least one hour at RT, neurons were incubated with specific primary 
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antibodies (Supplementary Table 1) overnight at 4°C followed by staining with appropriate Alexa 
fluor 594 or 488-conjugated secondary antibodies (Invitrogen; Carlsbad, CA) for 2 hr at RT. 
DAPI was added to PBS wash after secondary antibody incubation to label cell nuclei. 
Quantification for area occupied by pff-induced pathology was performed on 20x images using 
Image J (National Institute of Health). 
Sequential Extraction and Western Blot Analysis 
Neurons were scraped into Triton lysis buffer (1% TritonX-100 in 50 mM Tris, 150 mM 
NaCl, pH 7.6) containing phosphatase and protease inhibitor cocktail, sonicated, and 
centrifuged at 100,000 g for 30 min at 4°C. Pellets were washed once in Triton lysis buffer, re-
suspended into SDS lysis buffer (1% SDS in 50 mM Tris, 150 mM NaCl, pH7.6) at a volume that 
is ¼ of the Triton lysis buffer and centrifuged at 100,000 g for 30 min at 22°C. Supernatants from 
Triton and SDS extractions were resolved on SDS-PAGE, transferred to nitrocellulose 
membranes, and blocked in 5% milk or 7.5% BSA in TBS before immunoblotted with specific 
antibodies (Supplementary Table 1). 10 µg of proteins from Triton fractions and equal volume of 
corresponding SDS fractions were loaded per lane. 
Electron Microscopy (EM) 
Negative stain transmission EM (TEM) of tau pffs, TEM and immuno-EM of pff 
transduced primary hippocampal neurons were performed as previously described (Guo and Lee, 
2011; Volpicelli-Daley et al., 2011). Monoclonal antibody (mAb) MC-1 was used in the immuno-
EM of neurons. 
Table 3-S1. Antibodies used in Chapter 3. 
Antibody Specificity Host species Dilution Source or Reference 
17025 Human recombinant tau rabbit polyclonal 
1:1000 (WB), 
1:5000 of 
affinity purified 
(ICC) 
(Ishihara et al., 
1999) 
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AT8 p-Tau (phosphorylated at Ser 202 and Thr 205)  
mouse 
monoclonal 
1:1000 (WB), 
1:500 (ICC) Innogenetics 
MC-1 Tau in the pathological conformation 
mouse 
monoclonal 1:500 (ICC) 
Gift from Dr. 
Peter Davies 
Lab 
GAPDH 
(6C5) 
Glyceraldehyde-3-
phosphate 
dehydrogenase  
mouse 
monoclonal 1:3000 (WB) 
Advanced 
Immunochemical
T14 Human tau mouse monoclonal 
1:1000 (WB, 
ICC) 
(Kosik et al., 
1988) 
T49 Mouse tau mouse monoclonal 
1:1000 (WB, 
ICC) 
(Ishihara et al., 
2001) 
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CHAPTER 4: Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in 
Neurons* 
*This study was submitted on Jan 28, 2013. Guo, J.L., Covell, D., Daniels, J., Iba, M., Stieber, A., 
Zhang, B., Trojanowski, J.Q., and Lee, V.M. Distinct α-Synuclein strains differentially promote tau 
inclusions in neurons. 
4.1 Abstract 
Many neurodegenerative diseases are characterized by the accumulation of insoluble 
protein aggregates, including neurofibrillary tangles composed of tau in Alzheimer’s disease and 
Lewy bodies composed of α-synuclein in Parkinson’s disease. Moreover, different pathological 
proteins frequently co-deposit in the same degenerating brains. To test whether pathological α-
synuclein can directly cross-seed tau fibrillization, we employed recently developed 
synucleinopathy models in primary neurons and transgenic mice based on the administration of 
preformed α-synuclein fibrils assembled from recombinant protein to induce disease pathology. 
Remarkably, we discovered two distinct strains of synthetic α-synuclein fibrils which 
demonstrated striking differences in the efficiency of cross-seeding tau aggregation, both in 
neuron cultures and in vivo. Proteinase K digestion and further biochemical analyses revealed 
conformational differences between the two strains, which were generated through repetitive 
seeded fibrillization in vitro. We speculate that different strains of pathological α-synuclein likely 
exist in nature and may underlie the tremendous heterogeneity of synucleinopathies. 
4.2 Introduction 
A common feature of many neurodegenerative diseases is the accumulation of normally 
soluble proteins into filamentous insoluble aggregates, including neurofibrillary tangles (NFTs) 
composed of tau in Alzheimer’s disease (AD) and frontotemporal degeneration (Goedert et al., 
1988; Lee et al., 1991; Lee et al., 2001), and Lewy bodies (LB) composed of α-synuclein (α-syn) 
in Parkinson’s disease (PD) and dementia with LB (DLB) (Baba et al., 1998; Spillantini et al., 
1997). Both tau and α-syn are natively unfolded proteins without well-defined secondary or 
tertiary structures (Cleveland et al., 1977a; Eliezer et al., 2001; Schweers et al., 1994; Weinreb et 
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al., 1996). While tau is a microtubule-binding protein which stabilizes and promotes microtubule 
assembly in the axon (Drechsel et al., 1992; Witman et al., 1976), α-syn is a phospholipid-binding 
protein highly concentrated in the presynaptic terminals where it is shown to promote SNARE 
complex formation and modulate synaptic functions (Burre et al., 2010; Cabin et al., 2002; Iwai et 
al., 1995a; Murphy et al., 2000). Although the exact mechanisms whereby tau and α-syn 
aggregates induce neurodegeneration are not fully understood, they are thought to contribute to 
neuronal dysfunction and death through loss of normal functions and/or toxic gains of functions 
(Ballatore et al., 2007; Goedert, 2001). 
How normally soluble proteins undergo conformational changes to become insoluble and 
form aggregates is a long-standing mystery. However, there is increasing evidence that robust 
aggregation of disease-associated proteins, including tau and α-syn, can be induced by 
exogenously supplied preformed fibrils (pffs) in cultured cells, as well as in living animals (Frost et 
al., 2009; Guo and Lee, 2011; Iba et al., 2013; Luk et al., 2012a; Luk et al., 2012b; Luk et al., 
2009; Volpicelli-Daley et al., 2011). These studies suggest that small amounts of misfolded 
protein can act as seeds to initiate templated recruitment of their soluble counterparts into fibrillar 
structures. Moreover, cell-to-cell transmission of these amyloid protein aggregates are strongly 
implicated as an underlying mechanism for the stereotypical spatiotemporal progression of both 
AD and PD pathologies (Braak and Braak, 1991; Braak et al., 2002; Braak et al., 2003). 
Another recurrent theme of neurodegenerative diseases is the frequent co-occurrence of 
different disease protein aggregates in the same patient as exemplified by the fact that >50% of 
AD cases show LB pathologies (Hamilton, 2000; Jellinger, 2003; Kotzbauer et al., 2001; Lippa et 
al., 1998), while co-morbid AD pathologies, including Aβ plaques and NFTs, are also commonly 
found in PD and DLB cases (Gomez-Tortosa et al., 2000; Ince et al., 1991; McKeith et al., 1996). 
This phenomenon could be explained by global dysregulation of protein homeostasis in disease 
brains, whereby misfolding of one major protein overwhelms the proteostatic machinery and 
compromises the folding of other aggregation-prone proteins (Gidalevitz et al., 2006; Kikis et al., 
68 
 
2010). Alternatively or additionally, filamentous aggregates composed of one protein may directly 
cross-seed other amyloidogenic proteins owing to potentially shared structural features of amyloid 
fibrils (Kayed et al., 2007; O'Nuallain and Wetzel, 2002). Indeed, we showed  earlier  that α-syn 
and tau synergistically promote the fibrillization of each other in a cell-free system as well as in 
transgenic (Tg) mice (Giasson et al., 2003), while more recently α-syn pffs were shown to induce 
tau aggregation in cultured non-neuronal cells (Waxman and Giasson, 2011). To confirm this 
cross-seeding phenomenon in physiologically more relevant systems, we utilized recently 
developed synucleinopathy models in primary neurons and Tg mice, in which exogenously added 
α-syn pffs promote the recruitment and aggregation of endogenous α-syn (Luk et al., 2012b; 
Volpicelli-Daley et al., 2011). Remarkably, our study led to the discovery of two distinct “strains” of 
synthetic α-syn pffs generated in vitro that exhibited striking differences in the efficacy of tau 
cross-seeding, which we ascribe to divergent conformations between the two strains of pffs as 
revealed by biochemical analyses. 
4.3 Results 
Generation of different strains of α-syn pffs with differential cross-seeding of tau 
To investigate whether α-syn pffs can cross-seed tau in primary neurons, we incubated 
hippocampal neurons generated from mouse embryos overexpressing human mutant P301S tau 
(PS19) with α-syn pffs assembled de novo from Myc-tagged C-terminal truncated 1-120 
monomers (1-120-Myc). At 18 d post transduction, highly abundant LB and Lewy-neurite (LN) like 
α-syn inclusions that are resistant to Triton-X100 extraction were observed throughout the 
cultured neurons (see Figure 4-1A top panel). However, Triton-insoluble hyperphosphorylated tau 
aggregates were only infrequently found in neuronal processes and rarely colocalized with α-syn 
pathology, suggesting their formation is likely an indirect consequence of α-syn accumulation 
rather than a direct result of cross-seeding by α-syn. In neurons derived from non-Tg mice, no 
appreciable tau aggregates were induced (Figure 4-1A, bottom panel). 
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Figure 4-1. Generation of different strains of α-syn pffs with differential cross-seeding of tau in 
neurons. (A) Accumulations of insoluble phospho-α-syn (81A) and phospho-tau (AT8) induced by de novo 
1-120-Myc pffs (strain A) in primary hippocampal neurons dissociated from PS19 mouse embryos over-
expressing human tau with P301S mutation or from non-Tg mouse embryos. (B) Schematic diagram for 
procedures of repetitive seeded fibrillization in vitro which resulted in evolution of strain A pffs into strain B 
and post-B strains. (C) α-syn and tau pathologies caused by seeded 1-120-Myc pffs (strain B) in PS19 and 
non-Tg neurons. (D) Phenotypic changes in α-syn and tau pathologies induced by wt full-length α-syn pffs of 
different self-seeding passages. For (A), (C) and (D), neurons were fixed 18 d after the initial addition of pffs 
and 1% Triton-X100 was added to 4% PFA during fixing to remove soluble proteins. Scale bar: 50 μm. See 
also Figure 4-S1. 
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Remarkably, a very different pattern of Triton-insoluble α-syn and tau inclusions was 
observed in neurons treated with a preparation of 1-120-Myc pffs generated through repetitive 
seeded fibrillization in vitro, whereby 5 or 10% of pffs from each passage were included as seeds 
in the fibrillization reaction of the subsequent passage (Figure 4-1B). While α-syn pathology was 
somewhat less abundant in the 18 d post-transduction culture as compared to that transduced 
with the de novo 1-120-Myc pffs, widespread fibrillar tau aggregates that extensively colocalized 
with neuritic α-syn inclusions were observed in both PS19 and non-Tg neurons (Figure 4-1C). 
Surprisingly, the extent of endogenous mouse tau pathology induced in non-Tg neurons by these 
α-syn pffs dramatically exceeded that induced by synthetic tau pffs as reported recently (Guo and 
Lee, 2013). To distinguish the two types of α-syn pffs that exhibit distinct seeding properties in 
neurons and hence are reminiscent of prion “strains”, we designate pffs with limited cross-
seeding ability of tau, which were used in all our previous α-syn transmission studies (Luk et al., 
2012b; Luk et al., 2009; Volpicelli-Daley et al., 2011), as strain A, and the newly discovered pffs 
with efficient cross-seeding of tau as strain B (Table 4-S2). The generation of strain B through 
repeated self-seeding in vitro was reproduced using several different batches of 1-120-Myc 
monomer, as confirmed by a phenotypic transition from a relative paucity of insoluble tau in early 
passages to the appearance of robust tau pathology induced by later passages of 1-120-Myc pffs 
(Figure 4-S1A). 
To test whether wild type (wt) full-length (FL) α-syn can also form strains A and B α-syn 
fibrils, non-Tg neurons were incubated for 18 d with FL α-syn pffs generated de novo (P1) or 
through repetitive self-seeding in vitro (P2 onwards) (Figure 4-1B). P1 pffs always behaved as 
strain A, resulting in profuse α-syn inclusions with minimal tau aggregation (Figure 4-1D). FL α-
syn pffs of subsequent passages led to diminishing α-syn pathology with small amounts of 
neuritic tau pathology first emerging in neurons transduced with P4 or P5 pffs, followed by full 
conversion to strain B that induces abundant tau pathology usually by P6 or P7 (Figure 4-1D). 
Such conversion of FL α-syn pffs from strain A towards strain B through repeated self-seeding in 
vitro was accomplished using four different batches of FL α-syn monomer, although this process 
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did not always give rise to prototypical strain B pffs that are defined by extensive colocalization 
between α-syn and tau pathologies in transduced neurons. An intermediate phenotype with 
relatively abundant tau pathology accompanied by far more abundant α-syn pathology was  
Figure 4-S1. Evolution of strains through repetitive self-seeding in vitro. (A) Phenotypical changes in 
insoluble tau aggregates (AT8) induced by different passages of 1-120-Myc pffs in PS19 neurons. (B) An 
example of α-syn and tau pathologies induced in non-Tg neurons when repetitive self-seeding led to 
incomplete conversion to strain B pffs. (C) Examples of post-B strains which resulted in morphologically 
distinct α-syn inclusions (predominantly granular aggregates for 1, prominent cell body accumulations 
together with elongated neuritic threads for 2) accompanied by variable extent of tau pathology in non-Tg 
neurons. Strain 2 shown here also induced occasional cell body accumulations of tau. For (A) – (C), soluble 
proteins were removed from neurons by 1% Triton-X100 in 4% PFA during fixing. Scale bar: 50 μm. 
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sometimes observed (Figure 4-S1B), which is likely due to incomplete conversion of strain A to 
strain B, resulting in a mixture of the two strains. Notably, continual self-seeding in vitro after full 
or partial conversion to strain B led to “strain drift” within a few passages, resulting in what we 
refer to as “post-B strains”, which induce a variable amount of tau pathology and morphologically 
diverse α-syn inclusions (Figure 4-S1C, Table 4-S2).  
Characterization of neurons transduced with different strains of α-syn pffs 
A previous study used immuno-electron microscopy (immuno-EM) to show that abundant 
phospho-α-syn-positive filaments formed throughout the cell bodies and processes of neurons 
transduced with α-syn pffs that are now designated as strain A (Volpicelli-Daley et al., 2011). 
Similarly, we found cytoplasmic α-syn filaments in strain B pff-transduced neurons using immuno-
EM, but mostly confined to neurites (Figure 4-2A and B). Meanwhile, filamentous aggregates that 
are immunoreactive for phospho-tau were observed in neurons treated with strain B pffs, 
confirming that fibrillization of tau indeed was induced by pathological α-syn (Figure 4-2C and D). 
Immunocytochemistry on neurons incubated for different durations with α-syn pffs 
generated from either FL or 1-120-Myc α-syn more clearly revealed differences between the two 
strains (Figure 4-3 and Figure 4-S3, respectively). While non-Tg neurons transduced with strain A 
pffs were replete with α-syn pathology in the absence of any overt tau pathology at 10 d post-
transduction, those transduced with strain B pffs showed only sparse α-syn aggregates, but a 
small amount of neuritic tau accumulations was already detected (Figure 4-3A and Figure 4-S3A). 
However, by 14 d and 18 d post-transduction, the burden of α-syn aggregates increased in strain 
B transduced neurons, accompanied by a dramatic surge in the levels of tau aggregates, nearly 
all of which colocalized with the α-syn pathology (Figure 4-3A-D, Figure 4-S3A). In contrast, strain 
A-induced α-syn pathology appeared to plateau at 14 d post-transduction, but appreciable 
neuritic tau pathology never occurred despite higher abundance of α-syn inclusions in these 
neurons than in strain B-transduced neurons at all time points tested. The distinct seeding 
properties of the two strains of α-syn pffs were confirmed biochemically by immunoblotting 
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lysates from neurons that were sequentially extracted with 1% Triton-X100 lysis buffer followed 
by 2% SDS lysis buffer. Triton-insoluble tau was only detected in strain B pff-transduced neurons, 
being most prominent after 18 d incubation, even though Triton-insoluble α-syn was much more 
abundant in neurons treated with strain A pffs (Figure 4-3E and F, Figure 4-S3B). 
 
Figure 4-2. Ultrastructural analysis of strain B α-syn pff-induced cytoplasmic filaments by 
immuno-EM. (A) and (B) 81A immunoreactive α-syn filaments observed in strain B α-syn pff-
transduced neurons using immuno-EM labeled by nanogold. (C) and (D) AT8-positive tau 
filaments detected in these neurons by immuno-EM using nanogold amplification. Scale bar: 500 
nm. 
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Consistent with our previous study (Volpicelli-Daley et al., 2011), strain A pffs were highly 
toxic to neurons as evidenced by visual inspection after 14 d incubation, as well as by 
significantly increased Lactate dehydrogenase (LDH) release and reduced metabolic activity 
(Figure 4-3G, Figure 4-S3C and D). In stark contrast, strain B pffs had no negative impact on cell 
survival even after 18 d incubation. Immunostaining of microtubule-associated protein 2 (MAP2) 
and neurofilament light chain (NFL) in 18 d post-transduction neurons showed bundled but intact 
neuronal processes in strain B treated neurons, whereas the integrity of both dendrites and axons 
was severely compromised in strain A-treated neurons as indicated by a dramatic reduction in the 
density of both MAP2 and NFL staining and frequent beading of dendritic MAP2 staining (Figure 
4-S3E). The prominent reduction of soluble tau in 18 d strain A-transduced neuron lysates was 
most likely a result of extensive cell death as well (Figure 4-3E and F, Figure 4-S3B). As shown 
previously (Volpicelli-Daley et al., 2011), strain A pffs per se are not toxic to α-syn knock-out 
neurons, thus their toxicity in α-syn-expressing neurons must be due to the massive aggregation 
and/or simultaneous depletion of soluble functional α-syn. The lack of toxicity of strain B pffs at 
the post-transduction time intervals examined here is therefore most likely due to the reduced 
induction of α-syn pathology, but we surmise that toxicity could emerge after longer incubation. 
Although strain B pffs caused widespread aggregation of tau as detected by immunostaining, the 
actual amount of insoluble tau induced only constituted a very small fraction of total tau as shown 
by immunoblotting (Figure 4-3E and F). 
Biophysical and biochemical analyses of α-syn pff strains 
Since the distinct seeding properties of the two strains of α-syn pffs could reflect 
structural differences between them, we tested this hypothesis in a series of biophysical and 
biochemical analyses performed on α-syn strain A and B pffs that were verified by neuronal 
phenotyping. No convincing difference in the morphology of filaments could be identified between 
the two strains using negative staining transmission EM (TEM), which revealed that 1-120-Myc 
pffs of both strains are ~9 nm in diameter and FL α-syn pffs are ~10-11 nm in diameter (Figure 4-
4A). Equal concentrations of fibrils of both strains demonstrated a wide range of ThT  
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Figure 4-3. Inverse seeding capacity for α-syn and tau pathologies accompanied by differential 
cellular toxicity. (A) Immunostaining for insoluble phospho-α-syn (81A) and phospho-tau (AT8) at different 
time points (10 d, 14 d, 18 d) after the addition of strain A or strain B FL α-syn pffs into non-Tg neurons. 1% 
Triton-X100 was added to 4% PFA during fixing to remove soluble proteins. (B) and (C) Quantification of % 
area occupied by 81A- and AT8-labeled pathologies respectively for experiments described in (A) (n = 4 
different preparations of strain A and strain B pffs; results shown as mean +/- SEM. *: p < 0.05; **: p < 0.01; 
***: p < 0.0005). (D) Calculation of % of α-syn pathology with colocalizing tau pathology (area occupied by 
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81A/area occupied by AT8 x 100%) for strain B pff transduced neurons (n = 4 different preparations of strain 
B pffs; results shown as mean +/- SEM. ***: p < 0.0005; ****: p < 0.0001). (E) PS19 neurons treated with 
PBS, or transduced with strain A or strain B FL α-syn pffs were sequentially extracted with 1% Triton-X100 
lysis buffer (T) followed by 2% SDS lysis buffer (S) at different time points. Neuron lysates from T and S 
fractions were immunoblotted with 17025 (total tau), T14 (human tau), AT8 (phospho-tau), T49 (mouse tau), 
81A (phospho-α-syn), and GAPDH antibody (loading control). (F) Non-Tg neurons at 18 d post-transduction 
of strain A or strain B FL α-syn pffs were sequentially extracted and immunoblotted with AT8, T49, mouse α-
syn and GAPDH antibodies. (G) LDH assay on non-Tg neurons transduced with strain A or strain B FL α-
syn pffs at 14 d and 18 d post-transduction (n = 4 independent batches of neurons; results shown as mean 
+/- SEM. *: p < 0.05; ***: p < 0.005). Scale bar: 50 μm. See also Figure 4-S3. 
 
fluorescence signal without clear separation between them (Figure 4-4B). In addition, Fourier 
transform infrared spectroscopy (FTIR) and circular dichroism (CD) also failed to show 
conspicuous differences between these two strains (Figure 4-4C and D), suggesting that 
whatever structural differences exist must be too subtle to be revealed by techniques that only 
measure gross structural features. 
To test whether α-syn pff strains can be distinguished biochemically using proteinase K 
(PK) digestion, as originally demonstrated for human prion strains (Aguzzi et al., 2007; Parchi et 
al., 1996), different passages of FL α-syn pffs generated through self-seeding in vitro were 
incubated with PK at 37 °C. The digestion products predominantly consist of 5 bands running 
between 10 and 15 kDa, with the 5th band being least abundant for de novo P1 pffs that are 
strain A (Figure 4-5A). Notably, the 5th band consistently became highly prominent around P5-
P7, thereby correlating with the neuronal phenotypic transition into strain B. The relative intensity 
of the 5th band compared to the 1st band typically shows a decline from P1 to P2, followed by an 
upward trend at later passages (Figure 4-5B), suggesting stereotypical conformational changes 
generated by repetitive seeded fibrillization. 
To directly examine whether the two strains of pffs show distinct PK digestion patterns, 
neuronal phenotype-confirmed strain A and strain B pffs were incubated with different 
concentrations of PK (Figure 4-5C). No significant difference in overall PK resistance was  
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Figure 4-S3. Differential seeding capacity and toxicity of the two strains of α-syn pffs. (A) 
Immunostaining for insoluble phospho-α-syn (81A) and phospho-tau (AT8) at different time points (10 d, 14 
d, 18 d) after the addition of strain A or strain B 1-120-Myc α-syn pffs into non-Tg neurons. 1% Triton-X100 
was added to 4% PFA during fixing to remove soluble proteins. (B) PS19 neurons treated with PBS, or 
transduced with strain A or strain B 1-120-Myc pffs were sequentially extracted and immunoblotted with the 
same antibodies as in Figure 4-3. (C) LDH assay on non-Tg neurons transduced with strain A or strain B 1-
120-Myc pffs at 14 d and 18 d post-transduction (n = 4 independent batches of neurons; results shown as 
mean +/- SEM. *: p < 0.05; **: p < 0.01; ***: p < 0.005). (D) Alamar blue assay on non-Tg neurons after 18 d 
incubation with PBS, strain A or strain B pffs (n = 4 independent batches of neurons; results shown as mean 
+/- SEM. *: p < 0.05; ***: p < 0.005). (E) Immunostaining of differently treated non-Tg neurons at 18 d post-
transduction using antibodies specific for MAP2 and NFL. Scale bar: 50 μm. Arrows point to examples of 
dendritic MAP2 beading. 
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observed, such that no loss in the total amount of α-syn proteins was seen after each strain was 
treated with PK (Figure 4-S5A). Since the 1st band of the PK digestion products migrates with the 
same mobility as FL α-syn on denaturing gels, it presumably represents residual uncleaved FL α-
syn pffs in the reaction mixture. Detailed analysis of all 5 bands revealed a significantly higher 
ratio of cleaved species (sum of 2nd to 5th bands) to uncleaved α-syn (1st band) for strain B pffs at 
all tested PK concentrations (Figure 4-5D), and this difference was predominantly driven by 
increased relative abundance of the 3rd and 5th bands in the strain B digestion products, with the 
5th band most dramatically differentiating the two strains at 2.5 μg/ml PK (Figure 4-5E and F, 
Figure 4-S5B and C). 
N-terminal sequencing indicated that both the 2nd and the 4th bands primarily contain α-
syn peptides starting around residues 19-21, while the 3rd and the 5th bands both start at residue 
31 (Figure 4-5A). Epitope mapping, using a panel of antibodies recognizing different regions of α-
syn (see Table 4-S1), confirmed that all cleavage products (2nd to 5th bands) are N-terminal 
truncated except for a small fraction of N-terminal intact peptide contained in the 3rd band (Figure 
4-5G, SNL-4 and Syn506 immunoblots). As expected, the non-amyloid component (NAC) domain 
of α-syn, which makes up the central amyloidogenic core of α-syn fibrils (Giasson et al., 2001), is 
preserved in all PK-resistant fragments, including a faint 6th band that is only detected by NAC 
domain-specific antibody and only present in PK digested strain B pffs. A C-terminal specific 
antibody revealed that the extreme C-terminus (Figure 4-5G, syn102 immunoblot) is largely intact 
in the 2nd and 3rd bands but absent in the 4th and 5th bands. Although the exact C-terminal 
truncation sites for the 4th and 5th bands were not determined, the cleavage point is likely around 
residue 125 based on LB509 and Syn211 recognition (epitopes at amino acids 115-122 and 121-
125, respectively) of all 5 bands. In summary, both the 3rd and 5th bands, which are more 
prominent in PK-digested strain B pffs, consist of peptides N-terminally cleaved after residue 30, 
while the 5th band has an additional C-terminal cleavage site around residue 125 (Figure 4-5H). 
Increased N- and C-terminal truncation of strain B pffs by PK suggests that the two termini may 
be more exposed for PK access in strain B than in strain A pffs. Moreover, the two strains of pffs  
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Figure 4-4. Biophysical studies on the two strains of α-syn pffs. (A) Negative staining TEM images of 
strain A and strain B α-syn pffs assembled from FL α-syn and 1-120-Myc. Scale bar: 100 nm. (B) ThT 
binding assay of strain A and strain B FL α-syn pffs (n = 8; results shown as scatterplot with mean +/- 
SEM). (C) FTIR on the two strains of FL α-syn pffs (results from 3 independent experiments were 
superimposed). (D) CD on the two strains of 1-120-Myc pffs (n = 3, results shown as mean +/- SEM). 
 
made from 1-120-Myc, which lacks the C-terminal cleavage site for PK, also can be clearly 
distinguished by an elevated amount of PK digestion product starting at residue 31 for strain B 
(Figure 4-S5D), further supporting increased PK cleavage at the N-terminus as a biochemical 
signature for strain B pffs. 
Induction of pathological strains on endogenous α-syn 
Although strain B α-syn pffs can efficiently induce endogenous tau aggregation in non-Tg 
neurons, this cross-seeding phenomenon failed to occur in α-syn knock-out neurons (data not 
shown), thereby indicating that the fibrillization of mouse tau seen in non-Tg neurons must be 
mediated via endogenous mouse α-syn. It is conceivable that the internalized α-syn pffs  
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Figure 4-5. Conformational differences between the strains revealed by proteinase K (PK) digestion. 
(A) Different passages (P1-P7) of self-seeded FL α-syn pffs were incubated with 2.5 μg/ml of PK at 37°C for 
30 min, resolved on 12% Bis-Tris gel and stained with Coomassie blue. Results from one representative 
series were shown. N-terminal sequencing results for the 2nd to 5th bands were presented in brackets. (B) 
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Quantification of the relative intensity of the 5th band to the 1st band for experiments described in (A). 
Results from 3 series of self-seeded FL α-syn pffs were shown. (C) Pairs of strains A and B FL α-syn pffs 
made from the same batches of monomer were incubated with different concentrations of PK (1, 1.5, 2, 2.5 
μg/ml) at 37°C for 30 min. Digestion products from two pairs of pffs were shown here. Untreated pffs were 
loaded on the same gels (0 μg/ml). (D) Quantification of the ratio of cleaved species (sum of the 2nd to 5th 
bands) to uncleaved molecules (the 1st band) for experiments described in (C) (n = 4 sets of strains A and B 
FL α-syn pffs; results shown as mean +/- SEM. **: p < 0.01). (E) Quantification of the ratio of the 3rd band to 
the 1st band for the same samples shown in (D) (results shown as mean +/- SEM. *: p < 0.05; **: p < 0.01). 
(F) Quantification of the ratio of the 5th band to the 1st band for the same samples shown in (D) (results 
shown as mean +/- SEM. **: p < 0.01; ***: p < 0.001). (G) Three pairs of strains A and B FL α-syn pffs were 
digested with 2 or 2.5 μg/ml of PK at 37°C for 30 min and immunoblotted with antibodies recognizing 
different epitopes of α-syn indicated in brackets. (H) Deduced identities of major products from PK digestion. 
(I) 1% Triton-insoluble extracts from strain A or strain B pff transduced neurons were digested with 2 μg/ml 
of PK for 30 min at 37°C and immunoblotted with polyclonal antibody specific for mouse α-syn. For non-
digested control, neuron extracts loaded were 1/3 of that used for digestion. (J) Quantification of PK 
resistant Triton-insoluble endogenous mouse α-syn for experiments described in (H) (n = 4 different sets of 
strains A and B FL or 1-120-Myc α-syn pffs; results shown as mean +/- SEM. **: p < 0.005). See also Figure 
4-S5. 
 
Figure 4-S5. Biochemical analysis on the two strains of α-syn pffs. (A) Quantification of % PK-resistant 
α-syn (sum of 5 bands with PK digestion/non-digested pffs x100%) for experiments described in Figure 4-
5C. (B) Quantification of the ratio of the 2nd band to the 1st band for experiments described in Figure 4-5C. 
(C) Quantification of the ratio of the 4th band to the 1st band for experiments described in Figure 4-5C. (D) 
An example of strain A and strain B 1-120-Myc pffs digested with 2 μg/ml of PK at 37°C for 30 min, stained 
with Coomassie blue, and immunoblotted with different epitope-specific α-syn antibodies. N-terminal 
sequencing results were shown in brackets. 
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themselves provide an insufficient quantity of nucleating structures to directly trigger tau 
fibrillization, presumably due to a less efficient cross-seeding of tau than homotypic seeding of α-
syn, whereas endogenous α-syn aggregates templated by internalized pffs create additional α-
syn seeding structures that may reach a quantity sufficient to initiate the conversion of soluble tau 
into fibrillar aggregates. Such a 2-step templated recruitment mechanism is supported by an 
exponential increase in the percentage of α-syn pathology that colocalizes with tau pathology 
over time, which is consistent with the interpretation that tau aggregation lags behind that of α-
syn (Figure 4-3A and D). It thus follows that endogenous α-syn must have adopted distinct 
conformations upon seeding by different exogenous pff strains in order to give rise to the 
disproportionate extent of tau pathology. Indeed, Triton-insoluble mouse α-syn extracted from 
strain B pff-transduced neurons revealed consistently lower PK resistance than that extracted 
from strain A pff-transduced neurons (Figure 4-5I and J), even when higher amounts of lysates 
from strain B-transduced neurons were used for PK digestion to adjust for less abundant 
insoluble α-syn (data not shown), although no significant differences in the banding patterns were 
observed. Taken together, these experiments demonstrate that conformationally different α-syn 
aggregates can be generated not just from purified recombinant protein, but also from 
intracellularly expressed protein. 
The roles of N- and C- termini in strain conformations 
 Since possible conformational changes of α-syn pffs at the N- and C-termini correlate 
with phenotypic conversion from strain A to strain B, we further investigated whether the two 
termini play causal roles in strain evolution by testing self-seeded pffs assembled from N- or C-
terminal truncated α-syn molecules (Figure 4-6A, results summarized in Table 4-S3). 
Interestingly, pffs made from N-terminal truncated α-syn 58-140 and 32-140 almost always 
remained incapable of cross-seeding tau up to P10 of self-seeding despite efficient induction of α-
syn pathology (Figure 4-6B). One simple explanation for failed cross-seeding could be that the N-
terminus of α-syn pffs is required for direct interaction with tau to trigger its misfolding, but this 
possibility is unlikely since the experiments described above showed that exogenous strain B pffs 
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do not directly induce tau pathology, which implicates endogenous full-length α-syn as the 
obligatory mediator of tau aggregation regardless of the pffs that are transduced (Figure 4-6A). A 
more plausible alternative explanation is that the N-terminus of α-syn may be necessary for 
generating a cross-seeding competent conformation in the exogenous α-syn pffs which can then 
be conferred onto endogenous α-syn through templating. Besides the lack of tau cross-seeding, 
both 58-140 and 32-140 pffs remained phenotypically stable in terms of α-syn pathology induced 
by different passages of pffs in neurons. While 32-140 pffs constantly behaved as strong strain A 
pffs, inducing highly abundant LB and LN like α-syn inclusions after 7 d incubation and frequently 
resulting in extensive cell death at 18 d post-transduction, 58-140 pffs invariably led to 
morphologically distinct α-syn aggregates, consisting of unusually long fibrillar accumulations in 
neurites with almost no cell body inclusions (Figure 4-6B). The distinct pattern of α-syn inclusions 
induced by 58-140 pffs could be caused by near complete loss of the lipid-binding N-terminus in 
58-140, which may potentially alter pff uptake and/or intracellular seeding mechanisms. However, 
FL α-syn pffs are also capable of acquiring similar seeding properties in neurons when their in 
vitro fibrillization is templated by 58-140 pffs (Figure 4-S6A), thus pointing to a unique 
conformation adopted by 58-140 pffs that can be acquired by FL α-syn. 
 The similar behavior of 1-120-Myc and FL α-syn in strain evolution suggests the extreme 
C-terminus may play a minimal role in pff conformation. Surprisingly, 1-120 without a myc tag at 
the C-terminus stochastically gave rise to different strains of de novo pffs, i.e., sometimes strain 
A, occasionally weak strain B, but most frequently fibrils with phenotypes resembling one of the 
post-B strains inducing granular α-syn inclusions, or behaving as 58-140 pffs leading to elongated 
fibrillar aggregates of α-syn (Figure 4-S6B). There was also no predictable pattern of strain 
conversion through repetitive self-seeding. Therefore, unlike the N-terminus of α-syn which 
appears to contribute to conformational diversities of fibrils generated through repeated self-
seeding, the C-terminus seems to normally limit or impede the generation of structurally diverse 
strains. The much more predictable behavior of 1-120-Myc may be due to the enriched negative 
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charges in the Myc tag that is attached after residue 120, which happen to partially mimic the 
natural C-terminus of FL α-syn. 
Figure 4-6. The roles of N- and C-termini in strain conformations. (A) Schematic diagram for testing the 
roles of N- and C-termini in generating or adopting strains A and B conformation. (B) Pathology induced by 
de novo or self-seeded (P1-P10) 58-140 or 32-140 pffs in non-Tg neurons. Cells were fixed at 18 d post-
transduction for 58-140 pffs but at 7 d post-transduction for 32-140 pffs due to extensive cell death caused 
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by the latter at later time points. (C) Insoluble α-syn aggregates resulted from 1-120 or 58-140 pffs that were 
initially seeded by strain A pffs. Cells were fixed at 18 d post-transduction. (D) Insoluble α-syn and tau 
aggregates induced by FL α-syn, 58-140, 32-140, or 1-120 pffs that were seeded by strain B pffs at 18 d 
post-transduction. (E) Quantification of % area occupied by AT8-labeled tau pathology for experiments 
described in (D) (number of independent preparations of pffs tested: n = 5 for 10% seed control, n = 4 for 
FL, n = 5 for 58-140, n = 8 for 32-140, n = 4 for 1-120; results shown as scatterplot with mean +/- SEM. **: p 
< 0.005; ***: p < 0.0005; ****: p < 0.0001). (F) Calculation of % of α-syn pathology with colocalizing tau 
pathology for experiments described in (D) (same number of independent pff preparations tested as in (E), 
****: p < 0.0001). For (B), (C) and (D), soluble proteins were removed from neurons by 1% Triton-X in 4% 
PFA during fixing. Scale bar: 50 μm. See also Figure 4-S6. 
 
To test whether the N- and C-termini are merely facilitating the acquisition of strain-
specific conformations by middle regions of α-syn, or instead are an integral part of a particular 
conformation, N- or C-terminal truncated α-syn proteins were fibrillized in the presence of 10% 
strain A or 10% strain B pffs to test their ability to conform to these respective strains when 
seeded (Figure 4-6A, results summarized in Table 4-S3). For strain A-seeded fibrillization, an 
additional round of self-seeding was conducted on P2 fibrils to dilute out the original strain A 
seeds, which can potentially mask the phenotypes of seeded pffs formed by truncated α-syn. 
Unlike the stochastic nature of its spontaneous fibrillization, 1-120 faithfully acquired strain A 
phenotype when seeded by strain A pffs (Figure 4-6C). This cannot be accounted for by the 
residual 1% strain A seeds present in the fibrillization mixture (Figures 4-S6C), suggesting that 
the extreme C-terminus is not an essential part of strain A conformation, although it normally 
assists the other regions of α-syn to acquire that conformation. In contrast, strain A-seeded 58-
140 pffs still predominantly induced elongated α-syn accumulations with infrequent cell body 
inclusions (Figure 4-6C), similar to pathology induced by typical 58-140 pffs mixed with 1% strain 
A seeds right before transduction to simulate failed strain A conversion (Figures 4-S6C). 
Therefore, the absence of residues 1-57 impairs the acquisition of strain A conformation. As 
expected from the spontaneous generation of strain A pffs, 32-140 pffs seeded by strain A always 
displayed typical strain A phenotypes (data not shown), confirming that residues 1-31 are not an 
integral part of strain A core structure. This in turn points to residues 32-57 as an important region 
of α-syn needed to adopt the strain A configuration, accounting for the different properties of 32-
140 and 58-140 pffs. 
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Figure 4-S6. Conformational roles of N- and C-termini. (A) FL α-syn fibrillization was seeded by 10% of 
58-140 pffs and the resulted P2 pffs were used to seed another round of fibrillization of FL α-syn, leading to 
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the formation of P3 pffs. Pathology induced by these P3 pffs initially seeded by 58-140 pffs is 
indistinguishable from pathology induced by typical 58-140 pffs, and the extent of pathology significantly 
exceeded what could be caused by the residual 1% 58-140 pff seeds. Quantification of % area occupied by 
α-syn aggregates: n = 4 for 58-140 seeded FL pffs P3, n = 2 for 1% 58-140 pff control; results shown as 
scatterplot with mean +/- SEM; ***: p < 0.0005. (B) Phenotypic variations of de novo 1-120 pffs (P1) shown 
in non-Tg neurons. (C) Control experiment for Figure 4-6C: Non-Tg neurons were transduced with 99% 1-
120 pffs of various strains or 99% 58-140 pffs (1.98 μg per coverslip) mixed with 1% strain A pffs (0.02 μg 
per coverslip) right before being added to neurons to simulate failed strain A conversion. The pattern of α-
syn pathology induced appeared to be driven predominantly by 1-120 or 58-140 pffs which were added at a 
much higher dose. (D) Control experiment for Figure 4-6D: only sparse α-syn and tau pathologies were 
induced by 10% strain B seeds alone (0.2 μg per coverslip) in non-Tg neurons. For (A) – (D), soluble 
proteins were removed from neurons by 1% Triton-X100 in 4% PFA during fixing. Scale bar: 50 μm. 
 
When seeded by strain B pffs, FL α-syn, 32-140 and 1-120 all reliably acquired the ability 
to induce tau aggregation far beyond what could be attributed to the 10% strain B seeds present 
in the fibrillization mixture (Figure 4-6D and E, compare with Figure 4-S6D). The extensive 
colocalization between endogenous α-syn and tau pathology (Figure 4-6D and F) further supports 
the induction of specific endogenous α-syn conformers that are capable of cross-seeding tau. 
Therefore, although the initial 31 residues at the extreme N-terminus and the last 20 residues at 
the C-terminus may facilitate the spontaneous generation of strain B by FL α-syn through 
repetitive self-seeding, they do not constitute the core structure of the strain B conformation. 
However, we did notice significantly less abundant aggregation of both α-syn and tau induced by 
strain B-seeded 32-140 and 1-120 than by equivalently seeded FL α-syn pffs (Figure 4-6E), 
despite similar percentages of α-syn pathology with colocalizing tau pathology. This suggests that 
the lack of the extreme N- or C-terminus of α-syn may result in reduced efficiency in strain B-
templated fibrillization, although we cannot rule out the possibility that acquisition of the strain B 
conformation somehow compromises the internalization of N- or C-terminal truncated α-syn pffs. 
On the other hand, strain B-seeded 58-140 pffs still behaved exactly the same as spontaneously 
generated 58-140 pffs, with the vast majority of α-syn aggregates showing no colocalizing tau 
pathology and the sparsely distributed tau inclusions being entirely accounted for by the 10% 
residual strain B seeds (Figure 4-6D, E and F), thereby indicating a complete failure to adopt the 
strain B conformation. The striking difference between 32-140 and 58-140 when seeded by strain 
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B further implicates the critical role of residues 32-57 in the generation of the strain B 
conformation, as well as the strain A conformation as noted above. 
Strain-specific cross-seeding of tau pathology in vivo 
To test whether the two strains of α-syn pffs differentially induce tau pathology in vivo, we 
performed unilateral inoculation of strain A or B α-syn pffs into the hippocampus of 2-3 month old 
PS19 mice, which over-express human P301S mutant tau, prior to the onset of extensive 
transgene-induced tau pathology at ~12 months of age (Iba et al., 2013). The induction and 
spreading of tau inclusions were examined using immunohistochemistry at different time points 
after α-syn pff inoculation (Figure 4-7A). At 3 months post-injection, only a few rare cells showed 
abnormal accumulation of hyperphosphorylated tau recognized by mAb AT8 near the injection 
site of strain A-inoculated mice, whereas numerous neurons bearing AT8-positive tau inclusions 
were observed in strain B-injected mice around the same area (Figure 4-7A and B). Moreover, 
phospho-tau aggregates were also found in parts of the hippocampus that are more rostral and 
caudal to the injection site, which suggests transmission of cross-seeded tau pathology, and 
strain B-injected mice displayed significantly more tau inclusions in these regions as well. For 
reasons that are unclear, the caudal hippocampus consistently showed more abundant tau 
aggregates than the injection site, regardless of α-syn pff strain injected. The differential induction 
of pathological tau aggregates by the two strains of pffs was confirmed using mAb MC1, a 
monoclonal antibody (mAb) specific for a pathological conformation of tau (Jicha et al., 1997) 
(Figure 4-7C). 
At 6 months post-injection, mice inoculated with strain B pffs continued to show 
significant tau pathology, although there was only a minor increase in the rostral and caudal 
hippocampus and even a slight reduction of pathology around the injection site as compared to 
the 3 month post-injection mice. On the other hand, strain A-injected mice demonstrated an 
obvious increase in phospho-tau aggregates after 3 and 6 additional months of post-injection 
time, but even at 9 months post-injection, the extent of tau pathology in mice receiving strain A 
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was far less than that induced by strain B pff injection (Figure 4-7A and B). These results clearly 
illustrate the greatly enhanced tau cross-seeding capacity of strain B pffs compared to strain A 
pffs in living animals, exactly as observed in cultured neurons. 
Figure 4-7. Strain-specific cross-seeding of tau pathology in vivo. (A) AT8-positive tau 
aggregates detected in different parts of ipsilateral hippocampus (rostral, near injection site, 
caudal) at 3, 6, or 9 months after inoculation of strain A or strain B 1-120-Myc pffs into the 
90 
 
hippocampus of PS19 mice. (B) Quantification of AT8-positive neurons in different parts of 
ipsilateral hippocampus for different experimental groups (n = 4 for 3 months post-injection of 
either strain, n = 4 for 6 or 9 months post-injection of strain A, n = 3 for 6 months post-injection of 
strain B; results shown as mean +/- SEM. *: p < 0.05. **: p < 0.005. ***: p < 0.0005. ****: p < 
0.00001). (C) MC1 immunoreactivity in different parts of ipsilateral hippocampus at 3 months 
post-injection. (D) Tau inclusions cross-seeded by strain B pffs were recognized by TG3 and Ac-
K280. All sections were counterstained with hematoxylin to reveal cell nuclei. Scale bar: 100 μm. 
 
Further characterization revealed that tau aggregates cross-seeded by α-syn pffs were 
also recognized by TG3, a conformational specific phospho-tau mAb, and Ac-K280, a polyclonal 
antibody specific for acetylated tau (Figure 4-7D), thus distinguishing them from spontaneously 
developed tau pathology in aged PS19 mice (Iba et al., 2013). However, unlike pathology induced 
by tau pff injections, which showed ThS staining as early as 2 weeks post-injection, minimal ThS 
binding was found even for strain B α-syn pff-induced tau aggregates at 6 months post-injection 
(data not shown), suggesting that tau aggregates induced by α-syn pffs may mature more slowly 
into β-sheet rich structures than those induced by tau pffs. 
4.4 Discussion 
Here we describe for the first time two distinct strains of synthetic α-syn pffs generated in 
vitro with dramatically different seeding properties in primary neurons. Strain A is highly 
efficacious in recruiting endogenous α-syn into aggregates, resulting in pronounced cellular 
toxicity, while strain B induces α-syn pathology at a much slower rate and is therefore benign to 
neurons over the post-transduction time intervals studied here. More remarkably, strain A shows 
limited capacity to induce tau aggregation, whereas strain B demonstrates surprisingly high 
efficiency in cross-seeding tau pathology. The strain-specific cross-seeding efficacy for tau was 
also fully recapitulated in tau Tg mice injected with these α-syn pffs, providing in vivo evidence for 
distinct pathological properties of the two synthetic strains. Notably, strain B can be derived from 
strain A through repetitive self-seeded fibrillization in vitro, the process of which is associated with 
progressively enhanced exposure of the N- and C-termini of α-syn in the fibrillized form as 
revealed by PK digestion. Therefore, α-syn pff strains represent different conformers of fibrillar α-
syn species with distinguishable templating activities in healthy neurons. 
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The concept of “strains” originated from the prion field, whereby different strains of prion 
are associated with distinct histopathological lesion profiles with varying clinical aggressiveness 
and the phenotypic differences are believed to be encoded by conformational differences in the 
infectious prion particles (Aguzzi et al., 2007; Bessen et al., 1995; Bessen and Marsh, 1994; 
Telling et al., 1996). The different forms of α-syn pffs we describe here closely parallel prion 
strains in that they exhibit structural variations, differences in pathological manifestation, and 
heritability of phenotypic traits via direct seeding in vitro, except that most known prion strains 
originate in vivo from patients afflicted by a prion disease or animal models thereof and synthetic 
prions assembled from recombinant proteins generally show low infectivity in the absence of 
added cofactors (Colby et al., 2009; Makarava et al., 2010). Besides strain A and strain B, which 
are described in great detail here, we also observed several other α-syn strains with distinct 
seeding properties in neurons (summarized in Table 4-S2), exemplifying the diversity of synthetic 
α-syn strains that can be generated in vitro. 
Previous structural studies suggest the fibrillization core of α-syn spans from residues 30 
to ~100-110 (Comellas et al., 2011; Miake et al., 2002; Vilar et al., 2008), extending beyond the 
NAC domain (residues 61-95) that is both necessary and sufficient for α-syn fibrillization (Giasson 
et al., 2001; Iwai et al., 1995b; Luk et al., 2009). Here we showed that 58-140, which has an intact 
NAC domain, is fully capable of seeding intracellular fibrillization of endogenous α-syn, but 
generates a unique pathological conformer distinct from strain A or B, supporting the structural 
role of residues on the N-terminal side of NAC domain in regulating distinct α-syn fibril 
conformations. Moreover, in stark contrast to 32-140, 58-140 is deficient in acquiring either strain 
A or strain B conformation when seeded (Table 4-S3), suggesting that residues 32-57 constitute 
a critical part of the fibrillization core for both strains and the exact folding of this region within 
fibrillar α-syn strongly influences its seeding properties in neurons. The malleable nature of this 
region is consistent with a high resolution solid-state NMR study showing that the β-strand 
consisting of residues 38-49 displays more dynamic structure than other β-strands in the fibril 
92 
 
core, while residues in the NAC domain demonstrate the most rigid structure (Comellas et al., 
2011). 
Experiments on 32-140 and 1-120 (refer to Table 4-S3) revealed that the N- and C-
termini both facilitate the stereotypical conversion of strain A into strain B with continual seeding, 
although they themselves are not part of the core structure for either strain. Consistent with 
earlier studies (Miake et al., 2002; Murray et al., 2003; Vilar et al., 2008), our PK digestion 
experiments indicated that the N- and C-termini are more accessible than the NAC domain in α-
syn fibrils. NMR studies also suggest the two termini are structurally more flexible than the fibril 
core (Comellas et al., 2011; Vilar et al., 2008). The intriguing correlation between seeding 
phenotypes and relative exposure of the two termini in α-syn pffs revealed by PK digestion further 
suggests that increased exposure of the two termini may somehow promote rearrangement of the 
fibrillization core from strain A conformation towards strain B conformation. Interestingly, while the 
N-terminus appears to be required for spontaneous generation of structural diversity within the 
fibrillization core, the C-terminus normally restrains the core domain from stochastically evolving  
into diverse conformations, which could be related to the inhibitory effects of C-terminus on 
fibrillization (Crowther et al., 1998; Murray et al., 2003). On the other hand, since the two extreme 
termini lie outside the fibrillization core, PK digestion patterns which merely provide clues about 
relative accessibility of the termini can only be considered as a surrogate marker for strains. 
Detailed atomic-level analysis, such as high resolution solid-state NMR spectroscopy, would be 
required to unveil exact strain-specific folding patterns of fibrillar α-syn. 
In this study we demonstrated that a spectrum of α-syn strains can arise from the 
simplest reactions in a cell-free system without any cofactors. One can well imagine that in real 
human brains with a highly complex cellular and biochemical environment, the likelihood of 
forming diverse strains would be far greater. Interestingly, LBs found in midbrain structures such 
as the substantia nigra are morphologically different from those found in the cortical regions 
(Hurtig et al., 2000; Spillantini et al., 1998a), possibly representing distinct strains of α-syn 
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aggregates formed under specific cellular milieus associated with different brain regions. 
Moreover, in PD with dementia (PDD) or DLB cases with concomitant AD pathologies, NFTs are 
most frequently detected in the limbic and neocortical areas but not in the midbrain, independent 
from the density of LBs (Gearing et al., 1999; Gomez-Tortosa et al., 2000). This region-specific 
distribution of co-occurring NFTs could be due to selective vulnerability of different brain areas to 
tau aggregation, but it could also result from differential cross-seeding capacity of α-syn 
aggregates arising in these different regions analogous to synthetic α-syn strains observed in our 
study. In fact, close physical association of tau and α-syn deposits have been observed in 
synucleinopathies (Duda et al., 2002; Galloway et al., 1989; Ishizawa et al., 2003), supporting 
direct cross-seeding between the two types of pathologies. 
Besides differing cellular and biochemical factors, other events can also facilitate the 
generation of different α-syn strains in vivo. First, C-terminal truncation of α-syn has been 
detected in synucleinopathy brains (Baba et al., 1998; Campbell et al., 2001; Li et al., 2005). This 
cleavage event not only can accelerate fibrillization of α-syn (Crowther et al., 1998; Murray et al., 
2003), but was also shown to promote stochastic formation of diverse aggregated strains in our 
study. Thus, it is plausible that C-terminal truncated fibrils of different conformations can then 
serve as seeds to induce fibrillization of FL α-syn into different strains. Second, recent studies 
have implicated inter-neuronal transmission of α-syn aggregates as the underlying mechanism for 
stereotypical progression of α-syn pathology in PD and DLB (Luk et al., 2012a; Luk et al., 2012b). 
Since every transmission event from one neuron to the other can be viewed as a bona fide 
seeded fibrillization of α-syn in the recipient neuron and our study showed that continual seeding 
in vitro can lead to evolution of α-syn strains, it is possible that transmission of α-syn pathology 
along multiple neuronal connections could also give rise to divergent pathological strains. This 
hypothesis could potentially account for pathologically different LBs in substantial nigra versus 
neocortex, which are brain structures affected in distinct stages in the progression of LB diseases 
such as PD and DLB (Braak et al., 2003; Kosaka et al., 1988). 
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In addition to brain region-specific emergence of α-syn strains, different strains of α-syn 
aggregates could also underlie the tremendous heterogeneity of synucleinopathies among 
different individuals (Halliday et al., 2011). While mostly found in the neurites and neuronal cell 
bodies for the majority of synucleinopathies, α-syn inclusions are largely confined to 
oligodendrocytes in multiple system atrophy (Tu et al., 1998), which could be caused by a unique 
strain of pathological α-syn developing predominantly in oligodendrocytes but rarely in neurons. 
PDD and DLB, belonging to a continuum of LB diseases, are clinically stratified according to the 
interval between the onset of motor symptoms and that of cognitive deficits which can vary by 
decades (Ballard et al., 2006; McKeith, 2006; Tsuboi and Dickson, 2005). While co-morbid AD 
pathologies are more common in DLB than in PDD, a bimodal distribution of neocortical NFTs 
has been found in DLB cases (Gearing et al., 1999). Furthermore, several studies have 
suggested the existence of two subgroups of PDD patients, one group with younger onset, long 
motor-dementia interval and relatively long disease duration, and the other group with older 
onset, short motor-dementia interval and more malignant disease course (Compta et al., 2011; 
Halliday et al., 2008; Jellinger et al., 2002). Interestingly, the former usually presents purely LB 
pathologies, but the latter most often shows concomitant AD pathologies. Although co-morbid AD 
pathologies in PDD and DLB may develop independently from LB pathologies, our study raises 
the possibility that AD pathologies, especially NFTs, could be directly but variably induced by 
different strains of pathological α-syn, the underlying substrates for the vast clinical variations of 
synucleinopathies. 
Prior to our study, the ability for a single molecule of the same primary sequence to adopt 
multiple fibril structures has been shown for a variety of amyloidogenic proteins other than prion 
proten, including Aβ (Kodali et al., 2010; Meinhardt et al., 2009; Petkova et al., 2005), tau 
(Furukawa et al., 2011) and huntingtin with polyglutamine expansion (Nekooki-Machida et al., 
2009), although the pathological relevance of amyloid fibril polymorphism other than cellular 
toxicity has never been investigated in cells or animals. The recently developed neuronal and 
animal models of pathology transmission allowed us to demonstrate distinct pathological seeding 
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properties of specific α-syn fibril types generated in vitro and classify them into different strains. 
While future studies are required to verify the presence of α-syn strains in synucleinopathy brains, 
we speculate that perhaps besides inter-neuronal transmission of aggregated proteins, the 
existence of conformationally diverse protein strains underlying disease heterogeneity may be 
another common feature of neurodegenerative diseases which was thought to be unique to prion 
diseases. 
4.5 Materials and Methods 
Recombinant α-syn Purification and in Vitro Fibrillization 
FL α-syn (1-140), N-terminal or C-terminal truncated α-syn (32-140, 58-140, 1-120) and 
1-120 with a C-terminal Myc-tag (1-120-Myc) were expressed in BL21 (DE3) RIL cells and 
purified as previously described (Giasson et al., 2001). Fibrillization was conducted by diluting 
recombinant α-syn to 5 mg/ml in Dulbecco's PBS (Cellgro, Mediatech Inc; pH adjusted to 7.0) and 
incubating at 37 °C with constant agitation at 1,000 rpm for 5-7 d. Successful fibrillization was 
verified by sedimentation test and ThT-binding assay (see Extended Experimental Procedures). 
Pffs were stored at room temperature to avoid freeze and thaw. 
Repetitive self-seeding was carried out by including 5 or 10% of existing pffs (0.25 or 0.5 
mg/ml in the final reaction) in a fibrillization reaction containing 95% or 90% of fresh monomers 
(4.75 or 4.5 mg/ml in the final reaction) for generating the next passage of pffs and the process 
was repeated until passage 10 (de novo pffs considered as P1) (Figure 4-1B). For fibrillization 
directly seeded by strain A or strain B pffs, 10% of existing pffs of either strain was added to a 
fibrillization reaction containing 90% of fresh monomers. All seeded fibrillization was performed 
under the same conditions as de novo fibrillization. For each α-syn construct, at least two 
independently prepared monomer batches were tested for each fibrillization paradigm, and at 
least two series of self-seeded fibrillization were set up for each monomer batch. 
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Biophysical Analyses of α-syn pffs 
1-120-Myc α-syn strains A and B pffs were sonicated and diluted to a final concentration 
of 5 µM in 10 mM phosphate, 100 mM KF buffer (pH 7.3). CD spectra were collected according to 
a procedure adapted from the literature (Greenbaum et al., 2005). FL α-syn strains A and B pffs 
were spun at 100,000 g for 15 minutes and resuspended in D2O. This process was repeated two 
additional times and then each sample was sonicated 50 times. FTIR spectra were collected 
according to a procedure adapted from the literature (Huang et al., 2002). See Extended 
Experimental Procedures for details. 
PK digestion of α-syn pffs 
 10 μg of pffs were mixed with 1 to 2.5 μg/ml of PK in Dulbecco's PBS to a final volume of 
20 μl and incubated at 37°C for 30 min. Digestion was stopped with 1 mM PMSF. Reaction 
samples were boiled with SDS-sample buffer for 5 min and resolved on NuPAGE® Novex 12% 
Bis-Tris gels (Invitrogen). To identify the N-terminal sequences of PK-resistant fragments, 
samples were transferred from 12% Bis-Tris gel to a sequencing-grade PVDF membrane and 
individual bands were submitted to the Keck Biotechnology Resource Laboratory (Yale 
University) for N-terminal sequencing analysis. Epitope mapping of the PK digestion products 
was performed by immunoblotting samples that were transferred onto nitrocellulose membranes 
with epitope-specific antibodies to α-syn (see Table 4-S1). 
Primary Neuron Cultures and Fibril Transduction 
Primary neuron cultures were prepared from E15-E17 embryos from homo/het crosses of 
PS19 mice (Yoshiyama et al., 2007) or non-Tg CD1 mice (Charles River). All procedures were 
performed according to the NIH Guide for the Care and Use of Experimental Animals and were 
approved by the University of Pennsylvania Institutional Animal Care and Use Committee 
(IACUC). Dissociated hippocampal neurons were plated onto poly-D-lysine coated coverslips or 
dishes. Pff transduction was performed at 6 d or 7 d in vitro, whereby α-syn pffs were diluted to 
0.1 mg/ml in PBS and sonicated with 60 pulses before being added to neuron medium. For each 
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13 mm coverslip, 2 µg of pffs were added, and 8 µg of pffs were added per well for 6-well plates. 
Transduced neurons were harvested for immunocytochemistry or sequential extraction at time 
points indicated in the text. 
Immunocytochemistry  
Neurons were fixed with 4% paraformaldehyde (PFA) in PBS containing 2% sucrose for 
15 min and permeabilized with 0.1% Triton-X100 for 15 min, or fixed with 4% PFA containing 1% 
Triton-X100 for 15 min to remove soluble proteins. After blocking with 3% BSA and 3% FBS for at 
least 1 hr at room temperature, neurons were incubated with specific primary antibodies (see 
Supplementary Table 1) overnight at 4 °C followed by staining with appropriate Alexa fluor 594 or 
488-conjugated secondary antibodies (Invitrogen) for 2 hr at room temperature. Quantification for 
area occupied by pff-induced pathology was performed on 40x images using Image J (National 
Institute of Health). 
Sequential Extraction and Immunoblot Analysis on Neuron Lysates 
Sequential extraction of neurons and immunoblotting of neuron lysates was performed as 
previously described (Guo and Lee, 2013). See Extended Experimental Procedures for details. 
For PK digestion of neuron lysates, Triton-insoluble extracts were re-suspended in PBS and 
sonicated to clear the pellets before digested with 2 µg/ml of PK for 30 min at 37°C. Digested 
lysates were resolved on NuPAGE® Novex 12% Bis-Tris gels, transferred to nitrocellulose 
membranes and immunoblotted with polyclonal antibody specific for mouse α-syn (see Table 4-
S1). 
Cell Survival Assays 
LDH release assay and alamar blue assay were performed using CytoTox 96® Non-
Radioactive Cytotoxicity Assay kit (Promega) and alamarBlue® Cell Viability Assay kit 
(Invitrogen) respectively according to the manufacturers’ protocols (see Extended Experimental 
Procedures). 
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TEM and Immuno-EM 
Negative staining TEM of α-syn pffs and immuno-EM of transduced primary neurons 
were performed as previously described (Guo and Lee, 2011; Volpicelli-Daley et al., 2011). See 
Extended Experimental Procedures for details. 
Stereotaxic Surgery and Immunohistochemistry 
Unilateral inoculation of α-syn pffs into the hippocampus of 2-3 month old PS19 mice 
were performed using stereotaxic surgery as previously described (Iba et al., 2013) in accordance 
with protocols approved by the IACUC of the University of Pennsylvania. For each mouse, 5 µg of 
sonicated pffs were injected at a volume of 2.5 µl to one side of the hippocampus (Bregma -2.5 
mm, lateral +2 mm, and depth -1.8 mm). Immunohistochemical analysis of injected mice was 
conducted at 3, 6, and 9 months post-injection. Brains from perfused animals were fixed in 
formalin or 70% ethanol, embedded in paraffin blocks, cut into 6 µm-thick sections and 
immunostained with different antibodies (see Table 4-S1) using a polymer horseradish 
peroxidase detection system (Biogenex) and counterstained with hematoxylin. The number of 
neurons with cell body AT8 immunoreactivity was quantified using 20x images of coronal sections 
from 3 different regions (rostral hippocampus, medial hippocampus close to the injection site, 
caudal hippocampus). For each mouse, 2 sections from each of the 3 regions were used for 
quantification and the average of the 2 sections was included in the statistical analysis for 
individual regions. 
Statistical Analysis 
Two-tailed unpaired Student's t test was used for all the comparisons in the study, and 
differences with p values less than 0.05 were considered significant. 
4.6 Supplementary Materials 
Table 4-S1. Antibodies used in Chapter 4. 
Antibody Specificity  Host 
species 
Dilution Source or 
Reference 
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81A 
p-α-syn 
(phosphorylated at Ser 
129) 
mouse 
monoclonal 
1:5000 (ICC), 
1:1000 (WB), 
1:1000 (immuno-
EM) 
(Waxman and 
Giasson, 2008) 
AT8 
p-Tau (phosphorylated 
at Ser 202 and Thr 
205)  
mouse 
monoclonal 
1:1000 (WB, 
immuno-EM), 1:500 
(ICC), 1:10000 
(IHC) 
Innogenetics 
MC1 Tau in the pathological 
conformation 
mouse 
monoclonal 
1:2000 (IHC) Gift from Dr. Peter 
Davies Lab 
17025 Human recombinant 
tau 
rabbit 
polyclonal 
1:1000 (WB) (Ishihara et al., 
1999) 
T14 Human tau mouse 
monoclonal 
1:1000 (WB) (Kosik et al., 1988) 
T49 Mouse tau mouse 
monoclonal 
1:1000 (WB) (Ishihara et al., 
2001) 
GAPDH 
(6C5) 
Glyceraldehyde-3-
phosphate 
dehydrogenase  
mouse 
monoclonal 1:3000 (WB) 
Advanced 
Immunochemical 
Mse 40 Mouse α-syn (amino 
acids 115-125) 
rabbit 
polyclonal  
1:500 (WB) (Volpicelli-Daley et 
al., 2011) 
SNL-4 α-syn (amino acids 2-
11) 
rabbit 
polyclonal 
1:2000 (WB) (Giasson et al., 
1999) 
Syn506 α-syn (amino acids 2-
12) 
mouse 
monoclonal 
1:1000 (WB) (Waxman et al., 
2008) 
NAC α-syn (amino acids 75-
91) 
rabbit 
polyclonal 
1:500 (WB) (Giasson et al., 
2001) 
LB509 α-syn (amino acids 
115-122) 
mouse 
monoclonal 
1:2000 (WB) (Jakes et al., 1999) 
Syn211 α-syn (amino acids 
121-125) 
mouse 
monoclonal 
1:2000 (WB) (Giasson et al., 
2000b) 
Syn102 α-syn (amino acids 
131-140) 
mouse 
monoclonal 
1:1000 (WB) (Tu et al., 1998) 
TG3 
Conformational specific 
p-tau (phosphorylated 
at Thr 231) 
mouse 
monoclonal 1:250 (IHC) 
Gift from Dr. Peter 
Davies Lab 
Ac-K280 Tau acetylated at Lys 
280 
rabbit 
polyclonal 
1:2000 (IHC) (Cohen et al., 2011) 
17028 MAP2 rabbit 
polyclonal 
1:5000 (ICC) (Volpicelli-Daley et 
al., 2011) 
NFL Neurofilament light 
chain 
rabbit 
polyclonal 
1:2000 (ICC) In-house 
9E10 c-myc tag mouse monoclonal 1:1000 (WB) Santa Cruz 
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Table 4-S2. Summary of seeding phenotypes in non-Tg neurons for different strains of α-
syn pffs 
Strain Name α-syn pathology Tau pathology 
Strain A Highly abundant aggregation 
in both cell bodies and 
neurites. A mixture of short 
and long fibrillar 
accumulations. 
Little to rare neuritic 
accumulations. Punctate 
immunoreactivity associated 
with cell death does not 
colocalize with α-syn 
aggregates. 
Strain B Slow progression of 
aggregates which are mainly 
in the neurites. A mixture of 
short and long fibrillar 
accumulations. 
Widespread neuritic 
accumulations extensively 
colocalizing with α-syn 
aggregates. 
Post-B strain 1 Predominantly granular 
aggregates accompanied by 
long neuritic threads.  
Variably rare to frequent 
aggregates which colocalize 
with thread-like but not 
granular α-syn aggregates. 
Post-B strain 2 Prominent cell body inclusions 
accompanied by elongated 
neuritic accumulations. 
Variably rare to frequent 
neuritic aggregates with 
occasional cell body 
accumulations. 
58-140 like Long fibrillar accumulations 
along neurites with almost no 
cell body inclusions. 
None 
 
Table 4-S3. Summary of strains generated from different α-syn molecules under different 
seeding paradigms 
 Repetitive self-
seeding 
Seeding by strain A Seeding by strain B 
FL α-syn Strain A evolves into 
strain B 
Strain A Strain B 
58-140 58-140 like Predominantly 58-140 
like, with some strain 
A phenotype 
58-140 like 
32-140 Strain A Strain A Strain B 
1-120 Multiple strains Strain A Strain B 
 
Extended Experimental Procedures 
ThT binding assay 
1mM ThT diluted 40 fold in 100 mM glycine buffer (pH 8.5) was added to equal volume of 
50 fold diluted α-syn pffs and incubated for 5-10 minutes at room temperature. Fluorometric 
readings were taken at 450nm excitation and 510nm emission using SpectraMax plate reader. 
101 
 
 
Sequential Extraction and Immunoblot Analysis on Neuron Lysates 
Neurons were scraped into Triton lysis buffer (1% Triton X-100 in 50 mM Tris, 150 mM 
NaCl, pH 7.6) containing phosphatase and protease inhibitor cocktail, sonicated, and centrifuged 
at 100,000 g for 30 min at 4°C. Pellets were washed once in Triton lysis buffer, re-suspended into 
SDS lysis buffer (2% SDS in 50 mM Tris, 150 mM NaCl, pH7.6) at a volume that is ¼ of the Triton 
lysis buffer and centrifuged at 100,000 g for 30 min at 22°C. Supernatants from Triton X-100 and 
SDS extractions were resolved on SDS-PAGE, transferred to nitrocellulose membranes, and 
blocked in 5% milk or 7.5% BSA in TBS before immunoblotted with specific antibodies (see Table 
4-S1). 10 µg of proteins from Triton fractions and equal volume of corresponding SDS fractions 
were loaded per lane. 
 
Biophysical Analyses of α-syn pffs 
For CD analysis, sonicated and diluted pffs were transferred into a 1-mm quartz cuvette, 
and the CD spectra between 190 and 240 nm using 0.5 nm steps and 10 s averaging time were 
recorded using an Aviv model 202 spectrophotometer (Lakewood, NJ.). For all reported spectra, 
a background of pure buffer was subtracted and the spectra shown are an average of three 
samples with at least two fibril preparations measured. 
A Nicolet Magna-IR 860 spectrometer was used to collect FTIR spectra using 1 cm-1 
resolution. A CaF2 sample cell that was divided into two compartments and a Teflon spacer was 
used to allow the separate measurements of the sample and reference (D2O) under identical 
conditions. The optical path length of the sample cell was determined to be 52 µm by its 
interference fringe obtained from the transmittance signal of the empty cell. Temperature control 
with ~0.2 °C precision was obtained by a combination of a water bath (Haake K30) and a 
thermostated copper block. For all reported spectra, a background of pure buffer was subtracted 
and the spectra shown are an average of three samples with at least two fibril preparations 
measured. 
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TEM and immuno-EM 
For negative staining TEM, 6 μl of 50 fold diluted α-syn pffs was placed on 300 meshed 
Formvar/carbon film-coated copper grids (Electron Microscopy Sciences) for 3 min, washed twice 
with 50 mm Tris buffer (pH 7.6) for 5 min each, stained with 10–15 drops of 2% uranyl acetate, 
and visualized with Jeol 1010 transmission electron microscope (Peabody). 
For immuno-EM, pff transduced neurons were fixed in periodate-lysine-
paraformaldehyde, permeabilized with 0.05% saponin in PBS with 2% fish gelatin (PBS-FG) and 
0.05% thimerosal, incubated with mAb 81A (phospho-α-syn) or AT8 (phospho-tau) followed by 
incubation with goat anti-mouse IgG coupled to nanogold (Nanoprobes). The nanogold labeled 
neurons were postfixed and gold toned with 0.05% gold chloride.  
 
Cell survival assays 
 LDH release assay was performed on neuron medium at 14 d and 18 d after pff addition 
and medium was changed two days before each time point of test. After 30 min incubation of 50 
μl of medium with 50 μl of reconstituted substrate at room temperature, 50 μl of stop solution was 
added and absorbance at 490 nm was measured using SpectraMax plate reader. Background 
absorbance due to plain neuron medium was subtracted from all the readings. 
 For alamar blue assay, neurons were plated in 96-well plate for pff transduction. At 18 d 
post-transduction, 100 μl of fresh medium together with 10 μl of alamarBlue® reagent was added 
to each well of neurons and incubated for 4 hr in the 37°C incubator. Fluorometric readings were 
taken at 530nm excitation and 590nm emission using SpectraMax plate reader. 
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CHAPTER 5: General Conclusions and Further Discussion 
5.1 Templated recruitment as a common mechanism for the pathogenesis of 
neurodegenerative diseases 
  Studies described in chapter 2 and 3 demonstrated in non-neuronal cells as well as 
primary neurons that synthetic tau fibrils assembled from recombinant protein are able to 
spontaneously enter cells and nucleate the fibrillization of endogenous tau. In particular, the study 
in non-neuronal cells showed that a miniscule amount of internalized fibrils is sufficient to initiate 
robust aggregation of soluble tau, suggesting that templated recruitment is probably a self-
perpetuating process which, once started, will progress relentlessly. 
The transmissibility of fibrillar tau was further confirmed in an in vivo study (Iba et al., 
2013), whereby intracerebral injection of tau fibrils into transgenic mice over-expressing human 
mutant tau led to rapid induction and spreading of tau pathology to multiple brain regions. 
Intriguingly, different injection sites resulted in distinct patterns of pathology progression that 
coincide with neuronal projections, providing strong support for the notion that the spreading of 
transmissible tau species occurs along neuronal connections. Moreover, tau pathology induced 
by inoculated tau fibrils bears remarkable resemblance to NFTs in AD, including strong ThS-
binding, intense labeling by antibodies specific for acetylated tau (Ac-K280) and conformationally 
altered phospho-tau (TG3), and high PK resistance. These cardinal features of AD NFTs are not 
only absent from tau inclusions developed in aged uninjected transgenic mice used in this study, 
but are also rarely captured in other existing tau transgenic mice (ThS staining was occasionally 
reported but always in low abundance, or found only in the spinal cord but not brain), suggesting 
that pff-templated fibrillization via intracerebral injection may provide a more disease-relevant 
animal model than mere over-expression. 
As mentioned in the General Introduction, the phenomenon of cell-to-cell transmission 
has been demonstrated for multiple amyloidogenic proteins and suggested to be a shared 
mechanism underlying the pathogenesis of many neurodegenerative diseases. It is now 
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increasingly accepted that the initial protein misfolding event, which eventually leads to full-blown 
disease with widespread pathology, can start in a limited number of neurons that are most 
vulnerable to protein aggregation. Small amounts of misfolded protein in these neurons are 
adequate to launch massive recruitment of their soluble counterparts into fibrillar aggregates, 
which can be released into extracellular space or synaptic cleft and be taken up by neighboring or 
synaptically connected neurons, in which the internalized aggregates participate in a new round 
of templated recruitment; as this cycle of events repeats, increasing numbers of neurons would 
develop pathology, giving rise to the characteristic pattern of pathology progression as outlined by 
the Braak staging scheme for AD, PD and DLB (Braak and Braak, 1991; Braak et al., 2002; Braak 
et al., 2003; Kosaka et al., 1988). 
Meanwhile, as the study described in Chapter 4 suggests, transmissible fibrillar 
aggregates can exist as diverse strains with different conformations and highly variable kinetics in 
templated recruitment. Different strains may also display distinct cell tropism, owing to cell type-
specific cellular and biochemical environment that could differentially influence the seeding 
properties of particular strains. For example, a strain that is highly efficient in nucleating 
aggregation in the hippocampal neurons may show very low seeding capacity in the substantia 
nigral neurons. In addition, as shown in Chapter 4, the various strains may differ dramatically in 
their ability to cross-seed the aggregation of another amyloidogenic protein, causing differential 
extent of co-morbid pathologies. Given all these possibilities, conformationally diverse strains can 
potentially account for not only the frequent while variable co-deposition of different protein 
aggregates, but also the tremendous heterogeneity among disorders with the same major protein 
lesions. Moreover, the strain-specific conformation of the initial misfolded seeds may be passed 
down through templated recruitment, but new strains could also arise during repeated cell-to-cell 
transmission, leading to brain region-specific pathologies within one patient. 
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5.2 Differences between tau and α-syn shown by transmission models 
 Although synthetic fibrils assembled form both tau and α-syn are able to mediate the 
transmission of pathologies, studies in primary neurons and transgenic mice suggest that α-syn 
may be more “transmissible” than tau (Guo and Lee, 2013; Iba et al., 2013; Luk et al., 2012b; 
Volpicelli-Daley et al., 2011). Robust α-syn pathology can be induced by α-syn pffs in wt neurons, 
whereas highly limited tau pathology occurs in wt neurons transduced with tau fibrils. Also, 
injection of α-syn pffs into the striatum and overlaying cortex of transgenic mice over-expressing 
mutant α-syn led to widespread LB-like pathology throughout the brain, but injection of tau pffs 
into exactly the same areas in transgenic mice over-expressing mutant tau resulted in spreading 
of NFT-like pathology to much more restricted brain regions. While these differences could be 
partly due to the A53T variant of α-syn naturally expressed in wt mouse (A53T mutation 
accelerates α-syn fibrillization and is pathogenic in human) and differential transgene expression 
in the two lines of transgenic mice used for injection studies, we cannot rule out the possibility 
that pathological α-syn is intrinsically more efficient than pathological tau in templating and 
propagating aggregation. In fact, this possibility is consistent with the findings that tau pathology 
is restricted to the brain in various tauopathies, but α-syn pathology appears to initiate from the 
peripheral and enteric nervous systems and spread all the way to the brain in PD (Braak and Del 
Tredici, 2009). 
Several mechanisms could account for the superior transmissibility of α-syn: (1) α-syn 
has a higher propensity to fibrillize than tau as shown by in vitro studies. While α-syn readily 
assembles into fibrils without any co-factors, even seeded fibrillization of tau requires co-factors 
(Friedhoff et al., 1998). (2) In mature neurons, high local concentration of α-syn in the synaptic 
terminals may facilitate efficient templated recruitment. This is supported by experiments showing 
that pff-induced α-syn aggregation is first initiated in the axons before spreading to the cell bodies 
and dendrites, and the induction of pathology is far more efficient in more mature neuron cultures 
when α-syn concentration is higher in the axon terminals (Volpicelli-Daley et al., 2011). (3) 
Although the mechanism for cell-to-cell transmission of pathology is unknown, synaptic terminals 
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are probable sites for interneuronal transfer of misfolded proteins. If this is true, the unique 
subcellular location α-syn gives it an advantage in transmission. 
 Another discrepancy between the transmission models of tauopathies vs. 
synucleinopathies is that α-syn aggregation, but not tau aggregation, is consistently accompanied 
by cell death, both in neurons and animal models. Toxicity associated with α-syn aggregation 
probably arises from filamentous aggregates themselves, which were shown to impair protein 
degradation machinery and block the axonal transport of selective cargoes that are critical for cell 
survival (unpublished data). Although the buildup of insoluble α-syn is accompanied by a 
concomitant reduction of soluble endogenous α-syn, which may result in loss-of-function toxicity, 
the observations that neurons derived from α-syn knock-out mice are perfectly healthy and α-syn 
knock-out mice do not show structural abnormalities (Abeliovich et al., 2000) argue against this 
possibility. 
 On the other hand, two major possibilities could explain the lack of toxicity of tau 
aggregates in the pff transduction/injection models. First, NFTs per se may be benign to cells, but 
in tauopathy brains, reduced MT stability due to loss of soluble tau to the NFTs is harmful for 
neurons. This hypothesis is consistent with behavioral deficits observed in aged tau KO mice 
despite a compensatory upregulation of MAP1A (Dawson et al., 2010; Harada et al., 1994; 
Ikegami et al., 2000; Lei et al., 2012). In the pff-transduced primary neurons derived from tau 
over-expressing mice, however, only a very small fraction of endogenous mouse tau gets 
recruited into the insoluble aggregates, and the minor loss of soluble endogenous tau can be 
easily compensated by over-expressed human tau, thus MT integrity is unlikely compromised in 
these cells, similarly in pff-injected transgenic mice. Unless robust aggregation of endogenous 
mouse tau can be induced in wt neurons/mice without tau over-expression, it would not be 
possible to observe the loss-of-function toxicity resulted from tau aggregation. Second, although 
fibrillar tau is able to induce and propagate pathology that is highly reminiscent of AD NFTs, the 
truly toxic species of tau may be distinct from the transmissible species. Studies on infectious 
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prion particles have suggested a dissociation between infectivity and neurotoxicity (reviewed by 
Caughey and Lansbury, 2003; Sandberg et al., 2011), which may hold true for tau as well. It is 
possible that tau oligomers, instead of mature NFTs, are more toxic to cells. Tau pffs directly 
recruit soluble tau into filamentous aggregates and result in a complete bypassing of the slow 
oligomerization phase that normally occurs in uninjected transgenic mice prior to the onset of 
overt pathology. This in turn could explain the curious paradox of neuron loss in aged untreated 
mice bearing ThS-negative tau inclusions but not in pff-injected mice harboring more mature 
tangles. 
5.3 Therapeutic efforts and implications of recent studies 
 Currently available treatments for the major neurodegenerative diseases are mainly 
targeting malfunctioning neurotransmitter systems, such as L-DOPA (precursor to dopamine) 
administration for boosting dopamine levels in PD patients (Cotzias et al., 1969), use of the 
cholinesterase inhibitor donepezil and the N-methyld-aspartate (NMDA)-receptor modulator 
memantine for AD patients (reviewed by Lleo et al., 2006). Even though these treatments can 
ameliorate disease-associated symptoms, since they are not acting on the root cause of the 
diseases, they are unable to reverse disease course or even slow down progression. 
 In the last decade or so, advanced understanding in the cell and molecular mechanisms 
underlying these devastating diseases has led to increasing effort in developing disease-
modifying therapies. Take AD for example. A variety of Aβ or tau-targeted approaches are being 
actively explored now, including suppressing Aβ production (γ-secretase or β-secretase 
inhibitors, α-secretase activator), reducing tau hyperphosphorylation through kinase inhibition, 
inhibiting Aβ/tau fibrillization or promoting dissolution of pre-existing aggregates, stabilizing MTs 
to compensate for the loss of tau function, etc. (reviewed by Ballatore et al., 2007; Melnikova, 
2007). In addition, due to the central role of Aβ in the pathogenesis of AD and the extracellular 
location of Aβ plaques, a large number of studies have focused on Aβ immunotherapy aiming at 
lowering plaque load. Despite disappointment from the first clinical trial of active Aβ 
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immunotherapy, which was discontinued because of unwanted immune responses (Gilman et al., 
2005), continual effort has been dedicated towards improved immunotherapy that is safer and 
cost-effective (Fu et al., 2010). 
 The interneuronal transmission of protein aggregates demonstrated by recent studies has 
opened new avenues for therapeutic interventions. Immunotherapy, which was thought to be not 
particularly meaningful for intracellularly located protein aggregates, now becomes an attractive 
strategy for a variety of neurodegenerative diseases. Since cell-to-cell transmission likely involves 
release and uptake of misfolded proteins, drugs or antibodies that block either process would 
conceivably stop the spreading of pathology, thereby halting the disease progression. However, if 
diverse pathological strains truly exist, they may create challenges for effective immunotherapy, 
because antibodies that exhibit high binding affinity for one strain of protein aggregates may not 
be equally efficient in complexing with another strain. Therefore, a conformation-dependent 
antibody that recognizes a shared conformational epitope of multiple strains may have a broader 
application than antibodies recognizing highly specific epitopes, but the feasibility of this 
hypothetical approach awaits empirical testing. 
5.4 Unanswered questions and future directions 
Mechanisms mediating cell-to-cell transmission of protein inclusions 
 Recent studies, including my study shown in Chapter 2 (Guo and Lee, 2011), suggest 
that the uptake of tau fibrils occurs via endocytosis in a temperature-dependent manner, but the 
exact endocytic mechanism that mediates the internalization of fibrils made from tau or other 
proteins requires further studies. Adsorptive endocytosis was shown to enhance the uptake of 
both tau and α-syn fibrils (Guo and Lee, 2011; Volpicelli-Daley et al., 2011), and fibrillar tau was 
found to partially colocalize with dextran, a substrate of the fluid-phase endocytosis (Frost et al., 
2009; Wu et al., 2013). Considering the size of fibrils, receptor-mediated endocytosis, which 
requires specific interactions between ligands and cell-surface receptors, is most likely not a 
major mode for fibril entry. 
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 Similarly, it is unclear how aggregates are released into the extracellular space for 
transferring into unaffected cells. A number of cell culture studies have demonstrated secretion of 
monomeric or oligomeric α-syn and tau into the cell medium via exosomes (Danzer et al., 2012; 
Emmanouilidou et al., 2010; Saman et al., 2012). Moreover, two microdialysis studies in healthy 
mice were able to detect appreciable levels of tau and α-syn in the interstitial fluid, suggesting 
that these proteins may be routinely secreted out of healthy neurons for unknown reasons 
(Emmanouilidou et al., 2011; Yamada et al., 2011). So far, no studies have demonstrated 
mechanisms for the release of aggregated proteins. Since inoculation studies in mice 
demonstrated spreading of pathology along neuronal connections, it will be interesting to explore 
whether neurotransmission at the synapses is exploited by pathological aggregates to exit and/or 
enter neurons. 
The conundrum about 3R and 4R tau 
 The differential incorporation of tau isoforms into NFTs in different tauopathies (both 3R 
and 4R in AD, predominantly 4R in CBD and PSP, but predominantly 3R in PiD) has been a 
mystery in the field. It is well established that genetic mutations which disrupt the balance 
between 3R and 4R tau are pathogenic, but the exact mechanism is not clearly understood. 
Antibodies that are specific for 3R or 4R tau were used in immunohistochemical studies to 
examine the relationships between 3R and 4R tau in NFTs. All three patterns of isoform 
composition, i.e. 3R+/4R-, 3R-/4R+ and 3R+/4R+, were observed for NFTs and NTs in AD, and 
patterns appear to be consistent within each tangle-bearing neuron (Togo et al., 2004). However, 
it is unclear whether 3R and 4R tau form hybrid filaments in the 3R+/4R+ NFTs or 3R and 4R tau 
filaments merely lie adjacent to one another in the same inclusions. Curiously, extracellular ghost 
tangles are only labeled by 3R tau antibodies, either because 4R tau gets degraded in the 
extracellular tangles, or the 4R antibody epitope is embedded (Espinoza et al., 2008). A major 
concern with these studies is raised by frequent inconsistencies between staining pattern and 
biochemical analysis (de Silva et al., 2003; Espinoza et al., 2008). For example, cases with a 
paucity of 4R-immunoreactive NFTs in staining still show equal ratio of 3R and 4R tau on 
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immunoblots, same as other cases with more even immunoreactivity of 3R and 4R tau by 
immunohistochemistry. Such discrepancies could be explained by conformationally diverse tau 
filaments with differential masking of the epitopes recognized by isoform-specific antibodies, 
which in turn casts a doubt on the reliability of experiments using these antibodies to study 
isoform composition of NFTs. 
 Some of the questions regarding relationships between 3R and 4R tau in aggregation 
can be addressed using the recently developed pff-seeding paradigm both in cells and transgenic 
animals. In vitro studies have suggested conformational differences between fibrils assembled 
from 3R and 4R tau as well as a seeding barrier between them (Dinkel et al., 2011; Furukawa et 
al., 2011). In our unpublished study and a similar study by another group (Nonaka et al., 2010), 
inefficient cross-seeding between 3R and 4R tau was observed in cultured cells too. It would be 
interesting to test isoform-specific recruitment of tau in transgenic mice expressing both 3R and 
4R human tau with injection of either 3R or 4R tau fibrils. While it may be tricky to explain brain-
wide consistency in NFT composition for specific tauopathies if tau inclusions in different neurons 
develop cell-autonomously, the newly evolved transmission hypothesis has made it much easier 
to understand, whereby the isoform composition of the initial misfolded seeds likely determines 
the composition patterns in subsequently affected neurons – given a seeding barrier between 3R 
and 4R tau does exist in vivo. Consequently, the initial seeds for AD must contain both 3R and 
4R tau. 
Inspired by the study shown in Chapter 4 for α-syn, I am particularly curious to explore 
whether conformationally diverse tau fibrils can be similarly generated in vitro and whether 
different pathological strains of tau are indeed responsible for the tremendous variability among 
tauopathies. Unlike α-syn, the different isoforms of tau and the different polyanionic cofactors that 
can be used to promote tau fibrillization are expected to create even greater complexity in 
possible conformations. Furthermore, a strain of tau fibrils that could efficiently induce pathology 
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in wt neurons would be exceptionally useful for dissecting the toxic mechanism of tau 
aggregation. 
Relationships between Aβ and tau 
The identification of both senile plaques and NFTs in postmortem brain examination is 
required for a formal diagnosis of AD. However, the relationships between Aβ and tau are yet to 
be fully elucidated. Transgenic mice with abundant Aβ plaques usually have minimal neuron loss, 
whereas transgenic mice which develop tau inclusions often show prominent neuron death. 
Together with the fact that tau aggregation alone leads to diseases such as frontotemporal 
dementia while senile plaques are frequently found in aged but non-demented people, these 
converging lines of evidence have led to the hypothesis that tau may be a necessary mediator of 
neurodegeneration in AD (reviewed by Lee, 2001). A study showing ameliorated Aβ-induced 
behavioral deficits in tau KO mice further implicates tau as a downstream effector of Aβ-
associated neuronal dysfunction (Roberson et al., 2007). Nevertheless, different from AD, 
tauopathies without Aβ plaques usually do not have marked memory deficits but commonly 
present personality changes and motor deficits, suggesting that Aβ plaques may have a modifier 
effect on the downstream toxicity mediated by tau. 
 Although plaque accumulation in single transgenic mice over-expressing Aβ precursor 
protein (APP) does not lead to tau pathology (Games et al., 1995; Hsiao et al., 1996), double 
transgenic mice over-expressing both tau and APP show potentiated tangle development than 
single transgenic mice over-expressing tau alone (Lewis et al., 2001), and direct injection of Aβ 
fibrils into the hippocampus of tan transgenic mice led to dramatically increased numbers of NFTs 
in the amygdala where injected neurons project (Gotz et al., 2001b), suggesting Aβ aggregates 
accelerate tau aggregation in vivo. A more recent study from our lab further demonstrated that 
tau and APP double transgenic mice develop ThS-positive tangles which are rarely found in 
single tau transgenic mice (Hurtado et al., 2010). This study is intriguingly reminiscent of human 
diseases, whereby NFTs are ThS-positive in AD, but mostly ThS-negative in tauopathies without 
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Aβ plaques. Therefore, Aβ plaques may not directly trigger tau aggregation, but they appear to 
accelerate the formation and maturation of tau tangles that are initiated by tau itself. How 
extracellular Aβ accumulation is mechanistically linked to enhanced intracellular tau aggregation 
is an interest and important topic to investigate, and the primary neuron model described in 
Chapter 3 offers a convenient system to address this question. 
5.5 Concluding remarks 
 Together with other recent studies, my thesis work has provided compelling evidence 
suggesting templated recruitment of soluble protein and intercellular transmission of pathological 
protein aggregates as plausible mechanisms for the onset and progression of neurodegenerative 
diseases. Furthermore, the exact conformation of the template dictates its recruitment properties, 
possibly giving rise to enormous heterogeneity among diseases characterized by the same 
protein inclusions. I hope our study has laid the foundation for future research on the many 
questions that are yet to be answered and eventually lead to cures for these fatal diseases. 
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